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Preferentially expressed antigen in melanoma (PRAME) is a cancer-testis antigen that 
is expressed in many cancers and leukemias; in healthy tissue, PRAME is limited to 
the testes and ovaries, making it a highly attractive cancer target. PRAME is an 
intracellular protein that cannot currently be drugged. After proteasomal processing, 
the PRAME300-309 peptide (ALY) is presented in the context of human lymphocyte 
antigen HLA-A*02:01 molecules, for recognition by the T cell receptor (TCR) of 
cytotoxic T cells. We describe Pr20, a TCR mimic (TCRm) human IgG1 antibody 
discovered through phage-display technology that recognizes the cell-surface ALY 
peptide/HLA-A2 complex; Pr20 is an immunological tool and potential therapeutic 
agent. Pr20 bound to ALY peptide-pulsed cells and PRAME+/HLA-A2+ cancers. An 
afucosylated Fc form (Pr20M) directed antibody-dependent cellular cytotoxicity 
against PRAME+/HLA-A2+ leukemia cells and was therapeutically active in human 
leukemia models in vivo as a monotherapy. Interestingly, in some tumors, Pr20 
binding markedly increased upon IFNγ treatment, mediated by induction of the 
immunoproteasome catalytic subunit β5i. The immunoproteasome reduced internal 
destructive cleavages within the ALY epitope compared to the constitutive 
proteasome.  
 
The ALY/HLA-A2 epitope expression is far lower than traditional mAb targets and 
therefore we explored strategies to enhance potency of Pr20M. We demonstrate that 
combining Pr20M and CD47 ‘do not eat me’ signal blockade (using a SIRPα-variant 
peptide called CV1) led to enhanced antibody dependent cellular phagocytosis 
(ADCP) and dramatic therapeutic effects in leukemia xenograft models. We also 
engineer a bispecific T cell engager (BiTE) and chimeric antigen receptor (CAR) T 
cell using the Pr20 scFv. Pr20-BiTE and Pr20-CAR were both capable of potent 
redirected T cell lysis against PRAME+/HLA-A2+ leukemia in vitro, however these 
constructs also had off-target activities against HLA-A2+ cells despite undetectable 
binding of Pr20. 
 
Finally, we confirm the MAPK pathway as an important regulator of HLA-I 
expression through a high-throughput small molecule inhibitor screen and describe 
mTOR as a potential regulator of HLA-I. We also discover that a 5-lipoxygenase 
inhibitor BW-B70c can enhance HLA-I expression through transcriptional regulation 
but through a mechanism independent of 5-lipoxygenase. BW-B70c treatment 
increases tumor-antigen presentation on HLA-I and sensitizes cells to TCRm-mediated 
ADCC. We also explore the use of the cytomegalovirus immunoevasin US6 to 
modulate antigen presentation on HLA-I with the goal of identifying strategies to 
protect engineered cellular therapeutics harboring foreign or synthetic transgenes from 
immunological attack.  
 
The data provide rationale for developing TCRm antibodies as therapeutic agents for 
cancer, offer mechanistic insight on proteasomal regulation of tumor-associated 
peptide/HLA antigens, yield possible therapeutic solutions to these ultra-low surface 
presentation targets, and explore a strategy to protect genetically engineered cells 
harboring foreign genes from immunological attack. 
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INTRODUCTION 
 
Monoclonal Antibodies for Cancer Therapy 
Monoclonal antibodies (mAbs) are potent protein drugs that can modulate cellular 
signaling pathways in disease and redirect immunological attack1–3. Antibodies are 
produced naturally in the immune system for recognizing and neutralizing pathogens 
such as bacteria and viruses. They are produced in high amounts by differentiated B 
cells called plasma cells in several immunoglobulin (Ig) isotypes: IgG, IgM, IgE, IgA, 
and IgD4, however the vast majority of therapeutic antibodies are of IgG isotype3. IgG 
are Y-shaped antibodies containing a two-armed fragment antigen-binding (Fab) 
component generating two antigen binding sites, and one fragment crystallizable (Fc) 
portion. The antigen binding sites typically have extremely high-affinity interactions 
with a target epitope (up to pM to nM range), while the Fc constant region mediates 
interactions with other immune effector proteins and cells. Structurally, IgG are 
comprised of 4 polypeptide subunits: 2 immunoglobulin light chains (~25 kD) and 2 
immunoglobulin heavy chains (~50 kDa). The light chain comprises of a variable 
region (VL) and a constant region (CL)4. The heavy chain has 1 variable region (VH) 
and several constant regions (CH). Typically, each heavy chain is linked to a light 
chain through a disulfide bond between the CL and CH1 to form a dimer arm 
structure4. Meanwhile, the CH2 region of this arm forms a disulfide bond with another 
CH2 to generate a tetrameric two-armed structure5. Each variable region contains 
domains of hypervariable regions or complementarity determining regions (CDR1, 
CDR2, CDR3) where random somatic recombination of the V(D)J gene segments 
leads to generation of an extreme diversity of antibody paratopes6. Upon B cell 
activation, there is an additional process of somatic hypermutation at these regions 
resulting in a colossal antibody repertoire in addition to affinity maturation of specific 
	2 
antibody clones7. The subtype of IgG determines Fc effector functionality such that 
IgG1 and IgG3 have stronger immune effector activation capability through activating 
Fc Receptors (FcR) compared to IgG2 and IgG44.  These properties are mediated by 
affinity to either activating or inhibitory FcR found on specific immune cells such as 
macrophages, dendritic cells, and natural killer (NK) cells. For cancer therapy, mAbs 
are typically designed to either block receptor signaling cascades required for cancer 
growth, stimulate signaling cascades that enhance anti-tumor effects and immunity, or 
bind to cancer cells and mark them for immune attack by macrophages and NK cells. 
These immune cells can recognize mAb-coated tumor cells through activating FcR to 
engage in antibody dependent cellular phagocytosis and cytotoxicity3. Whereas the 
natural antibody responses in mammals generates a pool of polyclonal antibodies that 
bind varies epitopes on an pathogen, modern molecular and cellular techniques have 
allowed the generation of monoclonal antibodies that are identical in molecular 
structure and target epitope allowing for exquisite control over the mechanism of 
action and preventing unintended and often unpredictable off-target engagement8.  
 
The majority of modern mAbs are generated through either hybridoma technology or 
phage-display technology. The hybridoma approach requires immunization of an 
animal, typically mice, with the target antigen, then harvesting the plasma cells before 
fusing them with a cancerous myeloma cell to cause immortalization of plasma cells – 
called hybridomas9. Each hybridoma clone secretes a unique mAb that can be grown 
indefinitely in vitro. Although most US Food and Drug Administration (FDA)-
approved mAb drugs were produced through hybridoma technology, a major 
limitation is that the mAbs are murine of origin, which would lead to rapid clearance 
through an anti-murine immune response in humans. This typically would require 
subsequence processes to make chimeric (consisting of human Fc region with murine 
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Fab) or humanized (murine CDR sequences genetically grafted onto human antibody 
sequences). This can be circumvented through the use of transgenic mice that express 
human immunoglobulin genes such as the VelocImmune10 mouse (Regeneron) and 
Xenomouse11 (Amgen) technological platforms. The other major approach to 
generating mAbs is through phage-display library screening. In phage-display, a large 
genetic library of Fab regions is generated from donor B cells or a synthetic library is 
randomly generated through PCR techniques9,12. These libraries are then expressed as 
single chain variable fragments (scFv) in bacteriophage such that each phage displays 
only one unique scFv9,12–14. scFv are fusion proteins of the variable regions of the 
heavy (VH) and light chains (VL) of immunoglobulin, connected with a short linker 
peptide of ten to about 25 amino acids. Libraries can then be panned against a desired 
target such that reactive phages are bound while non-reactive phages are washed 
away. Sequences of desired clones are then cloned into a human IgG scaffold and 
expressed as full-length mAb and purified15. 
 
Indeed, mAbs have become an essential format in our armamentarium for cancer 
therapy. For example, the anti-CD20 mAb Rituximab for lymphoma and chronic 
lymphocytic leukemia2,16 and anti-HER2 mAb Trastuzumab for HER+ breast 
cancer17,18 have revolutionized the way we treat these diseases. Both Rituximab and 
Trastuzumab have multiple mechanisms of action. Rituximab binds CD20 on B-cell 
lymphomas to (1) initiate signaling cascades that lead to apoptosis, (2) recruit Fc-
dependent complement cascade to lyse tumor cells, and (3) to recruit Fc-dependent 
immune actions such as antibody-dependent cellular cytotoxicity (ADCC) and 
antibody-dependent cellular phagocytosis (ADCP)19. Trastuzumab can (1) block 
essential HER2 receptor kinase signaling in breast cancer cells, (2) trigger HER2 
degradation, and (3) recruit immune cells to mediate ADCC20. Indeed, the efficacy of 
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several mAb drugs against cancer is commonly attributed to the ability of mAbs to 
engage several independent mechanisms of action21. However, a major limitation of 
mAbs is that they are typically confined to only access cell-surface antigens while the 
vast majority of aberrations in cancers such as over-expressed tumor-associated 
antigens, point mutation proteins, and translocation products, are intracellular 
proteins22 and not accessible to traditional mAbs. Recent advances have led to exciting 
developments of cell-penetrating mAbs23 that can specifically target mutated 
oncogenic proteins such constitutively active KRas G12D24, However, these cell-
penetrating antibodies can suffer from low potency and do not activate immune 
engagement because the Fc portion is internalized into the cell and inaccessible to 
FcR-bearing cells such as macrophages and NK cells. 
 
MHC Class I Antigen Presentation Pathway 
Major histocompatibility complex (MHC) is a set of proteins that can complex with 
peptide fragments derived from other cellular and pathogenic proteins and functions to 
present these peptides on the cell-surface.25 T cells can survey these peptide/MHC 
(pMHC) complexes and can distinguish healthy cells versus cells expressing foreign 
proteins (infected cells) or mutated genes (malignant cells)25,26. This process is an 
exquisite mechanism of adaptive immune surveillance against intracellular pathogens 
and cancer. MHC class I (MHC-I) molecules are heterodimers structurally comprised 
of two polypeptide chains: the MHC-I α chain and beta-2-microglobulin (β2M)27. A 
short peptide fragment (typically 8-10 amino acids) complexes with a peptide-binding 
pocket in MHC-I formed by α1 and α2 chain26,27. All three components: MHC-I, β2M, 
and a bound peptide, are required for MHC-I stability. The cell-surface presentation of 
these pMHC antigens is a complex and highly regulated process. Generally, cellular 
proteins are degraded through the proteasome into peptide fragments in the cytosol. 
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These peptides are then translocated into the endoplasmic reticulum (ER) through the 
transporter associated with antigen presentation (TAP) complex, which is an ATP-
binding cassette family transporter28,29. TAP is a heterodimer made up of 2 subunit 
proteins: TAP1 and TAP2 both of which are required for function. The TAP complex 
associates with several other proteins in the peptide-loading complex such as tapasin, 
calreticulin, and calnexin27. Calnexin stabilizes MHC-I α chain until β2M is bound. As 
MHC-I is not stable without a bound peptide, calreticulin and other proteins act as 
chaperones that stabilize MHC-I until Tapasin recruits MHC-I/β2M heterodimers to 
the TAP complex to facilitate peptide loading27,28. These peptide/MHC-I complexes 
are then trafficked to and presented on the cell-surface where they can be surveyed 
and recognized by the T cell receptor (TCR) of cytotoxic T cells (Fig. 1.1). Upon 
successful engagement, the T cell will activate and release perforin and granzymes to 
lyse and kill the target cell30. As T cells develop through the process of thymic 
selection, mature T cells are selected for their inability to react to self-peptide and 
potential ability to recognize foreign peptides31.  Cancerous cells are characterized by 
genomic instability and have acquired several mutated and aberrantly-expressed 
proteins leading to uncontrolled cell growth32. Such proteins can give rise to peptide 
that are recognized as ‘foreign’ neo-antigens because they are not found on healthy 
cells30,33. In addition, there are exciting discoveries that antigenic peptides can also be 
presented on MHC-I as phosphopeptides34 or derived from alternative sources such as 
introns35,36 or proteasome-spliced peptide products37. If these neo-antigens and tumor-
associated antigens form stable complexes with MHC-I, they can be presented on the 
cell-surface to be recognized by T cells. Therefore, T cells provide the immune system 
a fined-tuned mechanism to distinguish between self and foreign peptides to ultimately 
recognize and kill infected or neoplastic cells. This is particularly important when 
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foreign or tumor-associated proteins are not expressed as membrane proteins on the 
cell surface and are not accessible to antibodies or humoral immunity.  
 
MHC-I in humans is known as human leukocyte antigen (HLA) encoded by three loci: 
HLA-A, HLA-B, and HLA–C for HLA class I (HLA-I), leading to six alleles per 
person due to the diploid nature38. HLA-I is highly polymorphic and there are several 
thousand annotated alleles generating a multitude of HLA-I proteins with varying 
peptide-binding pockets and unique sets of associated peptides39. The large diversity 
of HLA alleles likely resulted from the evolutionary advantage of presenting a larger 
repertoire of peptides allowing protection against more pathogens40. Nomenclature of 
HLA alleles consists of allele family (2 digit code) followed by subtype (third and 
fourth digit), then further subtypes with synonymous nucleotide polymorphisms or 
differences in introns or translated regions41. Although polymorphisms in the peptide 
binding cleft results in a range of specificities for different peptide motifs, the majority 
of variable residues lie toward the middle of the cleft, while conserved large aromatic 
residues constitute the ends. This leads to conserved peptide ‘anchor residues’ at the 
N-terminal and C terminal ends (typically second and last position of a peptide) that 
face into the HLA peptide binding cleft42. Some HLA alleles are more common than 
others such as the HLA-A*02 superfamily where the HLA-A*02:01 allele is found in 
approximately 30-40% of the United States population43–45. HLA-A*02:01 
(abbreviated here forth as HLA-A2) is one of the most common and well-studied HLA 
alleles and has shed light on several biochemical interactions and processes that define 
our understanding of peptide / MHC-I immunobiology. Peptides presented by HLA-
A2 generally utilize position 2 and positions 9/10 as the N- and C-terminal anchor 
residues respectively. Position 2 is anchored most dominantly by Leucine, Methionine, 
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or Valine while position 9/10 is typically anchored by Leucine, Isoleucine, 
Methionine, Valine, or Alanine46. 
 
MHC class II molecules (HLA-DP, -DM, -DOA, -DOB, -DQ, -DR in humans) is an 
additional system to present longer peptides (in the range of 11-30 amino acids) 
derived from extracellular proteins47. Peptide / MHC-II complexes are recognized by 
CD4+ T cells to activate a helper T cell response which is important for stimulating B 
cells to generate antigen-specific antibodies27. However, expression of MHC-II is 
typically limited to professional antigen presenting cells while MHC-I are expressed 
on all nucleated cells and therefore represent a much broader system for directly 
targeting cancer cells from a wide range of histological origins27. 
 
T Cell and TCR-based Strategies to Therapeutically Target Peptide/MHC-I 
Complexes 
The T cell receptor (TCR) of T cells recognize peptide / MHC complexes and allow T 
cells access to the universe of intracellular pathogen and cancer antigens. The 
enormous diversity of TCR specificities is generated through V(D)J recombination of 
two TCR chains, the TCR Vα and Vβ chains, which are linked as a pair through a 
disulfide bond48. Additionally, TCR are low-affinity and can be cross-reactive to 
several peptide / MHC epitopes allowing for the TCR repertoire to react against an 
even larger range of potential epitopes49. The attractive ability to target intracellular 
proteins has spurred the development of several strategies to use T cells and TCR-
based agents in cancer therapy, many of which are in clinical evaluations. These 
include cancer vaccinations, adoptive T cell therapy, re-infusion of TCR-transduced T 
cells, or TCR-based protein agents50. Cancer vaccines rely on immunizing patients to 
antigens found in their tumors. This can be performed through immunization with 
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tumor antigen whole proteins, peptides, or genetic material along with 
immunostimulatory adjuvants with the goal of generating cytotoxic T cells that can 
lyse the cancer cells. Indeed, patients vaccinated with these approaches have generated 
functionally reactive antigen-specific T cells in patients leading to clinical benefits 
when an immune response develops after vaccination51. Adoptive T cell therapy relies 
on isolating patient T cells before stimulating them with a tumor-specific antigen ex 
vivo with the goal of activating and expanding a polyclonal population of tumor 
antigen-specific T cells. Expanded anti-tumor T cells are then re-infused into the 
patient52. TCR-transduced T cells rely on extracting T cells from a patient, transducing 
them with a monoclonal TCR construct directed against a tumor antigen, then re-
infusing the T cells back into the patient53. Although these TCR-transduced T cells are 
endowed with anti-tumor lysis capabilities, they can lead to autoimmunity due to 
unpredictable cross-reactivity upon mis-pairing of the endogenous TCR Vα- or Vβ-
chain with the transgenic TCR53.  
 
The Constitutive Proteasome and Immunoproteasome 
The proteasome is a compartmentalized protease with a barrel structure that is 
important for cellular homeostasis. It functions to degrading proteins marked for 
catabolism – including misfolded or unneeded proteins54. The proteasome regulates 
several important biochemical pathways, achieved through using ubiquitin as a signal 
to slate proteins for proteasome degradation. Ubiquitin is a small (8.5 kDa) protein 
which can be enzymatically conjugated to typically a Lysine residue on a targeted 
protein through the action of ubiquitin-activating enzymes, ubiquitin-conjugating 
enzymes, and ubiquitin ligases55. Ubiquitination is an important protein post-
translational modification that has several functions in cellular processes including to 
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mark proteins for proteasomal degradation. Structurally, the 26S proteasome consists 
of a 20S proteolytic core that can be capped on both ends with a 19S regulatory 
particle56. Ubiquitinated proteins are delivered to the proteasome through Ub-
dependent chaperones and shuttling factors55. The 19S regulatory particle contains 
receptors that recognize Ubiquitinated proteins, unfold the protein through ATPases, 
and translocate the protein into the 20S complex for proteolysis55. Inside the 20S 
complex, there are several catalytic subunits generating three distinct proteolytic 
activities: chymotryptic, tryptic, and caspase-like cleavage57. These are hydrolysis 
reactions that attack the peptide bonds generating peptides of between 4-25 amino 
acids in length55. Although a major function of the proteasome is to degrade proteins 
for regulation and homeostasis, it also generates peptides that upon further processing 
can complex with MHC-I molecules to be presented at the cell-surface26,56.  
 
The proteasome is a multi-subunit complex that can exist in two major forms: the 
constitutive proteasome and the immunoproteasome, which have altered cleavage 
specificities and thus generate unique repertoires of peptides56,58. They differ in 3 
catalytic subunits: β1, β2, and β5 are found in the constitutive proteasome while β1i, 
β2i, and β5i comprise the immunoproteasome56,58–60. β1, β2, and β5 have caspase-like, 
trypsin-like, and chymotrypsin-like catalytic activity respectively while β1i, β2i, and 
β5i have chymotrypsin-like, trypsin-like, and chymotrypsin-like catalytic activities57. 
The increased chymotrypsin-like activity causes the immunoproteasome to generally 
favors cleavage after hydrophobic residues and enhances generation of peptides that 
can fit into the groove of HLA-I56,57. Several antigens are restricted to a specific 
proteasome form and such knowledge can help dictate immunotherapy strategies 
against these targets61–63. Basal expression of the immunoproteasome is typically 
restricted to immune cells, however most cell types can induce expression of the 
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immunoproteasome upon stimulation through pro-inflammatory cytokines such as 
IFNγ and TNFα57. Assembly of the 20s catalytic barrel is a highly regulated and 
complex process that proceeds sequentially and requires a chaperone protein UMP164. 
The β subunits are initially translated as pro-peptides and function as their own 
intramolecular chaperones to assemble the 20s barrel. This is important because 
during immunoproteasome assembly, β1i enters the assembly pathway earlier than β1 
during constitutive proteasome assembly64. This leads to favored β2i assembly 
because of β2i assembly is dependent on β1i. Finally, β5i is preferentially incorporated 
(over β5) into the intermediate containing β1i and β2i64. β5i-propeptide is required to 
ultimately process pro-β1i and pro-β2i into catalytically functional subunits. β5i also 
has a higher affinity to UMP1 than β5 and therefore preferentially incorporates into 
the 20s barrel64. Through these mechanisms, incorporation and maturation of the 
immunoproteasome subunits into the 20s barrel is a rapid process even in the presence 
of constitutive subunits.  
 
A third proteasome known as the thymoproteasome has also been characterized. The 
thymoproteasome incorporates an alternative subunit known as β5t (in place of β5/ 
β5i) along with β1i and β2i, leading to reduced chymotrypsin-like activity and less 
peptide-bond cleavage after hydrophobic residues65. The thymoproteasome is 
exclusively expressed in the cortical thymic epithelial cells (cTECs) and has been 
demonstrated to play an important role in the positive selection process of CD8+ T 
cells65,66. Despite a fascinating biology, its restricted expression to cTECs makes 
thymoproteasome-generated peptides less directly attractive targets in cancer therapy. 
 
The Cancer Testis Antigen “Preferentially Expressed Antigen in Melanoma” 
(PRAME) 
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Cancer-testis antigens are a group of tumor antigens that are over-expressed in many 
cancers, but exhibit limited expression in healthy adult tissue except for in the testes, 
ovaries, and endometrium67. The protein “preferentially expressed antigen in 
melanoma” (PRAME) is a cancer-testis antigen that was originally discovered as a 
melanoma antigen that elicited an immune response by a patients autologous cytotoxic 
T lymphocytes (CTL)68. PRAME is over-expressed in a broad range of cancer types 
including primary and metastatic melanoma (80-90% of cases) 67,69, breast cancer 
(27% of cases) 70, and neuroblastoma (>90% of cases) 70,71. PRAME is also highly 
expressed in hematopoietic malignancies including acute myeloid leukemia (AML) 
(40-60% of cases) 72,73, acute lymphoblastic leukemia (ALL) (20-40% of cases) 67,73, 
myeloma (20-50% of cases) 67, and chronic myeloid leukemia (CML) (30-40% of 
cases) 67,74. PRAME expression has been linked to poor prognosis in breast cancer 75 
and neuroblastoma71. PRAME is also expressed in the stem cells of CML 76 
suggesting that targeting PRAME could preferentially deplete the leukemia-initiating 
cell population. Although the biological function of PRAME is still not well 
elucidated, it is established that PRAME can inhibit retinoic acid receptor signaling 
and can prevent retinoic acid-mediated cellular differentiation, apoptosis, and cell 
cycle arrest. Biochemically, PRAME binds to the retinoic acid receptor preventing its 
interaction with a transactivator complex and thereby preventing transcription of 
retinoic acid-receptor-sensitive genes67,77. However, its function in cancers is complex 
and context dependent. In pediatric AML, higher PRAME mRNA expression 
correlated with favorable prognosis and prolonged survival70. However, in 
glioblastoma and premenopausal breast cancer, PRAME expression correlates with 
poor prognosis70. Although more careful studies will help to elucidate the biological 
role of PRAME in different contexts, its highly tumor-selective expression profile still 
makes PRAME an attractive therapeutic target. 
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PRAME is an intracellular protein67,78,79 making it impossible to target using 
traditional antibodies directed at cell-surface proteins and it cannot currently be 
inhibited using small molecules. Its function in tumor progression is complex, and in 
some contexts, PRAME over-expression can reduce malignancy of leukemia in vivo 
78. Due to its context-dependent role to both promote and inhibit tumorigenesis, direct 
functional inhibition of the protein may not prove to be therapeutically effective. After 
proteasomal processing, however, PRAME-derived peptides including the PRAME300-
309 peptide ALYVDSLFFL (ALY) are presented on the cell surface in the context of 
HLA-A*02:01 (HLA-A2) molecules 80,81. Several groups have demonstrated the 
ability to generate ALY/HLA-A2-specific CD8 cytotoxic T lymphocytes (CTLs) that 
can specifically lyse PRAME+/HLA-A2+ tumors and are reactive against primary 
leukemia 82–84 providing proof that this epitope is presented and can be targeted by 
immunotherapy.  
 
RATIONALE FOR CURRENT WORK 
Effective and safe cancer therapy is premised on the idea that neoplastic cells can be 
specifically identified and eliminated while healthy cells remain unharmed. Although 
a large number of cancer-specific changes in the cell have been identified, including 
tumor-specific mutations, glycosylation patterns and gene expression signatures, the 
vast majority of these cancer-specific markers and tumor-associated antigens cannot 
currently be targeted with either small molecule inhibitors or traditional antibodies. 
Recently, a strategy to target these heretofore-untargetable epitopes has been 
developed by use of T cell receptor mimic monoclonal antibodies (TCRm). TCRm 
have similar specificities as T cell receptors and are directed to peptides presented in  
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Figure 1.1. TCRm antibodies bind peptide/HLA class I complexes on cancer 
cells.* 
Proteins expressed in a cancer cell can be degraded by the proteasome and processed 
into peptides. Peptides are then chaperoned into the ER through the TAP transporter 
complex, loaded onto HLA class I molecules, and shuttled to the cell surface where 
they can be recognized by TCR on cytotoxic T cells. TCRm, which mimic the 
specificity of TCR for peptide/HLA class I complexes, can be designed or discovered 
to target these intracellular or ‘undruggable’ proteins. 
 
 
*Presented from Chang AY, Gejman R, Brea E, Oh C, Mathias M, Pankov D et al. 
Opportunities and challenges for TCR mimic antibodies in cancer therapy. Expert 
Opinion on Biological Therapy. 2016; DOI:10.1080/14712598.2016.1176138 
is an empirical process. Some peptides may be generated but
have low affinity to MHC. Other peptides may have high
affinity to MHC, but never reach the cell surface due to impro-
per processing.[9] Therefore, many potentially interesting tar-
gets are not available as MHC-presented cell-surface epitopes.
Furthermore, HLA restriction selects small subsets of amino
acid sequences for presentation, which means that an indivi-
dual TCRm may work only for a subset of patients with parti-
cular HLA types.[10] Lastly, because the epitope consists of a
linear peptide sequence within an MHC molecule (pMHC),
there is also the possibility of cross-reactivity with other linear
sequences that are homologous to the chosen epitope and
may be presented on nontarget cells.
The unique features of TCRm distinguish them from other
specific immunotherapies (Table 3). As discussed above, while
TCRm display many of the drug-like properties of traditional
mAbs, the nature of their target epitope provides both advantages
and disadvantages. However, once a TCRm of appropriate speci-
ficity and affinity is developed, its characteristics as an mAb make
its clinical development relatively predictable and rapid. TCRm
differ from TCR molecules because TCRm have predictable drug-
like features and greater affinity (100–1000×) for targets.[11] TCRm
also differ from cellular immunotherapies such as chimeric antigen
receptor (CAR) T cells and adoptive T cells because they are not
patient specific. CARs have demonstrated potent activity against
hematological malignancies and patients have durable outcomes.
[12–14] However, traditional CARs face the same limitations of
traditional mAbs in that they are directed to cell surface antigens.
In contrast, adoptive transfer of TCR-transduced T cells can be
directed against an intracellular protein. This approach is in clinical
trials and has the limitations of a patient-specific therapy. TCRs
typically have substantially lower affinity than TCRm and may
require re-engineering to improve their affinity. In addition, the
transduced cellsmay lead to autoimmunity due to cross-activation
of a previously tolerized T cell.[15] Therapeutic approaches that
use living cells, such as CARs or adoptive T cells, cannot be easily
controlled as to pharmacokinetics, level of therapeutic action at
the tumor site, or duration of effects, and may lead to unaccep-
table toxicity, including death. Finally, the introduced TCR may
dimerize with the endogenous TCR generating mismatched TCR
with unknown specificity. Instead, TCRm constructs can be used to
generate CARs that target intracellular proteins, offering an addi-
tional potent format. TCRm can be engineered (as with other
antibodies) to enhance or delete their Fc region functionalities,
alter their pharmacokinetics, or be re-engineered into bi-specific
antibodies, bi-specific T cell engagers (BiTEs), drug conjugates,
radioconjugates, or CAR T cells.
However, as we will discuss, TCRm face challenges that
traditional mAbs do not. The number of epitope sites for a
TCRm that are presented on the cancer cell surface may be
Article highlights
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surface targets.
● Most cancer-specific targets are not accessible to traditional mAb
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Figure 1. TCRm antibodies bind peptide/HLA class I complexes on the cancer cell.
Proteins expressed in a cancer cell can be degraded by the proteasome and processed into peptides. Peptides are then loaded onto HLA class I molecules and are
shuttled to the cell surface where they can be recognized by TCR on cytotoxic T cells. TCRm which mimic the specificity of TCR for peptide/HLA class I complexes can
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complex with major histocompatibility complex (MHC) or human leukocyte antigen 
class I molecules (HLA-I) (Fig. 1.1). In contrast to other TCR-based therapies, TCRm 
can be delivered to patients as off-the-shelf pharmaceutical agents, in a variety of 
biological formats allowing for exquisite control over handling and pharmacology. In 
the present study, we designed a TCRm against the cancer-testis antigen PRAME and 
studied the regulation of the epitope expression. Monoclonal antibodies (mAbs) have 
demonstrated potent anti-tumor efficacy in the clinic. Despite promising results, a 
major limitation of currently marketed mAbs is that they bind exclusively to cell-
surface and extracellular antigens, whereas the majority of aberrantly expressed 
proteins in cancer, including PRAME, are intracellular 43,67,78,79. We hypothesized that 
a TCRm antibody directed against the peptide-HLA complex formed by ALY and 
HLA-A2 would be capable of specifically binding to PRAME-expressing tumors and 
would be a novel cancer therapeutic against a formerly un-targetable protein.  
 
HLA-A2 is one of the most common HLA-I subtype found in approximately 30-40% 
of the United States population43–45 and generating cancer immunotherapies against 
antigens presented by HLA-A2 such as PRAME would benefit a substantial 
population. Clinical trials have also demonstrated that patients vaccinated against 
PRAME can develop PRAME-specific CTLs85 and helper T cells 86. However, there 
are several major constraints to cellular and vaccine based strategies. CTL-based 
therapies are patient-specific and often require laborious manipulation before 
reinfusion while vaccines may be less potent and responses are difficult to predict or 
control, depending on the patient’s immune repertoire and immunological status 87. 
 
Additionally, a TCRm antibody has substantially lower peptide/HLA-I target density 
compared to traditional antibody epitopes, potentially limiting therapeutic efficacy 
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especially when immune effector molecules or cells are required for cytotoxicity. 
Therefore, in developing the technology, it would be important to determine strategies 
to augment therapeutic efficacy. One strategy is to combine TCRm with agents that 
enhance antibody effector mechanisms such as ADCP. Blockade of the CD47 / SIRPα 
‘do-not-eat me’ signal axis has been demonstrated to enhance ADCP88. Therefore, it is 
important to determine whether CD47 blockade could synergize with ADCP activity 
of TCRm. In addition, alternative biological platforms could be utilized to enhance 
efficacy of a TCR mimic antibody. TCRm can be engineered into potent therapeutic 
formats such as a bispecific T cell engager (BiTE)89,90 or transduced as a chimeric 
antigen receptor (CAR)91,92 to redirect T cells against cancer cells. An additional 
strategy to enhance therapeutic potential of TCRm is through pharmacological 
regulation of HLA-I on target cancer cells. Increased expression of target 
peptide/HLA-I may enhance TCRm-mediated ADCC. Because HLA-I is a central 
mediator of immune recognition in cancer, increasing cell-surface HLA-I could also 
be used to potentiate a broad range of other immunotherapies including checkpoint 
blockade therapy, cancer vaccines, or TCR-transduced T cells. 
 
In the following chapters, we report several novel findings. First, we report the 
discovery and characterization of Pr20, the first TCRm monoclonal antibody against 
PRAME, which we have generated to recognize the ALY peptide in complex with 
cell-surface HLA-A2. We characterized the ability of Pr20 to bind PRAME+/HLA-
A2+ cancers and mediate cytotoxicity against PRAME-expressing malignancies in 
vitro and in vivo. In addition, we studied the role of the constitutive proteasome and 
immunoproteasome and their pharmacologic manipulation in generating the ALY 
peptide epitope, which may be important in the therapeutic use of this and other TCR-
based agents. Next, we report the first combination therapy study of TCRm and CD47 
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axis blockade to demonstrate that dramatic therapeutic efficacy can be achieved 
despite low-density peptide/HLA-I targets. We also evaluate activities of the potent 
BiTE and CAR constructs with the Pr20 scFv-targeting moiety. Finally, we explore 
pharmacological and biological methods to modulate HLA-I expression aiming to 
identify strategies to augment TCRm and other immunotherapies, and strategies to 
protect engineered cellular therapeutics from host immunological attack. 
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CHAPTER I: TARGETING IMMUNOPROTEASOME-REGULATED PRAME 
PEPTIDE/HLA-I ANTIGENS WITH A THERAPEUTIC ANTIBODY*,† 
 
INTRODUCTION 
 
PRAME is a cancer-testis antigen overexpressed in a broad range of luekemias and 
solid tumors. It is an adaptor protein and not an enzyme and therefore direct inhibition 
with a small molecule inhibitor is challenging. It also has a complex and context-
dependent biological function to either promote or inhibit tumor malignancy. 
Therefore, function inhibition may not necessarily lead to therapeutic benefit. Instead, 
its tumor-associated expression makes PRAME a prime candidate for immunotherapy 
approaches. Specific peptides from PRAME including PRAME300-309 (ALY) are 
processed and presented on HLA-A2 molecules. HLA-A2 is the most common HLA-I 
haplotype in the US. Therefore, developing an effective TCRm against the PRAME 
ALY/HLA-A2 complex would benefit a large portion of leukemia and solid tumor 
patients in the US. In addition, elucidating biochemical mechanisms required for cell-
surface presentation of ALY/HLA-A2 will shed light on what types of tumors may 
respond to immunotherapy against PRAME. The proteasome is a major determinant of 
HLA-I peptide processing and therefore we explore the role of the two major 
proteasome forms: the constitutive proteasome and the immunoproteasome, in the 
generation of the PRAME-derived ALY/HLA-A2 complex.  
 
* Modified from Chang AY, Dao T, Gejman RS, Jarvis CA, Scott A, Dubrovsky L et 
al. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME 
peptide/HLA-I antigens. J Clin Invest 2017; 127: 2705–2718. DOI:10.1172/JCI92335. 
† Some experiments were designed and conducted by or in collaboration with Cheng 
Liu from Eureka Therapeutics (Phage Display Panning and Screening and Fig. 1.2) 
Tao Dao (Fig. 1.3), Ronald C. Hendrickson, and Ron Gejman (Fig. 3.10) 
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MATERIALS AND METHODS 
 
Selection and Characterization of scFv Specific for PRAME Peptide/HLA-A2 
Complexes 
A human scFv antibody phage display library was used for the selection of mAb 
clones. In order to reduce the conformational change of HLA-A2 complex introduced 
by immobilization onto plastic surfaces, a solution panning method was used in place 
of conventional plate panning. In brief, biotinylated negative antigens RHAMM-
R3/HLA-A2 were first mixed with the human scFv phage library (7x1010 clones), then 
the antigen-scFv phage antibody complexes were pulled down by streptavidin-
conjugated Dynabeads M-280 through a magnetic rack and discarded. This step 
removed phage that bound to HLA-A2 along or HLA-A2 in complex with an 
irrelevant peptide. A repeat of this process on the positive ALY/HLA-A2 monomers 
was then conducted. ALY/HLA-A2-bound clones were then eluted and were used to 
infect E. Coli XL1-Blue. The scFv phage clones were expressed in the bacteria and 
were purified 93. Panning was performed for 3-4 cycles to enrich scFv phage clones 
binding to ALY/HLA-A2 complex specifically. Positive phage clones were 
determined by standard ELISA method against biotinylated single chain HLA-
A2/ALY peptide complexes. A total of 25 positive clones that possessed unique DNA 
coding sequences were subjected to further characterization. Binding to peptide/HLA-
A2 complexes on live cell surfaces was determined using a TAP-deficient, HLA-A2+ 
cell line, T2. T2 cells were pulsed with peptides (50 µg/mL) in the serum-free 
RPMI1640 medium, in the presence of 20 µg/mL β2M overnight. The cells were 
washed, and the staining was performed in following steps. The cells were first stained 
with purified scFv phage clones, and followed by staining with a mouse anti-M13 
phage coat protein mAb (Invitrogen MA1-12900), and finally the goat F(ab)2 anti-
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mouse IgG conjugated to A488 (Invitrogen A11017) before flow cytometry. Each step 
of the staining was done between 30-60 minutes on ice and the cells were washed 
twice between each step of the staining. 4 clones (Pr8, Pr17, Pr20, Pr29) showed 
robust and specific binding to T2 cells pulsed with ALY peptide but not to T2 cells 
left unpulsed or pulsed with the irrelevant control RHAMM-3 peptide, and were 
engineered into full length human mAb. 
 
Engineering Full Length mAb Using the Selected scFv Fragments. 
Full-length human IgG1 of the selected phage clones were produced in HEK293 and 
Chinese hamster ovary (CHO) cell lines, as described 94. In brief, antibody variable 
regions were sub-cloned into mammalian expression vectors, with matching human 
lambda or kappa light chain constant region and human IgG1 constant region 
sequences. Afucosylated Pr20M was produced in a similar method except in modified 
CHO cells as described 95. Molecular weights of the purified full-length IgG 
antibodies were measured under both reducing and non-reducing conditions by 
electrophoresis. 
 
Selection of Pr20 as Lead mAb Clone 
4 full-length human IgG1 clones (Pr8, Pr17, Pr20, Pr29) were assayed for binding to 
HLA-A2+ healthy donor PBMC populations and PRAME+/HLA-A2+ leukemia cell 
lines AML14 and BV173. Pr20 was chosen as the lead TCRm mAb clone due to 
robust binding to cell lines without substantial binding to healthy PBMC populations. 
Other clones were not pursued due to either non-specific binding to HLA-A2+ healthy 
donor PBMC populations or inability to bind or mediate ADCC against 
PRAME+/HLA-A2+ tumor cells, suggesting that these clones did not bind 
endogenously processed and presented ALY/HLA-A2 complexes which may have 
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subtle structural constraints compared to exogenously-loaded ALY on HLA-A2 in the 
T2 cell assay or monomers folded in vitro. 
 
Peptides 
All peptides were purchased and synthesized by Genemed Synthesis Inc. The peptides 
were dissolved in dimethyl sulfoxide and frozen at −80°C. Peptide pulsing 
experiments were performed by incubating TAP-deficient T2 cells overnight with 50 
µg/mL of peptide with 20 µg/mL β2M in either serum-free media or in the presence of 
5% dialyzed FBS overnight. Control peptides used were established HLA-A2 binding 
peptides RHAMM-R3 (ILSLELMKL) and EW (QLQNPSYDK). Experimental 
peptides included the ALY peptide (ALYVDSLFFL) and the elongated 20-mer ALY-
precursor peptide (LQCLQALYVDSLFFLRGRLD). 
 
Cells 
PBMC from HLA-typed healthy donors were obtained by Ficoll density 
centrifugation. Cell lines were maintained at Sloan Kettering and were originally 
obtained from the American type culture collection and frozen as aliquots in liquid 
nitrogen. BV173 was kindly provided by H. J. Stauss (University College London). 
The following cell lines were gifts from the listed labs at Memorial Sloan Kettering 
Cancer Center, New York, NY: AML14 was a gift from Ross Levine, SET2 was a gift 
from Richard J. O’Reilly. SK-Mel5 and SK-Mel37 were gifts from Jedd D. Wolchok, 
and SUDHL1 and SUDHL4 were gifts from Anas Younes. SKLY16, PC9, SK-Mel30, 
and SK-Mel2 were from cell line banks at Memorial Sloan Kettering Cancer Center. 
THP1, U266, A375, SW480, BJAB, NCI-H2228, MDA-MB231, T2, and HL60 were 
obtained from the American Type Culture Collection. UACC257 and UACC62 were 
obtained from the NCI. MAC1 and MAC2A were gifts from Mads H. Andersen 
	21 
(University of Copenhagen, Copenhagen, Denmark). Cell lines of unknown HLA were 
HLA typed by the Department of Cellular Immunology at Memorial Sloan Kettering 
Cancer Center. All cell lines were cultured in RPMI 1640 supplemented with 10% 
FCS, 1% penicillin, 1%streptomycin, 2 mM L-glutamine, and 10 mM HEPES at 37°C 
and 5% CO2. 
 
Flow Cytometry 
For cell surface staining, cells were blocked using FcR blocking reagent (Miltenyi 
130-059-901) at the manufactures recommended dilution for 15 minutes on ice, then 
incubated with appropriate fluorophore -conjugated mAbs for 30 min on ice and 
washed twice before resuspension in a viability dye (either DAPI or propidium iodide 
at 1 µg/mL). Antibodies used include anti-HLA-A2 clone BB7.2-APC (ebioscience 
17-9876-42), BB7.2-FITC (MBL K0186-4), anti-CD3-PerCP clone 7D6 (Invitrogen 
MHCD0331), anti-CD19-PE-Cy7 clone 1D3 (eBioscience 25-0193-81), anti-CD33-
BV711 clone WM53 (Biolegend 303423), CD14-PE clone 61D3 (eBioscience 12-
0149-42). Pr20 or its human IgG1 isotype control (Eureka Therapeutics ET901) was 
conjugated to APC using the lightning-link kit (Innova Bioscience 705-0010) and 
staining was performed at 3 µg/mL, which was determined to be a saturating 
concentration. Flow cytometry data were collected on a LSRfortessa (Beckton 
Dickinson) or an Accuri C6 (Beckton Dickinson) and analyzed with FlowJo V10 
software. 
 
Antibody-dependent Cellular Cytotoxicity 
Cancer cell lines used as ADCC target cells were incubated with 50 µCi of 51Cr for 1 
hour at 37 °C and washed 3 time to remove free 51Cr. Indicated concentrations of 
Pr20M or matched isotype control hIgG1 (afucosylated Eureka Therapeutics ET901) 
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were incubated with target cells and fresh PBMCs at effector:target ratios of 50:1 for 6 
hours at 37 °C. The assay was performed in 96-well format with 5000 target cells per 
well and 250,000 PBMC. The supernatant was harvested, and the cytotoxicity was 
measured by scintillation counting. For flow-based ADCC assays, PBMC and GFP+ 
tumor target cells were incubated at effector:target ratio of 30:1 overnight with 1 
µg/mL of Pr20M and flow cytometry was used to determine depletion of GFP+ tumor 
percentage. PBMC were also incubated alone with 1 µg/mL Pr20M to measure 
potential autologous toxicity to PBMC populations. 
 
Western Blot and qPCR Analysis 
Total cell lysate was extracted using RIPA buffer and quantified using the DC protein 
assay (Biorad). 15-30 µg of protein was loaded and run on 4-12% SDS PAGE gels. 
After 1 hr block with 5% milk at room temperature, immunoblotting was performed 
using the following antibodies (Enzo Life Science): anti-20s β5i (BML-PW8845-
0025), anti-20s β2i (BML-PW8350-0025), anti-20s β1i (BML-PW8840-0025), anti-
PRAME (Sigma-Aldrich HPA045153). Antibodies were probed at manufacturers 
recommended dilution overnight at 4°C before a secondary antibody conjugated to 
HRP was used for imaging. Replicate samples were probed using the indicated 
antibodies when noted, or blots were stripped with RestoreTM Western Blot Stripping 
Buffer (ThermoFisher Scientific 21063), re-blocked with 5% milk, and re-probed with 
an anti-GAPDH-HRP direct conjugated antibody (Cell Signaling Technology 3683) as 
a loading control. qPCR was performed using the Taqman real-time PCR system. 
RNA was extracted using the Qaigen RNeasy, 1 µg of RNA was reverse transcribed 
into cDNA using qScript cDNA SuperMix (Quanta Biosciences) TaqMan probes and 
primers were designed from 'assay-on-demand' gene expression products (Applied 
Biosystems). Primer and probes were PRAME (assay ID number: Hs01022301_m1) 
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and the endogenous reference gene control was TATA-box binding protein (TBP) 
(assay ID number: HS99999910). The results are presented as relative differences in 
expression vs the endogenous reference control gene (2-∆Ct), or fold changes based on 
the differences of normalized Ct values compared to control samples, assuming 
optimal primer efficiency (2-∆∆Ct). Samples that did not amplify after 40 cycles or 
amplified at an equal or later Ct value compared to a water sample were considered 
negative and are not plotted with a value. 
 
CRISPR knock-out Studies 
LentiCRISPRv2 (Addgene plasmid #52961) 96 was a gift from Feng Zhang (Broad 
Institute, Cambridge, MA). Guide RNA sequences targeting the immunoproteasome 
subunits were as follows: (β2i: GTCCCTCACGCACGCAAGAC, β5i: 
GTGCAGCAGACTGTCAGTAC, β1i: GGTGCCTTGCAGGGATGCTG). Cells were 
transduced with LentiCRISPRv2 and transduced cells were selected using 1-4 µg/mL 
puromycin for 48 hours. Successful knockout was confirmed by western blot analysis. 
 
Animals 
Eight- to ten-week-old NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ mice, known as NSG, were 
purchased from The Jackson Laboratory or obtained from the MSKCC animal 
breeding facility. Female mice were used for the BV173 and SET2 models while male 
mice were used for the AML14 model. C57BL/6 and B6.Cg-Tg(HLA-A/H2-D)Enge/J 
(HLA-A2 transgenic mice) (6 to 8 weeks old) for biodistribution experiments were 
also purchased from The Jackson Laboratory and bred at MSKCC. 
 
Therapeutic trials of Pr20M 
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GFP/luciferase-transduced AML14 cells were passaged once in NSG mice and bone 
marrow was harvested to generate a sub-culture line that engrafted more consistently 
in vivo. Using this AML14 sub-culture line, 3 million cells were injected intravenously 
into two groups of NSG mice. On day 7, tumor engraftment between the two groups 
was confirmed by luciferase imaging to have minimal inter-group variation. Groups 
were blindly assigned to either treatment groups (Pr20M or Isotype-treated). 50 µg of 
Pr20M or an afucosylated isotype control human IgG1 (afucosylated Eureka 
Therapeutics ET901) was injected intravenously twice weekly (every 3 or 4 days) 
starting on day 7 until the experiment endpoint on day 29. Tumor growth was assessed 
by weekly bioluminescent imaging and bone marrow was harvested on day 29 for 
flow cytometric analysis. For BV173 and SET2 therapy experiments, 0.5x106 SET2 
cells and 3x106 BV173 were engrafted into NSG mice through tail vein injection. 
Mice were treated with 50 µg of Pr20M on day 6, 10, 13, and 17 after engraftment or 
left untreated (control) and tumor burden was assessed by bioluminescent imaging on 
the indicated days. 
 
Pharmacokinetic and Biodistribution Studies 
Pr20 antibody was labeled with 125I (PerkinElmer) using the chloramine-T method. 
100 µg of antibody was reacted with 1mCi 125I and 20 mg chloramine-T, quenched 
with 200 mg Na metabisulfite, then separated from free 125I using a 10-DG column 
equilibrated with 2% bovine serum albumin in PBS. Specific activities of products 
were in the range of 4 to 8 mCi/mg. 2.5 µg of radiolabeled mAb was administered 
intravenously into each mouse through retro-orbital injection, and blood and/or organs 
were collected at indicated time points, weighed, and measured on a gamma-counter. 
 
In vitro Proteasome Digestion and LC-MS/MS Mass Spectrometry Analysis 
	25 
A 20-mer PRAME sequence peptide (LQCLQALYVDSLFFLRGRLD) termed the 
“precursor peptide,” encompassing the ALY epitope and elongated by 5 residues on each 
end was synthesized by Genemed and ensured to be over 95% pure by HPLC. The 
precursor peptide was dissolved in DMSO and stored at -80°C. Purified constitutive 
proteasome and immunoproteasome were purchased from Boston Biochem (E-360 and 
E-370 respectively). 10 µg of precursor peptide was mixed with either 5 µg of 
constitutive or immunoproteasome in 100 µL of assay buffer per replicate. Assay buffer 
consisted of 2 nM MgAc2, 1 mM DTT, 20 mM HEPES/KOH at a pH of 7.8. The 
reaction was incubated at 37°C and at each time point, a 20 µL aliquot was removed and 
quenched with 2 µL of 10% TFA in water. Samples were stored frozen at -80°C until MS 
analysis. Each sample was analyzed separately by microcapillary LC with electrospray 
ionization coupled with tandem MS. We used a NanoAcquity LC System (Waters) with 
a 100-µm inner diameter × 10-cm length C18 analytical column (1.7 µm BEH130; 
Waters) configured with a 180-µm × 2-cm trap column coupled to a Q-Exactive Plus 
mass spectrometer (Thermo Fisher Scientific). A nanoelectrospray source (Proxeon, 
Thermo Scientific) set at 1800 V and a 25-micron (with 10-micron orifice) fused silica 
nano-electrospray needle (New Objective, Woburn, MA) was used to complete the 
nanoelectrospray interface.  For each time point, the sample was diluted 1:20 in HPLC 
grade water with 0.1% (v/v) formic acid and 1 µL was loaded onto the trap column, 
washed with 3x loop volume of buffer A (Water with 0.1% (v/v) formic acid) and the 
flow was reversed through the trap column and the peptides eluted with a 90 min linear 
gradient from 1-50 % buffer B (Acetonitrile with 0.1% (v/v) formic acid) at 300 nL / 
min. The QE Plus was operated in automatic, data-dependent MS/MS acquisition mode 
with one MS full scan (400–1800 m/z) at 70,000 mass resolution and up to ten concurrent 
MS/MS scans for the ten most intense peaks selected from each survey scan. Survey 
scans were acquired in profile mode and MS/MS scans were acquired in centroid mode 
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at 17500 resolution and isolation window of 1.5 amu and normalized collision energy of 
27. AGC was set to 1 x 106 for MS1 and 5 x 104 and 100ms IT for MS2.  Charge 
exclusion of unassigned and greater than 6 enabled with dynamic exclusion of 15s. 
Degradation products were identified and quantified by in silico analysis of mass 
spectrometry data. Briefly, all HPLC peaks were identified using the "findpeaks" method 
in the "pracma" R package. For each retention time during which a HPLC peak appeared, 
the ms1 spectra was analyzed to identify series of peaks. Identified peak series were 
matched to a database of all possible precursor peptide degradation products. Total 
intensity of each degradation product was quantified by adding up the intensities of each 
product ion. If two degradation products yielded the same peak series (e.g. FFL and 
LFF), intensity was assigned to each product in proportion to the a2 and b2 product ions. 
 
Statistical Analysis 
Values reported represent means ± SEM unless otherwise noted. P-values were 
calculated with GraphPad Prism 6 (GraphPad Software Inc), using the paired 
Wilcoxon signed-rank test where appropriate, or student’s t-test (unpaired, two-tailed) 
with P < 0.05 (*), P < 0.01 (**), P < 0.001 (***), and P < 0.0001 (****) considered 
significant. Binding affinity of Pr20 was determined on AML14 cells using Scatchard 
analysis after linear-transformation of [bound] and [bound]/[free] Pr20. The two-phase 
exponential decay model was used for analyzing Pr20M pharmacokinetics. 
Experiments were performed at least 3 times unless otherwise noted. 
 
Study Approval 
All animal studies were conducted in accordance with IACUC-approved protocols. 
After informed consent on Memorial Sloan Kettering Cancer Center Institutional 
Review Board approved protocols, peripheral blood mononuclear cells (PBMC) from 
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HLA-typed healthy donors were obtained by Ficoll density centrifugation. Frozen 
cells from AML patients were obtained under specific biospecimen banking protocols 
at Memorial Sloan Kettering after informed consent and research authorization.   
 
RESULTS 
 
Pr20 binds to ALY/HLA-A2 complexes in PRAME/HLA-A2 expressing 
leukemias 
TCRm clones reactive with ALY/HLA-A2 complexes were identified through a 
phage-display library screen as described previously 43. We aimed to identify a TCRm 
antibody that recognized ALY/HLA-A2, but not HLA-A2 alone or in complex with 
irrelevant HLA-A2-binding peptides. Briefly, single phage clones selective for the 
ALY/HLA-A2 complex were picked by a positive panning strategy on in vitro-folded 
ALY/HLA-A2 monomers and a negative panning against RHAMM-R3/HLA-A2 
irrelevant peptide control monomers. Specificity of phage clones was further screened 
on live cells using the TAP-deficient HLA-A2+ T2 cells, (which have low levels of 
endogenously presented HLA-A2 peptides) pulsed with or without ALY or an 
irrelevant peptide. A more detailed description of phage-display library panning, 
positive clone screening, and scFv characterization can be found in the Supplemental 
Information: Methods. Four phage clones that selectively bound ALY-peptide pulsed 
T2 cells were engineered into full-length human IgG1. Pr20 IgG1 was selected as the 
lead clone after it was determined to have a low nM affinity (approximately 4-5 nM 
KD) as measured by a binding assay with HLA-A2/ALY monomers using ForteBio, 
and by Scatchard analysis of binding PRAME+/HLA-A2+ AML14 cells (Fig. 1.2). 
mAb clones Pr8, Pr17, and Pr29 were not pursued due to non-specific binding to 
HLA-A2+ healthy donor peripheral blood mononuclear cells (PBMC), lower 
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estimated affinity, or inability to bind to target cells, possibly due to subtle structural 
differences between in vitro-folded ALY/HLA-A2 and endogenously-presented 
ALY/HLA-A2. 
 
 
 
 
Figure 1.2. Pr20 exhibits a low nM affinity for ALY/HLA-A2. 
(A) A Fortebio device was used to determine the affinity of Pr20 for the target protein 
complex ALY/HLA-A2 monomer. After biotinylated ALY/HLA-A2 monomers were 
loaded (2), excess antigen was washed off and the instrument was re-equilibrated (3). 
The association phase (4) and dissociation phase (5) data are shown. (B) Scatchard 
analysis was performed on the PRAME+/HLA-A2+ AML14 cells using increasing 
concentrations of I125-Pr20. Affinity of Pr20 to the complex and avidity of Pr20 TCRm 
to AML14 was confirmed to be in the low nM range by the assays, respectively. 
Experiment in (A) was performed once and experiment in (B) was performed 2 times 
with 3 technical replicates per experiment. 
 
To determine the specificity of Pr20, T2 cells were pulsed with ALY peptide or with 
the irrelevant control EW peptide (Fig. 1.3A). Pr20 did not bind T2 cells pulsed with 
EW peptide but readily bound T2 cells pulsed with ALY peptide as measured by flow 
cytometry, demonstrating that Pr20 bound to the ALY/HLA-A2 complex and not to  
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Figure 1.3. Pr20 binds ALY/HLA-A2 complexes and PRAME+ / HLA-A2+ 
leukemia. 
Pr20 was directly labeled by conjugation to the fluorophore APC. (A) TAP-deficient 
T2 cells were pulsed overnight with 50 µg/mL of ALY peptide, irrelevant control EW 
peptide, or left unpulsed. Flow cytometry was used to determine P20 binding. (B) 
Each non-anchor residue in the ALY peptide was substituted for alanine and peptides 
were pulsed onto T2. Pr20 binding was determined by flow cytometry relative to 
native ALY peptide-pulsed T2. Cell-surface HLA-A2 was also measured by flow 
cytometry to ensure altered peptides maintained the ability to bind and stabilize HLA-
A2 compared to unpulsed T2. (C) PRAME mRNA expression was determined by 
qPCR and samples that did not amplify after 40 cycles were considered negative. (D) 
The indicated cell lines were stained with Pr20 or an isotype control antibody and 
binding was determined by flow cytometry. Surface HLA-A2 was also assessed 
compared to an isotype control. All data from (A-D) are representative of at least 3 
experiments. (E) Whole blood populations from HLA-A2+ healthy donors were 
stained with Pr20 to determine possible cross-reactivity. Representative gating 
strategy and Pr20 histogram compared to isotype control is shown and data from all 
HLA-A2+ healthy donors (n=5) is summarized. Staining was performed once 
independently for each healthy donor and an AML14 PRAME+HLA-A2+ leukemia–
positive control was included in each assay to ensure assay reliability. 
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HLA-A2 alone or an irrelevant peptide/HLA-A2 complex. To more carefully map the 
TCRm epitope, each residue on the ALY peptide was replaced with alanine (except 
the canonical anchor residues on position 2 and 10 which are important for binding to 
HLA-A2) and Pr20 binding was assessed on peptide-pulsed T2 cells (Fig. 1.3B). 
Single alanine residue substitutions on positions 5, 7, 8, and 9 reduced or abrogated 
Pr20 binding at a saturating concentration of Pr20, suggesting that Pr20 primarily 
contacted the ALY peptide’s C-terminal half (Fig. 1.3B left panel). Decrease in Pr20 
binding was not due to instability of peptide/HLA-A2 complexes as each peptide 
increased surface HLA-A2 over un-pulsed T2 cells in the assay indicating that the 
peptides complexed with and stabilized HLA-A2 (Fig. 1.3B right panel). The data 
demonstrated that specific changes to the native peptide sequence can abrogate Pr20 
binding, consistent with other reported TCRm 43,97.  
 
After the preliminary biochemical and specificity characterization, we sought to test if 
Pr20 could recognize cancer cells expressing endogenous PRAME protein. PRAME 
mRNA expression was assessed by qPCR and surface HLA-A2 expression and Pr20 
binding were assessed by flow cytometry across a panel of HLA-A2+ hematopoietic 
and solid tumor cell lines, several of which have been reported to express PRAME by 
other groups (Table 1.1 and Fig. 1.3C). Pr20 binding was readily detected in 
PRAME+/HLA-A2+ leukemia AML14, SET2, BV173 and the T cell lymphoma 
MAC2A demonstrating that Pr20 can detectably bind endogenously processed and 
presented peptides (Fig. 1.3D). Pr20 did not bind the PRAME+/HLA-A2- AML cell 
line HL60 indicating that the epitope was restricted by HLA-A2. In addition, Pr20 did 
not bind PRAME negative/HLA-A2+ tumors of various histological types including 
SKLY16 lymphoma, MDA-MB231 breast adenocarcinoma, and NCI-H2228 lung 
carcinoma. (Fig. 1.3D and Table 1.1). We detected minimal or no Pr20 binding on T, 
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B, myeloid, monocyte or neutrophil populations in whole blood taken from HLA-A2+ 
healthy donors (Fig. 1.3E). 
 
Table 1.1.  PRAME expression, Pr20 binding, and surface HLA-A2 expression on 
cancer cell lines. 
PRAME expression in a panel of cell lines was determined by qPCR and expression 
was binned into the follow groups based on relative expression to the constitutive gene 
TBP as calculated by standard 2-∆Ct method based on a standard 40-cycle qPCR: 
negative(-) = no amplification, low(+) = <0.01, medium(++) = <5, and high(+++) = 
>5. Surface HLA-A2 expression and Pr20 binding was determined by flow cytometry 
with the following bins determined by MFI relative to an isotype control. Pr20 binding 
was binned based on Pr20 MFI / Isotype MFI: negative(-) = <2, low(+) = <5, 
medium(++) = <10, and high(+++) = >10. Surface HLA-A2 was binned based on 
HLA-A2 MFI / Isotype MFI: negative(-) = <2, low(+) = <10, medium(++) = <50, and 
high(+++) = >50. 
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ity. Such Fc sugar modifications are well established as enhancing 
mAb-mediated ADCC (32–35). Pr20M’s ability to mediate ADCC in 
vitro was assessed on PRAME+ leukemia in the presence of healthy 
human donor PBMC effectors. We demonstrated that Pr20M could 
direct ADCC against PRAME+HLA-A2+ leukemia AML14, SET2, 
BV173, and lymphoma line MAC2A in a dose-dependent manner in 
vitro (Figure 2A). Pr20M did not mediate substantial ADCC against 
the PRAME+HLA-A2– HL60 leukemia or the PRAME–HLA-A2+ 
lymphoma SKLY16, confirming Pr20M specificity. To determine 
whether Pr20M would direct cytotoxicity against healthy cells, we 
performed overnight autologous killing assays on HLA-A2+ PBMCs 
in the presence of Pr20M. Pr20M did not mediate depletion of T 
cells (CD3+), B cells (CD19+), myeloid cells (CD33+), or monocytes 
(CD14+) in healthy HLA-A2+ PBMCs in vitro (Figure 2B), indicating 
the lack of toxicity to the major normal hematopoietic lineages. As 
a positive control in the same assay, PRAME+HLA-A2+ lymphoma 
cells (MAC2A) were depleted by approximately 50%.
TCRm Abs have been observed as mediating direct cyto-
toxicity using effector-independent mechanisms, such as trig-
gering caspase-mediated apoptosis (36). To investigate whether 
Pr20M mediated direct cytotoxicity, we incubated Pr20M with 
PRAME+HLA-A2+ leukemia in vitro for 48 or 72 hours and assayed 
for metabolically viable cells. Pr20M did not substantially affect 
viability or cause growth inhibition in vitro (Supplemental Figure 
2), suggesting that Pr20M does not mediate direct cytotoxicity 
and requires immune effector cells for redirected lysis.
Pr20M is therapeutically active against disseminated leukemia 
models in vivo. To determine the therapeutic utility of the afuco-
sylated Pr20M TCRm, pharmacokinetics and biodistribution were 
examined in vivo. Pr20M exhibited a blood serum pharmacoki-
netic half-life of approximately 4.5 days in C57BL/6 mice, similar 
to other reported TCRm, demonstrating that Pr20M was stable in 
vivo (Supplemental Figure 3A). This serum half-life was similar to 
that of other reported TCRm (33). Although murine PRAME pro-
tein does not contain the ALY peptide, HLA-A2 transgenic mice 
can be used for potential off-target binding and toxicity studies, as 
the HLA-A2 can present potential crossreactive murine protein–
derived epitopes that might be shared with the human proteome. 
Biodistribution studies in HLA-A2 transgenic mice showed that 
at 24 hours, there was no substantial Ab sink in any organ exam-
ined compared with isotype control Abs (Supplemental Figure 3B), 
suggesting no organ-specific or widely HLA-A2–presented murine 
peptide sequences were recognized by Pr20. While the mouse and 
human proteome are not identical, they are homologous. Taken 
together, our data suggest that Pr20 is relatively specific to the 
ALY sequence and that potential crossreactive sequences are not 
processed or presented in normal mouse tissues.
To determine whether Pr20M could be therapeutically active 
against leukemia models, B, T, and NK cell–deficient nonobese 
diabetic/severe combined immunodeficiency/IL-2 receptor gam-
ma deficient (NSG) mice (37) were xenografted with HLA-A2+/
PRAME+ human leukemias BV173 (ALL), SET2 (AML), and 
AML14 (AML), which were transduced to express GFP and lucifer-
ase. Mice were treated twice a week with 50 μg of Pr20M from day 
6 or 7 until the experiment end point. Pr20M significantly reduced 
the growth of BV173, SET2, and AML14, as measured by biolumi-
nescent imaging (BLI) (Figure 3, A–C) in vivo. In the BV173 model, 
were detected compared with an isotype control in 3 samples, and 
there was no relationship to PRAME mRNA levels as measured by 
qPCR. Several primary AMLs that had high expression of PRAME 
by mRNA did not bind Pr20, suggesting that mRNA expression 
alone was insufficient for Pr20 binding and that additional regula-
tory mechanisms are required for cell-surface presentation of the 
ALY peptide. While mRNA expression may not always equate to 
sufficient protein expression, which is required for generation of 
the ALY peptide, we pursued a detailed investigation of the ALY 
presentation process as described below.
Pr20M mediates Ab-dependent cellular cytotoxicity against 
PRAME+ leukemia. Therapeutic mAbs can mediate cytotoxicity by 
various mechanisms, including direct cytotoxicity and Ab-depen-
dent cellular cytotoxicity (ADCC), but low expression of peptide/
HLA-I epitopes can reduce activity of the TCRm. To study wheth-
er Pr20 could be cytotoxic against leukemia, we engineered an 
afucosylated Fc form of the Ab (designated Pr20M) that provides 
enhanced effector recruitment properties via increased FcR affin-
Table 1. PRAME expression, Pr20 binding, and surface HLA-A2 
expression on cancer cell lines
Cell line Tumor origin PRAME mRNA Pr20 binding Surface HLA-A2
BV173 B-ALL + + +++
AML14 AML ++ +++ +++
SET2 AML + ++ ++
THP-1 AML ++ + +
U266 Myeloma ++ + +++
MAC1 T lymphoma ++ +++ +++
MAC2A T lymphoma ++ +++ +++
SK-Mel5 Melanoma +++ + +++
SK-Mel30 Melanoma + – +
SK-Mel2 Melanoma +++ – +++
SK-Mel37 Melanoma +++ – ++
UACC257 Melanoma +++ – ++
UACC62 Melanoma +++ – +
A375 Melanoma ++ – +
SW480 Colon adenocarcinoma + – ++
B-JAB Burkitt lymphoma + – ++
SUDHL1 Lymphoma + – ++
SUDHL4 B lymphoma + – ++
PC9 Non–small cell lung + – +
NCI-H2228 Non–small cell lung – – ++
SKLY16 B lymphoma – – ++
MDA-MB231 Breast adenocarcinoma – – ++
HL60 AML ++ – –
PRAME expression in a panel of cell lines was determined by qPCR, and 
expression was binned into the follow groups based on relative expression 
to the constitutive gene TBP as calculated by standard 2–ΔCt method based 
on a standard 40-cycle qPCR: negative (–) = no amplification; low (+) = 
<0.01; medium (++) = <5; and high (+++) = >5. Surface HLA-A2 expression 
and Pr20 binding were determined by flow cytometry with the following 
bins determined by MFI relative to an isotype control. Pr20 binding was 
binned based on Pr20 MFI/isotype MFI: negative (–) = <2; low (+) = <5; 
medium (++) = <10; and high (+++) = >10. Surface HLA-A2 was binned 
based on HLA-A2 MFI/isotype MFI: negative (–) = <2; low (+) = <10; 
medium (++) = <50; and high (+++) = >50.
Downloaded from http://www.jci.org on July 24, 2017.   https://doi.org/10.1172/JCI92335
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Fc-enhanced Pr20 (Pr20M) mediates ADCC against PRAME+ leukemia 
Therapeutic mAbs can mediate cytotoxicity by various mechanisms including direct 
cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC), but low expression 
of peptide/HLA-I epitopes can reduce activity of the TCRm. To study whether Pr20 
could be cytotoxic against leukemia, we engineered an afucosylated Fc form of the 
antibody (designated Pr20M) that provides enhanced effector recruitment properties 
via increased FcR affinity. Such Fc sugar modifications are well-established to 
enhance mAb-mediated ADCC 98–101. Pr20M's ability to mediate ADCC in vitro was 
assessed on PRAME+ leukemia in the presence of healthy human donor PBMC 
effectors. We demonstrated that Pr20M could direct ADCC against PRAME+/HLA-
A2+ leukemia AML14, SET2, BV173, and lymphoma line MAC2A in a dose-
dependent manner in vitro (Fig. 1.4A). Pr20M did not mediate substantial ADCC 
against the PRAME+/HLA-A2 negative HL60 leukemia or the PRAME 
negative/HLA-A2+ lymphoma SKLY16, confirming Pr20M specificity. To determine 
if Pr20M would direct cytotoxicity against healthy cells, we performed overnight 
autologous killing assays on HLA-A2+ PBMC in the presence of Pr20M. Pr20M did 
not mediate depletion of T cells (CD3+), B cells (CD19+), myeloid cells (CD33+), or 
monocytes (CD14+) in healthy HLA-A2+ PBMC in vitro (Fig. 1.4B), indicating the 
lack of toxicity to the major normal hematopoietic lineages. As a positive control in 
the same assay, PRAME+/HLA-A2+ lymphoma cells (MAC2A) were depleted by 
approximately 50%. 
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Figure 1.4. Pr20M mediates Antibody dependent cellular cytotoxicity in vitro on 
PRAME+/HLA-A2+ leukemias and lymphoma. 
 (A) ADCC assay was performed on hematopoietic cancers, 51Cr-labeled target 
leukemia or lymphoma cells were incubated with healthy donor peripheral blood 
mononuclear cells (PBMC) at an effector:target ratio of 50:1. Pr20M or an 
afucosylated isotype control antibody was added at the indicated concentration. 
Supernatant was collected after 6 hours and scintillation counting was used to 
determine % specific lysis. Data represent at least 3 experiments for each cell line 
except SKLY16 and MAC2A (done twice). (B) Healthy donor PBMC were incubated 
overnight with 1 µg/mL of Pr20M or afucosylated isotype control. Flow cytometry 
was used to determine populations of B cells (CD19+CD3-), T cells (CD3+CD19-), 
monocytes (CD14+CD19-), and myeloid cells (CD33+CD19-). 1 representative 
analysis (n=3) is shown including a positive control to demonstrate that PBMCs in all 
assays were capable of depleting a PRAME+/HLA-A2+ lymphoma (CD19- and 
transduced with GFP). Data from HLA-A2+ healthy donor PBMC (n=3) performed 
independently are summarized and plotted. Data analyzed by paired Wilcoxon signed-
rank test. 
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TCRm antibodies have been observed to mediate direct cytotoxicity using effector-
independent mechanisms such as triggering caspase-mediated apoptosis 102. To 
investigate if Pr20M mediated direct cytotoxicity, we incubated Pr20M with 
PRAME+/HLA-A2+ leukemia in vitro for 48 or 72 hours and assayed for  
metabolically viable cells. Pr20M did not substantially affect viability or cause growth 
inhibition in vitro, (Fig. 1.5) suggesting that Pr20M does not mediate direct 
cytotoxicity and requires immune effector cells for redirected lysis. 
 
 
 
 
 
Figure 1.5. Pr20M does not mediate direct cytotoxicity or growth inhibition on  
PRAME+/HLA-A2+ leukemia. 
PRAME+/HLA-A2+ leukemia cells were incubated with the indicated concentration 
of Pr20M for 48 or 72 hours. An ATP-based viability assay (Promega – CellTiter Glo) 
was used to determine relative cell viability compared to cells incubated with an 
isotype control antibody. The assay was performed as recommended by manufacturer. 
Data is representative of 3 experiments with 3 technical replicates for each dose and 
time point. 
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Pr20M is therapeutically active against disseminated leukemia models in vivo 
To determine the therapeutic utility of the afucosylated Pr20M TCRm, 
pharmacokinetics and bio-distribution were examined in vivo. Pr20M exhibited a 
blood serum pharmacokinetic half-life of approximately 4.5 days in C57BL6 mice, 
similar to other reported TCRm, demonstrating that Pr20M was stable in vivo (Fig. 
1.6A). This serum half-life was similar to other reported TCRm99. Although murine 
PRAME protein does not contain the ALY peptide, HLA-A2 transgenic mice can be 
used for potential off-target binding and toxicity studies, as the HLA-A2 can present 
potential cross-reactive murine protein-derived epitopes that might be shared with the 
human proteome. Bio-distribution studies in HLA-A2 transgenic mice showed that at 
 
 
 
Figure 1.6. Pr20M demonstrates favorable blood pharmacokinetics and does not 
obviously accumulate in major organs in vivo. 
Pr20M was radiolabeled with 125I. (A) WT C57BL/6J mice (n=3) were injected retro-
orbitally with trace amounts (2.5 µg) of radiolabeled Pr20M. Peripheral blood was 
collected at the indicated time points, scintillation counting was used to determine 
amount of Pr20M, and % initial dose (ID) / mL is graphed. Experiment was performed 
once. (B) HLA-A2 transgenic mice were injected retro-orbitally with 2.5 µg of 
radiolabeled Pr20M (n=3 per treatment group). 24 hours later, indicated organs were 
harvested and the % injected dose/g normalized to each mouse’s % injected dose/g in 
blood is graphed. Experiment was performed once. 
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24 hours, there was no substantial antibody sink in any organ examined compared to 
isotype control antibody (Fig. 1.6B), suggesting no organ-specific or widely HLA-A2 
presented murine peptide sequences were recognized by Pr20. While the mouse and 
human proteome are not identical, they are homologous. Taken together, our data 
suggest that Pr20 is relatively specific to the ALY sequence and that potential cross-
reactive sequences are not processed or presented in normal mouse tissues.  
 
To determine if Pr20M could be therapeutically active against leukemia models, B, T 
and NK cell-deficient non-obese diabetic/severe combined immunodeficiency/IL-2 
receptor gamma deficient (NSG) mice 103 were xenografted with HLA-A2+/PRAME+ 
human leukemias BV173 (ALL), SET2 (AML) and AML14 (AML), which were 
transduced to express GFP and luciferase. Mice were treated twice a week with 50 µg 
of Pr20M from day 6 or 7 until the experiment end-point. Pr20M significantly reduced 
the growth of BV173, SET2, and AML14 as measured by bioluminescent imaging 
(BLI) (Fig. 1.7A, B, C) in vivo. In the BV173 model, Pr20M-treated mice at day 13 
had reduced leukemia burden compared to day 6 (Fig. 1.7A). In the AML14 model, 3 
out of 4 mice in the isotype-treated group succumbed to severe hind-leg paralysis by 
day 29, whereas none of the Pr20M-treated mice displayed such clinical signs. On day 
29, recurrent AML14 leukemia was examined in the bone marrow. Bone marrow 
leukemia burden was significantly reduced in mice treated with Pr20M as measured 
by flow cytometry (Fig. 1.7D). No down-modulation of HLA-A2 or the Pr20-epitope 
was detected in AML14 cells harvested Pr20M-treated mice compared to the isotype-
treated mice (Fig. 1.7E). Target down-regulation was therefore not a major mechanism 
of resistance to Pr20M in these models, confirming previously described observations 
with other TCRm therapies 104. Our data demonstrates that Pr20M has broad 
therapeutic activity against several human leukemias. 
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Figure 1.7. Pr20M is therapeutically active against ALL and AML in vivo and 
target epitope down-regulation is not a mechanism of Pr20M resistance. 
BV173 (ALL), SET2 (AML), and AML14 (AML) were transduced to express 
luciferase and GFP. NSG mice were engrafted though tail vein injection and on day 6 
or 7, mice were randomized into groups and treated with 50 µg of Pr20M twice a 
week, left untreated (control for BV173 and SET2), or treated with an afucosylated 
isotype control antibody (AML14). Tumor burden was determined by BLI for BV173 
(n=5 mice) (A), SET2 (n=5 mice) (B), and AML14 (n=4 mice) (C) once a week 
throughout the experiment and the BLI data is summarized below the images. The 
scale for day 7 and 14 for AML14 is lowered to indicate engraftment and early tumor 
growth. Total flux (photos/sec) was normalized to each mouse’s total flux on day 6 or 
7 immediately before initiation of Pr20M therapy and summarized with mean ± SEM. 
(D) Mice from the AML14 experiment were sacrificed on day 29 and bone marrow 
was harvested to determine tumor burden by flow cytometry for GFP+/HLA-A2+ 
AML14 cells. Representative plots (n=4 mice per group) are shown and data is 
summarized. (E) MFI of AML14 for HLA-A2 and Pr20 was determined by flow 
cytometry. Because Pr20M-treated mice presumably had Pr20M already bound on 
tumor cells, staining was performed by an additional Pr20 stain on all samples 
followed by a secondary PE-conjugated anti-human antibody (n=4 mice per group). 
Experiments were performed once per model. Differences were evaluated using the 
unpaired T tests on indicated times and samples. AML14 BLI data is representative of 
3 similar experiments while SET2 and BV173 BLI data is from 1 experiment each. 
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PRAME protein expression alone is not sufficient for Pr20 binding, but IFNγ can 
enhance Pr20 binding in PRAME+ solid tumors and enhance ADCC 
Interestingly, neither PRAME mRNA levels nor PRAME protein levels correlate with 
Pr20 cell surface binding. Several HLA-A2+ cancers that expressed high levels of 
PRAME, such as the melanoma cell lines SK-Mel5, UACC257, and A375, did not 
readily bind Pr20 (Table 1.1). Therefore, we hypothesized that PRAME and HLA-A2 
expression alone is necessary but not sufficient to generate the ALY/HLA-A2 
complex. Hematopoietic cells are well known to express an alternative form of the 
proteasome called the immunoproteasome58, and indeed, most PRAME positive 
leukemias bound Pr20. We hypothesized that the immunoproteasome is important for 
processing the ALY peptide. Although not highly expressed in most tissues, the 
immunoproteasome can be up-regulated by pro-inflammatory cytokines such as IFNγ 
and TNFα 60.  
 
PRAME+ melanoma cell lines SK-Mel5, UACC257, and A375, and a PRAME+ colon 
adenocarcinoma SW480, were treated with IFNγ for 72hr to induce 
immunoproteasome expression. Upon IFNγ treatment, these cell lines showed 
dramatically increased binding to Pr20 (Fig. 1.8A top panels). As IFNγ can cause up-
regulation of HLA-I, it was possible that the increased Pr20 binding was partly driven 
by increased cell surface HLA-A2. However, Pr20 binding increased far more (up to 
10 fold) than HLA-A2 (2-6 fold) (Fig. 1.8A Bottom panels), suggesting that increases 
in HLA-A2 were not the dominant cause of the increased Pr20 binding. Importantly, 
pre-treatment of the tumor cells with IFNγ led to enhanced Pr20M-mediated ADCC in 
vitro, indicating that up-regulation of the target epitope might enhance therapeutic 
utility (Fig. 1.8B). Increased Pr20 binding was not observed on several samples of 
HLA-A2+ healthy donor PBMC populations after IFNγ treatment (Fig. 1.9). PRAME 
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mRNA and protein expression did not increase after IFNγ treatment, and indeed, 
decreased slightly (Fig. 1.8C), suggesting that IFNγ-mediated regulation of PRAME 
protein expression was not the cause of increased ALY peptide presentation. Protein 
expression of the immunoproteasome subunits β1i, β2i, and β5i increased after IFNγ 
treatment (Fig. 1.8D) possibly leading to enhanced generation of the ALY peptide.  
 
The immunoproteasome catalytic subunit β5i is important for IFNγ-mediated 
regulation of Pr20 binding 
We hypothesized that IFNγ could enhance generation of the ALY peptide by altering 
the proteasome components. To determine if increased Pr20 binding was due to 
immunoproteasome up-regulation, we generated CRISPR knockouts of each 
immunoproteasome subunit in the SK-Mel5 melanoma. After knockout by Cas9, β1i, 
β2i, and β5i were not measurable by western blot analysis compared to a vector 
control (Fig. 1.10A). The immunoproteasome subunit knockouts were treated with 
IFNγ for 72 hours and Pr20 binding was assessed by flow cytometry (Fig. 1.10B). β5i 
knockout led to significantly less Pr20 binding, demonstrating that β5i plays an 
important role in IFNγ-mediated  processing  of  the  ALY  peptide  epitope.  CRISPR 
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Figure 1.8. Melanomas and other solid tumors do not readily bind Pr20, but 
treatment with IFNγ induces immunoproteasome expression and dramatically 
increases Pr20 binding. 
(A) HLA-A2+ melanomas and a colon adenocarcinoma that expressed PRAME by 
qPCR (Table 1) were either left untreated (blue) or treated with 10 ng/mL of IFNγ for 
72 hours (red) and stained with Pr20 compared to untreated cells stained with an 
isotype control antibody (grey). HLA-A2 staining was performed in parallel. Data 
represents 3 independent experiments. (B) Melanomas were pre-treated with 10 ng/mL 
IFNγ for 72 hours or left untreated before 51Cr-ADCC assay was used to determine 
specific lysis by Pr20M. Samples were assayed in 3 technical replicates and data is 
representative of 3 experiments per cell line. (C) PRAME expression after 72 hours of 
IFNγ treatment was also measured by qPCR and western blot analysis. qPCR data was 
analyzed by unpaired T test and is representative of 3 experiments with 3 technical 
replicates per experiment where mean ± SEM are plotted. Western blot data is 
representative of 3 experiments. (D) The expression of each immunoproteasome 
subunit was also determined after IFNγ treatment by western blot analysis. Data is 
representative of 3 experiments. 
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Figure 1.9. IFNγ does not induce substantial Pr20 binding in HLA-A2+ healthy 
donor PBMC populations. 
HLA-A2+ healthy donor (HD) PBMC were left untreated or incubated with 10 ng/mL 
IFNγ for 72 hours. Flow cytometry was used to determine Pr20 binding in major 
PBMC populations (T, B, myeloid, and monocyte). Gating strategy was performed as 
in figure 2B. The experiment was performed on PBMC from n=3 HLA-A2+ healthy 
donors. 
 
 
knockout of β5i yielded the same effect in UACC257, another HLA-A2+/PRAME+ 
melanoma (Fig. 1.10B Bottom Panel), and SW480, an HLA-A2+/PRAME+ colon 
adenocarcinoma (Fig. 1.11). Surface HLA-A2 expression was not affected by β5i 
knock out in the SK-Mel5 model and only minimally decreased in the UACC257 
model (Fig. 1.10B). ONX-0914, a selective inhibitor of β5i was used to provide 
orthogonal validation that the immunoproteasome is important for generation of 
ALY/HLA-A2. SK-Mel5 and UACC257 were treated with IFNγ for 72 hours with or 
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Figure 1.10. Immunoproteasome catalytic subunit β5i is important for IFNγ-
mediated Pr20 binding in melanomas and other solid tumors. 
β1i, β2i, and β5i were knocked out in the SK-Mel5 melanoma line using a CRISPR 
approach. A CRISPR construct against GFP was used as a vector control. (A left 
panel) Cells were treated with 10 ng/mL IFNγ for 72 hours and western blot analysis 
was used to demonstrate successful knock-outs. Blots were derived from replicate 
samples run on parallel gels with the GAPDH loading control shown from the β2i 
blot. (B) Flow cytometry was used to determine Pr20 binding and surface HLA-A2 on 
the indicated knock-outs (sgRNA against β1i, β2i, and β5i) untreated or treated with 
IFNγ for 72 hrs. (B top panels) Data is normalized to MFI of untreated GFP sgRNA 
CRISPR control. (B lower panels) β5i CRISPR knock-out experiments were 
performed in the same manner on the UACC257 melanoma line. Successful knock-out 
was determined by western blot (A right panel) and Pr20 binding and surface HLA-A2 
was determine by flow cytometry (B lower panel). (C) SK-Mel5 and UACC257 cells 
were left untreated or treated with 10 ng/mL IFNγ for 72 hours in the presence or 
absence of 200 nM of the β5i inhibitor ONX-0914. Flow cytometry was used to 
determine MFI relative to untreated cells. All data are representative of 3 experiments 
with 3 technical replicates per experiment and mean ± SEM plotted. Statistical 
significance was determined by unpaired T test compared to control. 
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without the presence of ONX-0914. ONX-1014 was used at 200 nM, a concentration 
reported to have potent biochemical inhibition of β5i but minimal inhibition of other 
proteasome catalytic subunits 59. As expected, cells treated with ONX-0914 had 
reduced Pr20 binding compared to cells treated with IFNγ alone (Fig. 1.10C). Taken 
together, our data suggest the shift from the constitutive proteasome to the 
immunoproteasome is an important mechanism for increased epitope presentation and 
Pr20 binding. Furthermore, SK-Mel5 cells treated with bortezomib alone, a potent 
inhibitor of the constitutive proteasome β5 subunit and to a lesser extent the β1 subunit 
105, did not substantially alter binding to Pr20 at doses that were not cytotoxic.  We 
also explored the use of demethylating agents in an attempt to increase the level of 
PRAME protein expression and thereby possibly peptide epitope on the surface. We 
observed only modest increases in Pr20 binding after decitabine treatment (Fig 1.12). 
 
 
The constitutive proteasome mediates internal destructive cleavage of the ALY 
peptide 
Proteasomal degradation can regulate the generation of a specific HLA-I associated 
peptide through enhancing the required N or C-terminal cleavages, or through 
reducing destructive internal cleavages. Several tumor-associated antigens exhibit 
restriction to the immunoproteasome because the peptide is largely destroyed by the 
constitutive proteasome and thus intact peptide cannot be presented 61,63. To elucidate 
the differing proteolytic mechanisms between the constitutive and immunoproteasome 
involved in generating increased ALY peptide epitope on the surface, an elongated 20-
mer ALY-precursor peptide was synthesized with 5 residues extending from each 
terminus (PRAME295-314). The ALY-precursor peptide was incubated with either 
purified constitutive proteasome or immunoproteasome in vitro and digest fragments 
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Figure 1.11. β5i knock-out by CRISPR abrogates IFNγ-mediated Pr20 binding in 
colon adenocarcinoma SW480.  
CRISPR constructs against the immunoproteasome subunit β5i or the irrelevant GFP 
was generated and transduced as described in figure 4. (A) Western blot analysis was 
used to confirm successful knock-out. (B) SW480 cells transduced with the CRISPR 
construct against β5i or GFP were treated with 10 ng/mL IFNγ for 72 hours and Pr20 
binding and surface HLA-A2 expression was measured by flow cytometry. 
Normalized %MFI is plotted with and without treatment. Experiment was performed 3 
times with 3 technical replicates per experiment. Mean ± SEM are plotted from one 
representative experiment. Differenced analyzed by unpaired T test. 
 
were analyzed by mass spectrometry. The major detectable fragments were then 
mapped to specific cleavage sites. Of the detected major digest fragments, the 
immunoproteasome had increased ratio of non-destructive / destructive cleavages in 
the ALY sequence (Fig. 1.13A), while the immunoproteasome maintained                
the intact ALY 10-mer. In addition, the immunoproteasome catalyzed a major                    
cleavage site after Q296 and L298 (LQ/CLQALYVDSLFFLRGRLD and 
LQCL/QALYVDSLFFLRGRLD) 1 and 3 residues N-terminal to the ALY 10-mer 
(Fig. 1.13B). Such cleavage may prime the peptide for amino-peptidase trimming.       
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Figure 1.12. Decitabine increases Pr20 binding in vitro. 
SET2 and AML14 cells were treated with the indicated dose of decitabine or DMSO 
vehicle for 72 hrs. Due to decitabine instability at 37° C, media with decitabine was 
replaced daily. Flow cytometry was used to determine MFI of Pr20 and HLA-A2 
relative to DMSO vehicle control. Experiments were performed twice with SET2 and 
once with AML14. 
 
 In contrast, the constitutive proteasome mediated a major destructive                     
cleavage site after A300 (LQCLQA/LYVDSLFFLRGRLD) and after V303 
(LQCLQALYV/DSLFFLRGRLD). Our analysis demonstrates that the relative 
cleavage after the C-terminal L309 (LQCLQALYVDSLFFL/RGRLD) was 
comparable between constitutive and immunoproteasome, suggesting that C-terminal 
cleavage of the ALY peptide was not a major mechanism of immunoproteasome 
restriction (Fig. 1.13B). An N-terminal cleavage after the Q299 
(LQCLQ/ALYVDSLFFLRGRLD) was not a major cleavage site for either 
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proteasome form. The major differences in cleavage specificities between the 
constitutive and immunoproteasome on the precursor peptide is schematized (Fig. 
1.13C). Taken together, the biochemical data show that the immunoproteasome 
enhances generation of the ALY 10-mer peptide through decreased internal 
destructive cleavage and increased N-terminal upstream cleavage, relative to the 
constitutive proteasome. 
 
DISCUSSION 
Immunotherapy has demonstrated potent clinical utility for several cancers. However, 
successful therapy would be improved by use of targets that are cancer-selective to 
minimize toxicity to essential healthy tissue. Although highly selective onco-fetal or 
cancer-testis tumor-associated antigens have been described, most are intracellular 
proteins that cannot be targeted by small molecule inhibitors or by using antibodies 
directed at cell-surface targets. Furthermore, most of these tumor antigens, such as 
PRAME, have context-dependent function and are not necessarily oncogenic. Thus, 
functional inhibition may not offer therapeutic benefit. Several groups have studied 
TCR-transgenic T cells specific against intracellular tumor-associated antigens, but 
this strategy has been limited due to challenges of large-sale manufacturing and safety 
concerns of the transgenic TCR recombining with the native TCR generating unknown 
specificity and possible auto-immune reactivity 53. Recently described ‘ImmTAC’ 
molecules use a TCR-based recognition domain offering similar reactivity to TCRm 
antibodies, and also demonstrate high affinity 106. TCRm antibodies such as Pr20 can 
target these ‘undruggable’ proteins with high affinity for redirected immune mediated 
cytolysis.   
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Figure 1.13. The Immunoproteasome catalyzes increased non-destructive 
cleavages on an ALY-precursor peptide. 
A 20-mer ALY-elongated precursor peptide was incubated with purified constitutive 
proteasome or immunoproteasome for the indicated times. (A) All detectable 
fragments and their respective ion intensities were assigned to be “non-destructive” or 
“destructive” depending on if the N or C-terminal cleavages required to generate that 
fragment would have resulted in destruction of the ALY 10-mer. Ratios of ion 
intensity sums for “non-destructive/destructive products” are plotted. (B) Major 
cleavage sites along the precursor peptide after 1 hr were mapped by summing the ion 
intensities of each fragment resulting from a cleavage after the specific residue. Heat 
map with arbitrary units corresponding to ion intensities is shown, with 3 replicates 
illustrated in 3 bars for each proteasome preparation. Only fragments identified to be 
at least 2 residues or more could be mapped and thus cleavages before Q296 or after 
L313 were not accounted for. (C) Major differences in cleavage specificity between 
constitutive and immunoproteasome are schematized and mapped by red arrows. The 
green arrow denotes the canonical proteasomal cleavage to generate the C-terminal 
end of the ALY 10-mer. Data are from three technical replicates per experimental 
condition with mean ± SEM plotted. Groups compared using multiple T tests. 
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Pr20 specificity analyses were consistent with binding to the ALY peptide primarily 
on the C-terminal half amino acids at positions 5-9. However, because minimal 
contact residues were predicted in the N-terminus, we cannot exclude the possibility of 
cross-reactive peptide/HLA-A2 epitopes in the exome that share high C-terminal 
homology to ALY. Whether other theoretical peptide epitopes in the exome are 
expressed and processed appropriately in normal tissues is difficult to explore. The 
data shown here suggest that if potential cross-reactive peptides in the human exome 
are expressed, properly processed, and sufficiently presented, they are infrequent. 
Peptides have specific processing requirements including not only proteasomal 
degradation, but also aminopeptidase and oligopeptidase processing 107 which likely 
limit generation of cross-reactive epitopes. In addition, potential cross-reactive 
peptides may lack high affinity to HLA-A2 and thus will not form stable 
peptide/HLA-A2 complexes at the cell surface. Pr20 did not bind PRAME-
negative/HLA-A2+ cells and did not bind more than a dozen other HLA-A2+ tumor 
lines, suggesting there were no broadly-presented cross-reactive peptides. In addition, 
Pr20 did not bind to or accumulate in any major organ in HLA-A2 transgenic mice, 
nor bind to normal human blood cell populations in healthy HLA-A2+ donors. Taken 
together, the data suggests that cross-reactive epitopes presented on HLA-A2 are non-
abundant. Importantly, such off-targets are not increased in normal cells after IFNγ 
treatment. 
 
The afucosylated Pr20M demonstrated therapeutic efficacy in vivo. Interestingly, at 
the experimental end-point, Pr20 binding to AML14 in Pr20M-treated mice was 
significantly higher than in AML14 in isotype-treated mice. This is intriguing because 
first, it shows that target down-regulation is not a mechanism of tumor escape in this 
model; and second, it also suggests that cellular interactions during Pr20M therapy 
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may increase epitope expression on target cells. This may be due to cytokines released 
by immune effectors during ADCC, as observed with other therapeutic antibodies 
16,108. It is important to note that the NSG mouse xenograft poorly models the human 
effector populations and the cytokine milieu that would be produced in a patient. In 
addition, because HLA-I is well characterized to be regulated by inflammatory 
cytokines and TCRm targets are presented in complex with HLA-I, it is possible that 
TCRm targets are regulated in a ‘feed-forward’ system where TCRm-mediated 
cytolysis leads to local cytokine release and increased target expression on 
neighboring tumor cells. Human IgG1 also has different affinities to mouse FcR and 
human FcR, and NSG mice lack functional NK cells and have defective macrophages 
and dendritic cells. Therefore, lack of and poorly functional effector cell populations 
in this model may limit efficacy of a TCRm which requires immune effectors for 
ADCC 104 which may in part explain the lack of tumor eradication and relapse within 
weeks. It is reasonable to hypothesize that TCRm therapy in an immunocompetent 
patient or model would demonstrate more potent therapy. To better understand the 
incomplete responses to the therapy in vivo, we tested whether combination of Pr20M 
antibody therapy with a second therapeutic TCRm antibody directed to an unrelated 
epitope also found on the target cells, would increase therapeutic effects (Fig. 1.14). 
This would yield more than double the target epitope numbers on each cell (based on 
radio-immunoassays to quantify TCRm epitope sites) and also rule out the issue of 
leukemia escape by down-regulation or loss of the PRAME epitopes from the 
leukemia cells. No significant improvement in leukemia control was demonstrated in 
these experiments, further bolstering the argument that lack of effector cell function 
and effector cell numbers were the critical deficiencies, not lack of (or loss of) target 
PRAME epitopes on the leukemia. 
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Figure 1.14. Pr20M and an additional TCRm (ESKM) are not additive in TCRm 
therapy in vivo. 
NSG mice were engrafted with 0.5x106  SET2 cells (AML) or 3x106  BV173 cells 
(ALL) through tail vein injection. On day 6, mice were randomized into groups of 5. 
Mice were treated on day 6, 10, 13, and 17 after engraftment with 50 µg of Pr20M 
alone, 50 µg of ESKM (a TCRm against a peptide from WT1) alone, or Pr20M and 
ESKM in combination. Control mice were left untreated and tumor burden was 
assessed by bioluminescent imaging on the indicated days. Mean group BLI ± SEM is 
shown. BLI data was not significantly different on day 20 or 29 for either SET2 or 
BV173 models between the the ESKM + Pr20M combination group versus the ESKM 
alone or Pr20M alone (unpaired t-test). Experiment was performed once in the BV173 
model and once in the SET2 model. 
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Generating an immunocompetent syngeneic mouse model in which to test these agents 
is difficult because murine PRAME does not comprise the human ALY peptide, which 
would have to be introduced genetically along with use of mice with transgenic human 
HLA-A2. It is also unknown if the ALY peptide can be properly cleaved and 
processed by the murine antigen presentation machinery and presented on transgenic 
HLA-A2 molecules. Co-infusion of human immune cell populations into NSG mice 
may provide an alternative model for effector cells and cytokines in these mice, but 
also leads rapidly to graft-versus-host disease and graft versus leukemia activity 
complicating the analysis, as seen in previous studies 43. 
 
Binding studies demonstrated that Pr20 robustly bound to several PRAME+/HLA-
A2+ leukemias and lymphomas cell lines, but did not bind well to a small sample size 
(n=9) of previously frozen PRAME+/HLA-A2+ primary AML. This is consistent with 
the lack of binding to several PRAME+/HLA-A2+ cancer cell lines. Our data 
demonstrates that PRAME and HLA-A2 expression alone is necessary, but 
insufficient for Pr20 binding. It is also important to note that the number of ALY 
peptide epitopes presented on HLA-A2 is highly limited (estimated at less than 0.1% 
of the HLA molecules on the surface based on Scatchard analyses) and may be below 
the detection limit of the flow cytometry assay with Pr20 in some cells. It is also 
possible that low epitope presentation is undetectable with our assays yet sufficient to 
initiate redirected lysis, however this could not be reliably studied with frozen primary 
AML samples. 
 
Pr20 did not initially bind several PRAME+/HLA-A2+ melanomas and other solid 
tumors despite high levels of PRAME expression, but Pr20 binding dramatically 
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increased upon treatment with IFNγ, which was partially mediated by increases in the 
immunoproteasome β5i expression. β5i is well-characterized to have chymotrypsin-
like enzymatic activity, cleaving after hydrophobic amino acids 56. However, the 
specificity is complex and not fully understood. For instance, β5i cleavage can be 
inhibited by the presence of an additional hydrophobic residue directly C-terminal of a 
site as demonstrated in vitro using the enolase-1 protein as a model substrate 109. IFNγ 
decreased PRAME protein expression, which may be caused by decreased mRNA 
expression but may also be due to differing kinetics of the immunoproteasome. Using 
a biochemical digestion assay in vitro, we demonstrated that the immunoproteasome 
cleaves and yields a presentable ALY-precursor peptide more efficiently then the 
constitutive proteasome. ALY peptide precursors generated through proteasomal 
digestion in vitro have been described 84, however direct comparison between 
constitutive proteasome and immunoproteasome on digestion of the ALY peptide has 
not been studied. The constitutive proteasome catalyzed a major destructive cleavage 
site after the first A300 of ALY (LQCLQA/LYVDSLFFLRGRLD), whereas the 
immunoproteasome did not, possibly due to inhibition by the adjacent hydrophobic 
leucine. In addition, the immunoproteasome better catalyzed cleavages slightly N-
terminal to the ALY peptide. Minor N-terminal elongated intermediate peptide may 
prime the peptide for amino-peptidase trimming into the ALY 10-mer; however, this 
was not studied. The knowledge of target presentation has broad implications when 
designing peptide vaccines, TCR, and TCRm antibodies for determining which tumors 
may respond best to these therapies. In addition, checkpoint blockade therapy, which 
has demonstrated effective clinical utility, relies on tumor-antigen presentation and 
CTL recognition to direct tumor cell lysis. Therefore, understanding the biochemical 
mechanisms of immunogenic peptide generation and presentation is critical for 
designing checkpoint blockade strategies and determining ideal tumor targets. Our 
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data suggest that tumors expressing the immunoproteasome such as leukemia and 
lymphomas would better respond to immunotherapies against ALY/HLA-A2 and that 
other cancer types may need pharmacologic up-regulation of the immunoproteasome 
in conjunction to make the immunotherapy effective. 
 
Pr20 binding requires peptide presentation in the context of HLA-A2, and thus 
strategies to enhance HLA-A2 expression may also augment Pr20M-mediated therapy. 
It will be important to discover pharmacological modulators of HLA-I that can be used 
for combination therapy with TCRm antibodies or other HLA-I-based 
immunotherapies. For example, recent reports demonstrate that inhibition of MEK can 
increase cell-surface HLA-I which may enhance TCRm antibody therapy 110. 
Additionally, several pharmacological agents that target histone-modifying enzymes 
such as methytransferase inhibitors and histone deacetylase inhibitors can induce 
expression of tumor-associated antigens including PRAME, and lead to enhanced 
cytolysis by effector T cells 111–113. It would be important to understand if these agents 
could enhance antigen expression and synergize with TCRm therapy. However, these 
epigenetic drugs can also have context-dependent effects on immune cell function and 
therefore must be evaluated carefully to ensure they do not also inhibit the effector 
cells required for TCRm-mediated cytotoxicity 112,114. 
 
Our data demonstrate the ability to target PRAME with a TCRm antibody. This 
approach enables us to target intracellular proteins to which the generation of small 
molecule inhibitors is not possible. TCRm allow access to a new universe of antibody 
protein targets, far larger and more tumor-specific than the currently available cell-
surface protein targets. They also bypass the patient-specific limitations of CTL-based 
therapies. Only a few TCRm have been studied in pre-clinical models as agents for 
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cancer therapy 43,50,97,102,115–117. Therefore, the present study on Pr20 adds additional 
proof-of-concept that TCRm can be potent and selective therapeutic agents. Finally, 
due to the well-characterized mAb format of TCRm, they can be readily engineered 
into alternative formats such as Fc-enhanced forms, as shown in this study, bispecific 
T cell engager 89,118 forms (BiTE), as done with a TCRm to WT1, or transduced as a 
chimeric antigen constructs (CARs) in T cells 91,92. These additional formats may be 
required for effective targeting of these ultra-low density targets. 
Radioimmunoconjugates 119 and antibody-drug conjugates may also be explored in the 
context of TCRm in an effort to enhance potency against cancer cells. 
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CHAPTER II: ENHANCING THERAPEUTIC EFFICACY OF TCRm 
THROUGH CD47/SIRPα BLOCKADE AND ENGINEERED BiTE AND CAR T 
CONSTRUCTS*,† 
 
INTRODUCTION 
 
CD47/SIRPα Signal Axis in Phagocytes and the SIRPα-variant CV1 
Our data prove the concept that an antibody-based construct can therapeutically target 
the ALY/HLA-A2 complex on cancers. However, a major limitation of TCRm 
antibodies is that the epitope density is far lower than traditional antibody targets and 
have been estimated to be as low as approximately 200-1000 sites per cell43,50. This 
may limit therapeutic efficacy especially when immune effector mechanisms are 
critical for activity. Indeed, our data demonstrates that although Pr20M has therapeutic 
activity (Fig 1.7), leukemia-bearing mice treated with Pr20M do not have deep 
regressions and ultimately have progressive disease. Therefore, we hypothesized that 
therapy could be augmented using strategies to enhance immune effector activity such 
as CD47 axis blockade. CD47 is a transmembrane protein found on all cells and serves 
as a ‘do not eat me’ signal for phagocytes such as macrophages and dendritic cells. 
CD47 binds to SIRPα on phagocytes which signals through intracellular 
immunoreceptor tyrosine-based inhibitory motifs (ITIMs) to recruit and activate 
phosphatases SHP-1 and SHP-2120. This leads to inhibition of macrophage activation 
 
* Modified from Mathias M, Sockolosky J, Chang AY, Tan K, Liu C, Garcia KC, 
Scheinberg D. CD47 Blockade enhances therapeutic activity of TCR mimic antibodies 
to ultra low density cancer epitopes. Leukemia. 2017 DOI:10.1038/leu.2017.223 
 
† Some experiments were designed and conducted by or in collaboration with 
Jonathan Sockolosky at Stanford University (Fig. 2.1) and Melissa Mathias (Fig. 2.3). 
The Pr20-BiTE and Pr20-CAR constructs were made by Eureka Therapeutics. 
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in addition to inhibition of myosin elements and therefore prevention of phagocytic 
engulfment121. Several studies have demonstrated that CD47 blockade can be effective 
as cancer therapy especially when used in combination with antibodies that promote 
ADCP88,122. Based on these and other preclinical data, anti-CD47 mAbs have entered 
early stage clinical trails123. However, CD47 blockade using mAb or Fc-fusion protein 
approaches has also demonstrated substantial toxicity to healthy red blood cells 
leading to anemia, hypothesized to be caused by Fc engagement of the antibody 
despite an IgG4 isotype124. Instead, the Garcia group at Stanford University developed 
a high-affinity soluble SIRPα-variant called CV1 which lacks an Fc portion and does 
not cause anemia in mouse models125. CV1 has also demonstrated potent synergy with 
traditional mAb therapy such as Rituximab124. We therefore hypothesized that 
combination therapy of Pr20M with CV1 would lead to enhanced Pr20M-mediated 
ADCP and therefore substantially enhanced therapy.  
 
It is also important to note that CD47 has additional functionality and is not just a ‘do 
not eat me’ signal for phagocytes. CD47 also binds the ligand thrombospondin-1 
(TSP-1). Although context and cell type dependent, CD47 engagement can trigger 
apoptosis in some cell types through an interaction of the cytoplasmic tail of CD47 
with BNIP3 pro-apoptotic BH3 domain protein126. In fact, CD47 knockout cells have 
demonstrated remarkable advantages in self-renewal126. In addition, CD47 had 
implicated roles in regulating mitochondria-dependent death pathways and 
autophagy126,127. These cell-intrinsic functions are important to understand and 
consider when utilizing CD47 blockade immunotherapy to ensure that strategies 
promote tumor cell death and not tumor-protective effects.  
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Bispecific Antibodies 
Whereas naturally produced antibodies are canonically multivalent but clonally mono-
specific, mAbs can be generated or engineered with multiple specificities. The most 
common and well studied for cancer therapy is the bispecific antibody. These consist 
of several formats but are broadly grouped into bispecific IgG (BsIgG) or bispecific 
antibody fragments (BsAb fragments)1,128. The major benefit of bispecific antibodies 
is that each molecule can engage two unique targets at once allowing for novel 
antibody functionality. This can include dual blockade of two receptors, fine-tuning of 
targeting only cells expressing dual epitopes, and redirected immune engagement not 
possible with natural antibodies129. The concept of bispecific antibodies has been 
demonstrated since 1961128, however technologies to generate bispecific antibodies on 
a commercially feasible scale were not available till more recently. A major challenge 
of generate BsIgG is chain mispairing during co-expression of 2 light chains and 2 
heavy chains in the same cell, leading to low yield of desired BsIgG and challenges to 
purifying the BsIgG from the mis-paired contaminants. Undesired heavy chain 
homodimers and light chain mispairing with non-cognate heavy chains can generate 9 
theoretical undesired IgG products in addition to the desired BsIgG128. Innovative 
engineering approaches have allowed more efficient generation of BsIgG using 
strategies such as ‘knob-in-hole’ where a ‘knob’ mutation disfavors homodimerization 
and favors heterodimerization of a corresponding ‘hole’ mutation128,130. Other 
strategies include rationale electrostatic mutations as well as Fab arm exchange 
through processes such as the biochemical phenomenon of split inteins128,131. 
 
BsAb fragments are a class of bispecific antibodies that lack full antibody constant 
regions. Although several iterations of BsAb fragments have been generated, the most 
common consist of heavy and light chains connected through a short peptide linker. 
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The linker promotes inter-chain pairing and prevents intra-chain pairing of VH and VL 
domains such that 2 scFv chains can be co-expressed in a cell to produce a bispecific 
fragment called a diabody. Another common BsAb fragment design is a tandem scFv. 
Two scFv’s are linked through a linker region allowing dual specificity to be encoded 
on one polypeptide chain. This construct is the basis of the bispecific T cell engager 
(BiTE) designed to redirect T cells as discussed following. 
 
Bispecific T cell Engager (BiTE) Molecules  
An additional method to improve potency of Pr20 is through adaptive the targeting 
moiety of the Pr20 mAb scFv to more potent biologic formats. The Bispecific T cell 
engager (BiTE)90,132 construct is a powerful biologic agent that has recently reached 
clinical approval with the anti-CD19xanti-CD3 Blinatumomab (Amgen) which 
demonstrated significant responses and complete remission in 43% of adult patients 
with relapsed refractory cell acute lymphocytic leukemia disease3,132. BiTEs are 
antibody-based single-chain protein constructs composed of a tumor-antigen targeting 
scFv moiety linked to an anti-CD3 scFv moiety. The molecular weight of a BiTE 
molecule is approximately 55 kDa. The BiTE design allows engagement of a target 
tumor cell with the CD3 molecule of T cells. Upon engagement, BiTEs force target 
cell and T cells into extremely close proximity resulting in an immune synapsing, 
downstream CD3 signaling, and ultimately T cell activation, target cell lysis, and T 
cell proliferation90,133. This is unique to the natural T cell response because BiTEs 
bypass the need for peptide/MHC-specific priming through antigen presenting cells 
and therefore can redirect a polyclonal T cell response irrelevant of a T cell’s 
endogenous specificity for peptide/MHC. In xenograft studies, BiTEs could potently 
redirect human T cells for tumor lysis without the need for additional co-
stimulation134, a required process of the natural T cell response. Additionally, whereas 
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mAbs typically harness innate immune effectors such as NK cells and macrophages, 
BiTEs can engage any T cell (the most abundant lymphocyte population) against the 
tumor, providing a much larger pool of immune effector cells. In addition, BiTEs can 
induce a phenomenon of epitope spreading whereby the activation of the polyclonal 
pool of T cells through the BiTE has been reported to induce a response to 
independent tumor antigen peptide/MHC targets89. This response may be through 
reactivation of inhibited or exhausted T cell after BiTE reactivity.  
 
Although BiTEs have demonstrated functional potency and therapeutic benefit, they 
have challenges for their clinical use. These fusion proteins typically have a very short 
half-life of only a few hours in the serum133. This is owed to the lack of a Fc region 
and therefore BiTEs cannot undergo the process of neonatal Fc receptor (FcRn)-
mediated recycling133. The extremely short half-life makes dosing BiTEs a 
cumbersome process and currently BiTEs are administered through continuous 
intravenous infusion pumps133. In addition, cytokine release associated with T cell 
engagement presents a concern for side effects. As a precaution, BiTEs are currently 
administered along with dexamethasone, a glucocorticoid that can mitigate 
inflammation-related side effects133. 
 
Similar to BiTEs, bispecific killer cell engagers (BiKEs) are also a single-chain 
protein construct that uses an scFv against a tumor antigen linked to a scFv against 
CD16, the activating FcR found on NK cells135. Instead of engaging T cells, BiKEs 
engage NK cells with higher affinity than an antibody allowing BiKEs to function 
even when NK cells express low levels of CD16 as in myelodysplastic syndrome 
patients135. They can also be engineered into a novel trispecific killer cell engager 
(TriKE) construct consisting of the BiKE with an added arm to stimulate the IL15 
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receptor on NK cells promoting NK cell activation, proliferation, and serial 
killing136,137. 
 
Chimeric Antigen Receptor T cells (CAR T) 
Chimeric antigen receptor T cell (CAR T)138 constructs are powerful biologic agents 
that have recently reached clinical approval and have demonstrated significant 
responses in patients138,139. Current CAR T cells are a form of cellular therapy where 
an artificial receptor is transduced into T cells containing an extracellular targeting 
moiety composed of a scFv and an intracellular signaling moiety typically composed 
of the CD3ζ chain and either CD28 or 41BB co-stimulatory domains139. Upon target 
cell engagement, the CAR mediates activation and phosphorylation of CD3ζ, 
recruitment of ZAP70, and subsequence T cell activation and ultimate cytotoxicity139. 
CAR T cells have only recently gained FDA approval status but has already 
demonstrated robust and meaningful clinical outcomes in hematological malignancies.  
Clinically approved CAR T cells include the anti-CD19 CAR	 Tisagenlecleucel140 
(Novartis) for the treatment of refractory B cell lymphoblastic leukemia in pediatric 
and young adult patients and another anti-CD19 CAR Axicabtagene ciloleucel141 (Kite 
Pharma) for treatment of adults with a specific type of B cell non-Hodgkin’s 
lymphoma. 
 
It is important to appreciate the history of CAR T cell technological development 
because it represents a paradigm-shift in cellular therapy and what is considered a 
‘drug’. Indeed in 2017, CAR T cells made history as the first FDA-approved gene 
therapy but the technology to make CAR T cells required decades of work and the 
cumulative advances in basic understanding and engineering in several fields –
virology, immunology, molecular biology. First generation CAR T cells were reported 
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in 1989 as a construct consisting of an scFv targeting domain, a transmembrane 
domain, and the CD3ζ signaling domain (signal 1)142. Although these constructs 
proved the concept that T cells could be endowed with a novel specificity, they had 
limited efficacy in clinical trials, believed to be due to activation-induced cell death 
and limited expansion143,144. Second generation CAR T cells mitigated this through the 
addition of a co-stimulatory domain (signal 2) to the CAR cytoplasmic tail such as 
CD3ζ-CD28 or CD3ζ-41BB. Third generation CAR T cells combine multiple co-
stimulatory domains on the CAR cytoplasmic tail such as CD3ζ-CD28-41BB or 
CD3ζ-CD28-OX40, to augment potency139. Excitingly, new generations of ‘armored’ 
CAR T cells are further engineered to secrete cytokines or express functionally active 
ligands145. For example, The Brentjens group at Memorial Sloan Kettering has 
developed an armored CAR constitutively secreting the cytokine IL-12. The IL-12 
secretion dramatically improved anti-tumor efficacy and could overcome the tumor 
microenvironment in mouse models146. 
 
Like mAbs, current FDA-approved BiTEs and CARs only target cell-surface receptors 
namely CD19 in B cell leukemias and lymphomas147. However, because BiTEs and 
CARs utilize scFv as the targeting moieties, the scFv of a TCRm antibody could be 
grafted into a BiTE or CAR vector to generate these T cell-redirecting biologic agents 
against peptide/MHC-I targets. Indeed this has been studied pre-clinically for a select 
few TCRm constructs91,92,148–150. Although a TCRm-CAR may have similar specificity 
for peptide/MHC-I as a TCR-transduced T cell, the engineered intracellular signaling 
moieties in a CAR T cell provide them with biochemically unique activation abilities 
due to coupled activation and co-stimulatory signals. This is thought to benefit the 
CAR activation, function, and persistence139 compared to TCR transduced T cells.  
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We hypothesize that rational combination therapy of Pr20M with CV1 to enhance 
macrophage-mediated ADCP would augment therapeutic efficacy compared to either 
agent alone in animal models of leukemia. We also hypothesize that engineered Pr20-
BiTE and Pr20-CAR constructs would lead to enhanced redirected cytotoxicity and 
robust therapeutic efficacy. 
 
MATERIALS AND METHODS 
 
Antibody Dependent Cellular Phagocytosis (ADCP) Assays 
Human and mouse macrophage-mediated antibody-dependent cellular phagocytosis 
(ADCP) assays were performed as follows.  Human blood was obtained from the 
Stanford Blood Center using IRB approved protocols and monocytes were isolated via 
CD14 positive selection (Miltenyi) and magnetic isolation. Recovered CD14+ 
monocytes were plated at a density of 10,000,000 monocytes per 150 mm TC treated 
dishes in IMDM + GlutaMAX media (Gibco) supplemented with 10% human serum 
and 1% P/S and cultured for 7 days at 37 °C to yield human monocyte derived 
macrophages (MDMØ). Phagocytosis assays were repeated in duplicate. 
Mouse macrophages were derived from bone marrow (BMDMs).  Mouse bone 
marrow cells were flushed with a syringe from the tibia and femurs of NSG mice into 
IMDM + GlutaMAX supplemented with 10% FBS and 1% P/S.  Cells were collected 
by centrifugation followed by RBC lysis with ACK buffer for 3 – 5 mins (Gibco), 
quenched with complete media, and filtered through a 70 µM cell strainer.  Cells were 
pelleted by centrifugation, re-suspended in media containing 10 ng/mL M-CSF 
(Peprotech) and plated on 3 x 10 cm untreated petri dishes per mouse in 10 mL media 
and cultured for 7 days without replenishing or changing media to derive BMDMs. 
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To quantify macrophage-mediated ADCP, tumor cells were harvested, labeled with 
carboxyfluorescein succinimidyl ester (CFSE), washed with serum free IMDM + 
GlutaMAX, and plated at a density of 100,000 cells/well in 25 µL in a 96-well ultra 
low attachment round bottom plate (Costar, Cat. 7007) on ice.  Tumor cells were 
opsonized by addition of 25 µL of various antitumor antibodies, CD47 blocking 
reagents, and/or controls for 30 min on ice.  Macrophages were harvested by 
enzymatic dissociation and cell scraping, pelleted, washed in serum free IMDM, and 
added to opsonized tumor cells at a density of 50,000 cells/well in 50 µL media for a 
final assay volume of 100 µL and an effector to tumor cell ratio of 1:2.  ADCP was 
measured after incubation for 2 hr at 37 °C with the following test groups: MØ + 
cancer cells alone, MØ + cancer cells opsonized with TCRm or control antibody alone 
(10 µg/mL mAb final), MØ + cancer cells opsonized with CV1 alone (100 nM final), 
and MØ + cancer cells opsonized with the combination (10 µg/mL mAb + 100 nM 
CV1).  Cells were then pelleted and washed with autoMACS running buffer 
(Miltenyi), and stained with a 1:100 dilution of anti-mouse F4/80-APC (Biolegend) 
for mouse BMDMs or a 1:100 dilution of anti-human CD206–Alexa647 (Biolegend) 
for human MDMØ in autoMACS buffer for 1 hr at 4 °C.  Cells were pelleted, washed, 
and re-suspended in a 1:10000 dilution of DAPI and analyzed by FACS using the 
CytoFLEX equipped with a high throughput sampler.  Phagocytosis was quantified 
gating based on SSC-A and FSC-A, singlets, live/dead (DAPI negative/low), and 
phagocytosis quantified as the percentage of F4/80-APC or CD206-Alexa647 positive 
macrophages that are also CFSE positive.  
 
Flow Cytometry 
For cell surface staining, cells were blocked using FcR blocking reagent (Miltenyi 
130-059-901) at the manufactures recommended dilution for 15 minutes on ice, then 
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incubated with appropriate fluorophore -conjugated mAbs for 30 min on ice and 
washed twice before resuspension in a viability dye (either DAPI or propidium iodide 
at 1 µg/mL). Antibodies used include anti-HLA-A2 clone BB7.2-APC (ebioscience 
17-9876-42), BB7.2-FITC (MBL K0186-4). Pr20 or its human IgG1 isotype control 
(Eureka Therapeutics ET901) was conjugated to APC using the lightning-link kit 
(Innova Bioscience 705-0010) and staining was performed at 3 µg/mL, which was 
determined to be a saturating concentration. Flow cytometry data were collected on a 
LSRfortessa (Beckton Dickinson) or an Accuri C6 (Beckton Dickinson) and analyzed 
with FlowJo V10 software. 
 
CAR T Cell Transduction 
Healthy donor PBMC were isolated through ficoll density centrifugation. Quantities 
described as follows were scaled up when more cells were required. 5x106 PBMC 
were washed and resuspended in 2 mL of RPMI media with 10% FBS. 125uL of anti-
CD3/CD28 Dynabeads (Invitrogen) were washed once before resuspension 125 uL 
and added to the PBMCs. Recombinant human IL-2 was added to a concentration of 
100 IU/mL. 6-well non-tissue culture treated plates were coated with RetroNectin 
(Clontech) by diluting Retronectin to 20 ug/mL with PBS and coating plates with 2 
mL of diluted Retronectin for 1 hours at 37° C. Retronectin was removed and the plate 
was blocked with 2% BSA in PBS for 30 mins at room temp. Plates were washed once 
with PBS before transduction. Transduction was performed 48 hours after CD3/CD28 
Dynabead activation. 2 mL of activated T cells at 0.5x106 cells/mL was added to each 
well of RetroNectin-coated plate. 100 uL of concentrated lentivirus was added per 
well (MOI 5). Spinoculation was performed at 2000xg for 1 hr at 30° C. Cells were 
then rested at 37° C overnight. 2 mL of fresh media was then added with 100 IU/mL 
IL-2. Two days later, virus and Dynabeads were removed from cells by pipetting to 
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disaggregate beads from cells and using a magnet to remove the beads. Cells were 
then assayed for transduction efficiency using ALY/HLA-A2 tetramer staining and 
used for experiments. 
 
T Cell Activation and Cytotoxicity Assays 
Jurkat T cells transduced with Pr20-CAR or incubated with Pr20-BiTE, were labeled 
with CFSE and incubated overnight at the indicated E:T ratios with the indicated 
target cell lines. Flow cytometry was used to gate for CD3+ T cells (Clone OKT3 
eBioscinece11-0037-41) and median fluorescence intensity (MFI) for the early 
activation marker CD69-APC (eBioscience 17-0691-80) was quantified. For primary 
healthy donor T cell assays, after successful Pr20-CAR transductions, Pr20-CAR T 
cells or mock-transduced were incubated with CFSE-labeled AML14 cells at an E:T 
of 3:1. AML14 cells were labled with CFSE by washing cells twice with PBS, 
incubating them with 100 nM CFSE for 10 minutes, then quenching the reaction with 
complete media and washing with media 3 times. 16 hours later, flow cytometry for 
CFSE+ AML14 cells was used to determine depletion of AML14 cells. For Pr20-
BiTE experiments, Healthy donor PBMCs and AML14-GFP target cells were co-
cultured in the presence of 0.01 ug/mL Pr20-BiTE or control BiTE for 16 hours at an 
E:T of 30:1. Flow cytometry was used to determine proportion of GFP+ AML14 cells 
to measure depletion.  
 
Statistical Analysis 
Due to sample size and anticipated non-linearity of the time effect, we analyzed the 
data as area under the curve (AUC) for leukemic burden per mouse. Tumor burden 
expressed as AUCs were compared between groups using the Kruskal-Wallis test. 
When the Kruskal-Wallis test indicated significant differences among the groups 
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(p<0.05), subsequent pairwise comparison were conducted. Survival studies were 
done using bilateral hind leg paralysis as surrogate for death or using predetermined 
morbidity characteristics. Overall survival was estimated by the Kaplan-Meier 
approach and compared among groups using the log-rank test. ns is defined as p > 
0.05. * is defined as p< 0.05. ** is defined as p<0.01. *** is defined as p < 0.001. All 
statistical tests were conducted using a permutation test procedure.43 Statistical testing 
were performed using R 3.3.1 (R Core Team, Vienna Austria), 
 
Trials of Pr20M with CV1 in Mice 
Mouse research was conducted under protocols approved by the MSK institutional 
animal care and use committee. Therapeutic trials were conducted in human xenograft 
models in 6-week-old male non-obese/diabetic severe combined immunodeficient 
(NOD/SCID) with IL2γ receptor negative (NSG) mice from Jackson laboratory. Mice 
were engrafted via tail vein injection with 3 million BV173 and AML14 cells 
transduced with the firefly luciferase gene. Disseminated engraftment of leukemia was 
confirmed via bioluminescent imaging (BLI) in all mice before beginning treatment. 
Mice were randomly assorted into the following five treatment groups with equal 
mean BLI flux (photons/second): 1) control without treatment, 2) TCRm antibody 
alone, 3) CV1 alone, 4) CV1 and an afucosylated isotype control antibody, and 5) 
CV1 and TCRm antibody. TCRm antibodies were administered retro-orbitally 
biweekly at doses of 50 µg. For combination therapy studies CV1 was administered 
daily via intraperitoneal injection at doses of 100 µg. Leukemic burden was assessed 
by bioluminescence imaging, recorded as flux of protons per second and repeatedly 
measured at days 6, 13, 20, and 27, post engraftment.  Mice were treated twice a week 
beginning on day 6 through 27 for a total of six doses of TCRm and/or 21 daily doses 
of CV1. Additional mouse or human PBMC’s were not administered. 
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RESULTS 
 
Pr20M can mediate ADCP and combination of Pr20M with CD47/SIRPα axis 
blockade leads to superior therapy against leukemia models in vivo 
Although therapeutic activity was observed in Pr20M mono-therapy in vivo, tumor 
growth was only reduced and animals all ultimately progressed with disease. NSG 
mice are deficient in T, B and NK cells, and have poorly functional macrophages103. 
However, we hypothesize that NSG macrophages are a major immune effector 
population that could mediate ADCP in our models. In addition, cancer cells often 
upregulate CD47, the ‘do not eat me’ signal that interacts with SIRPα on 
macrophages. This functionally inhibits macrophages phagocytosis of tumor cells and 
is believed to be a resistance mechanism developed by cancers to evade immune 
elimination. We hypothesized that the addition of CV1, a high-affinity soluble SIRPα- 
variant125 could block CD47 and enhance Pr20M-mediated ADCP. To evaluate 
whether Pr20M could mediate ADCP, we incubated human monocyte-derived 
macrophages and NSG splenic macrophages with CFSE-labeled AML14 cells in vitro. 
Using flow cytometry, we determined proportion of CFSE+ macrophages indicating 
phagocytosis. We evaluated the ability of CV1 to enhance Pr20M-dependent 
macrophage phagocytosis of leukemia cells in vitro in AML14 and BV173 cells – both 
of which express PRAME, HLA-A2, and CD47. The HLA-A2-negative cell line 
HL60 was used as a negative control. Blockade of leukemia cell CD47 with CV1 
alone did not promote macrophage phagocytosis of AML14, BV173 or HL60 (Fig. 
2.1A). Pr20M alone did not promote ADCP of HL60 or BV173, but significantly 
increased phagocytosis of AML14 (Fig. 2.1A). The combination of TCRm mAb and 
CV1 significantly increased macrophage phagocytosis of AML14 and BV173, but not  
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Figure 2.1. CD47 blockade using CV1 enhances Pr20M-mediated ADCP of 
leukemia cells in vitro.  
(a) Human macrophage phagocytosis of AML14, BV173, and HL60 treated with 
various combinations of TCRm and CV1 quantified by flow cytometry. Experiments 
were completed in duplicate with various human donors. (b) Left panel: AML14 cells 
were pretreated with 100 ng/µl of IFNγ for 72 h. Isolated human macrophages were 
incubated with pretreated AML14 cells in the presence of (1) PBS, (2) CV1 alone, (3) 
Pr20M alone, (4) combination therapy with Pr20M and CV1, (5) positive control 
B6H12 (previously described), (6) B6H12 with Pr20M (7) irrelevant control mAb and 
(8) irrelevant control mAb with CV1. All groups showed an increase in ADCP with 
IFNγ pretreatment. Increase was most significant in Pr20M alone, combination 
therapy, and B6H12 with Pr20M. Right panel: BV173 cell line was pretreated with 
100 ng/µl of IFNγ for 72 hours. Isolated Human macrophages were incubated with 
pretreated BV173 cell line as above. All groups show an increase in ADCP with IFNγ 
pretreatment. Increase is significant in combination therapy, positive control, and 
positive control with Pr20. (c) NSG-derived mouse macrophage ADCP of CSFE 
labeled AML14 cells quantified by flow cytometry. These experiments were 
performed in duplicate with consistent results. 
 
treatment. Blocking SIRPα signaling may alter neutrophil transmi-
gration, trafﬁcking and therapeutic activity.11 Interestingly,
relapses that occurred in BV173 engrafted mice were outside of
sites with high phagocytic cell densi y. Third, the leukemias we
evaluated preferentially engrafted in organs with high intrinsic
numbers of phagocytic cells. Fourth, cross-species differences in
Fc receptor biology, as well as alternat ve xenogeneic ligand-
receptor interactions between human tumor cells and mouse
immune effectors may alter antibody and immune cell function.12
NSG mice are B cell-, T cell-, and NK cell-deﬁcient, and although
they have intact IFNγ-dependent signaling, they have defective
innate immunity and cytokine signaling pathways.13 While it is
difﬁcult to draw parallels between human and mouse systems, in
the human, a greater variety of more potent effectors and an
immunocompetent host that responds to pro-inﬂammatory
signaling could allow even greater efﬁcacy of this drug combina-
tion in the human patient. In addition, NSG mice have low
circulating IgG levels that could compete with TCRm for Fc
receptor interactions.13
We found no other upregulated cytokines in the serum of CV1-
treated mice other than IFNγ. IFNγ secretion caused by CV1 is
likely contributing indirectly to the therapeutic effects seen
through a new mechanism. IFNγ contributes directly to the innate
and adaptive immune response.14 However, NSG mice have no T
or NK cells.15 Not surprisingly, we found that IFNγ-dependent
signaling enhanced TCRm mAb-dependent, macrophage-
mediated phagocytosis in vitro. This enhancement of phagocytosis
was likely mediated through multiple mechanisms including
direct IFNγ-dependent macrophage activation, as well as
indirectly via TCRm-speciﬁc mechanisms involving increases in
tumor cell in HLA expression and antigen presentation. Thus,
strategies that promote an IFNγ response, such as CD47
blockade,15 could uniquely potentiate the activity of TCRm,
beyond what might be seen with traditional mAbs. This is
consistent with the increase in serum concentrations of IFNγ we
observed in mice treated with CV1. Notably, IFNγ alone did not
cause cell cytotoxicity. Therefore, the combination of CV1 and
TCRm in this speciﬁc milleu leads to remarkable tumor kill.
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Figure 1. ADCP of leukemia cells in vitro. (a) Human macrophage phagocytosis of AML14, BV173, and HL60 treated with various combinations
of TCRm and CV1 quantiﬁed by ﬂow cytometry. Experiments were completed in duplicate with various human donors. (b) Left panel: AML14
cell line was pretreated with 100 ng/µl of IFNγ for 72 h. Isolated human macrophages were incubated with pretreated AML14 cell line in the
presence of (1) PBS, (2) CV1 alone, (3) Pr20M alone, (4) combination therapy with Pr20M and CV1, (5) positive control B6H12 (previously
described), (6) B6H12 with Pr20M (7) irrelevant control mAb and (8) irrelevant control mAb with CV1. All groups showed an increase in ADCP
with IFNγ pretreatment. Increase was m st signiﬁcant in Pr20M alone, combinatio th rapy, and B6H12 with Pr20M. Right panel: BV173 cell
line was pretreated with 100 ng/µl of IFNγ for 72 hours. Isolated Human macrophages were incubated with pretreated BV173 cell line as
above. All groups show an crease in ADCP with IFNγ pretreatment. Increase is signiﬁcant in combination therapy, positive control, and
positive control with Pr20. (c) NSG-derived mouse macrophage ADCP of CSFE labeled AML14 cells quantiﬁed by ﬂow cytometry. These
experiments were performed in duplicate with consistent results.
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the control HL60, indicating the effect was TCRm antigen-specific. As expected, the 
positive control anti-CD47 blocking IgG1 antibody, B6H12, induced a significant 
increase in ADCP of all three leukemia cell lines, and potentiated TCRm-mediated 
phagocytosis of AML14 and BV173. ADCP with NSG mouse macrophages showed 
improved phagocytosis with CV1 alone and significantly increased phagocytosis with 
CV1 and TCRm Pr20M in combination (Fig. 2.1C). Collectively, these results indicate 
that CD47 blockade is effective at improving ADCP in vitro of antibodies that target 
ultra-low density tumor antigens, such as TCRm mAbs. IFNγ is a potent 
immunocytokine with pleiotropic effects, including induction of MHC class I and II 
expression and increased antigen processing and presentation151. Anti-CD47 mAb 
therapy triggers a phagocyte type I and II interferon (IFN) response in the tumor 
microenvironment that presumably increases tumor cell surface peptide-MHC 
(pMHC) density88. As the epitope target of TCRm mAbs is presented by pMHC, we 
hypothesized that promoting IFNγ signaling may boost TCRm mAb effector functions 
by increasing target antigen density on the tumor cell surface. IFNγ treatment of 
AML14 increased HLA-I expression, resulting in increased binding of Pr20M (Fig. 
2.2). IFNγ significantly increased expression of TCRm mAb epitopes of interest and 
increased macrophage-mediated ADCP of both AML14 and BV173 in vitro (Fig. 
2.1B). CV1 treatment alone did not increase HLA-I expression on either cell line. We 
next asked if combination CV1 and Pr20M therapy would improve potency in vivo. 
Although Pr20M mAb or CV1 monotherapy significantly reduced leukemia burden in 
the AML14 model (Fig. 2.3A), combination therapy had an markedly increased effect 
compared to either agent alone, with a 3 log reduction in leukemia burden relative to 
control untreated mice, a 10-fold reduction relative to the single agent groups (Fig. 
2.3A), and significantly improved survival for the combination therapy (Fig. 2.3B). 
After therapy was stopped on the final day of bioluminescent imaging, leukemia  
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Figure 2.2. Effects of IFNγ on PRAME antigen expression. 
A) AML14 cell line was pretreated with 100 ng/mL IFNγ for 72 hours. Treated (red) 
displayed a doubling of HLA expression compared to untreated controls (blue). B) 
Treated (red) showed a 10-fold increase in Pr20 binding compared to untreated 
controls (blue). 
 
relapsed not at the initial sites (bone marrow and spleen), but in lymphomatous 
nodules. Our data demonstrate that combination therapy of CD47 blockade with a 
TCRm can lead to dramatic therapeutic efficacy despite an extremely low mAb 
epitope density. 
 
Pr20-BiTE and Pr20-CAR Formats Potently Direct Tumor Lysis However Also 
Lead to Off-target Activities 
To determine whether the BiTE or CAR formats could be used to enhance therapeutic 
potential of Pr20, we tested these constructs in an in vitro depletion assay. Pr20-CAR 
was successful transduced into primary T cells using lentiviral infection leading to 
approximately 70% transduction efficiency overall with successful transduction in 
both the CD4 and CD8 T cell compartments as measured by ALY/HLA-A2 tetramer 
analysis. (Fig. 2.4). The transduction efficiency is comparable to the CARs used in  
Pr20M HLA-A*02:01 
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Figure 2.3. Combination Therapy with CV1 and Pr20 leads to leukemia 
suppression and prolonged survival in AML14 cell line in vivo. 
(A) NSG Mice were engrafted via tail vein injection with 3x106 cells/mouse of 
AML14 transfected with Luciferase gene. Mice were imaged via BLI on day 6. Mice 
were randomized to have equal group mean engraftment. Treatment started on day 6. 
Pr20M was administered retro-orbitally biweekly at 50ug. CV1 was administered 
intraperitoneally daily at 100ug. Mice were imaged once a week for 3 weeks. B) 
Graph showing normalized mean flux in photons/second of mice at days 6, 13, and 20, 
and 27. C) Kaplan Meir Survival curve showing survival data. Control and Single 
treated groups had 100% death within 50 days. Experiment was truncated at 100 days 
at which time 4 of 5 mice were alive. P<0.0001. D) At 67 days, 1 mouse in 
combination group had lymphomatous growth requiring sacrifice. The 4 remaining 
animals had lower tumor burden via BLI than on day of engraftment. 
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Figure 2.4. Pr20-CAR can be transduced into primary human healthy-donor T 
cells with high efficiency. 
Healthy-donor primary T cells were activated using anti-CD3/CD28 beads and 
recombinant human IL-2. Lentiviral particles were transduced into T cells and 24 
hours later CAR transduction was assessed by ALY/HLA-A2 tetramer analysis using 
flow cytometry. Total bulk cells, CD8+ T cells, and CD4+ T cells were analyzed for 
ALY/HLA-A2 tetramer positive cells. 
 
clinical practice and reactivity to the ALY/HLA-A2 tetramer demonstrates that the 
CAR protein is appropriately expressed, a potential issue when engineering scFv onto 
transmembrane scaffolds. Both Pr20-BiTE and Pr20-CAR mediated lysis against 
approximately 90% of PRAME+/HLA-A2+ AML14 cells in vitro within 16-18 hours 
demonstrating superb potency of the constructs (Fig. 2.5). We next evaluated whether 
potency of Pr20-BiTE or Pr20-CAR would lead to off-target toxicities. Using a panel 
of cell lines, Jurkat T cells were co-cultured with tumor cell lines in the presence of 
Pr20-BiTE or a Control-BiTE. Using the early activation marker CD69, we observed 
that Pr20-BiTE mediated CD69 activation of Jurkat T cells when co-cultured with the 
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Figure 2.5. Pr20-BiTE and Pr20-CAR mediate cytotoxicity against a 
PRAME+/HLA-A2+ AML in vitro. 
(A) Healthy donor PBMCs and AML14-GFP target cells were co-cultured in the 
presence of 0.01 ug/mL Pr20-BiTE or control BiTE for 16 hours at an E:T of 30:1. 
Flow cytometry was used to determine proportion of GFP+ AML14 cells to measure 
depletion. (B) Healthy donor T cells were transduced with Pr20-CAR and incubated 
with CFSE-labeled AML14 cells at an E:T of 3:1. 16 hours later, flow cytometry for 
CFSE+ AML14 cells was used to determine depletion. 
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AML14  (PRAME+ / HLA-A2+) 
SKLY16  (PRAME-  / HLA-A2+) 
MDA-MB231  (PRAME-  / HLA-A2+) 
TPC1   (PRAME-  / HLA-A2+) 
HL60   (PRAME+ / HLA-A2-) 
 
Figure 2.6. Pr20-BiTE and Pr20-CAR activate T cells in co-cultures with 
PRAME+/HLA-A2+ cancer cells, but induce non-specific activation. 
Jurkat effector T cells were labeled with CFSE before cells were co-cultured with 
indicated cell lines overnight at an E:T of 2:1  in the presence or absence of 0.01 
ug/mL Pr20-BiTE or a control-BiTE. For Pr20-CAR experiments, Pr20-CAR was 
transduced into Jurkat T cells and >98% ALY/HLA-A2 tetramer+ purity was 
determined before assays. Pr20-CAT Jurkat cells or mock-transduced Jurkat cells 
(Mock T) were co-cultured with indicated target cells overnight. Flow cytometry using 
an anti-CD69 antibody was used to measure early T cell activation on the jurkat cells 
for both Pr20-BiTE and Pr20-CAR experiments and MFI is graphed. 
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PRAME+ / HLA-A2+ positive control AML14 (Fig. 2.6). However, we also observed 
substantial CD69 activation after co-culture with several PRAME-negative / HLA-
A2+ cell lines such as SKLY16, MDA-MB231, and TPC1. We detected minimal 
CD69 activation after co-culture with the PRAME+/HLA-A2-negative leukemia 
HL60, suggesting off-target activation was dependent on HLA-A2 expression. We 
performed similar experiments for the Pr20-CAR construct co-culturing tumor cells 
with Pr20-CAR transduced Jurkat T cells or mock transduced Jurkats. Similar to the 
Pr20-BiTE data, although Pr20-CAR Jurkats demonstrated CD69 activation against 
PRAME+/HLA-A2+ AML14, they also activated against PRAME-negative / HLA-
A2+ cell lines demonstrating off-target activation (Fig. 2.6). To determine whether the 
Pr20-BiTE off-target activation was intrinsic to cancer cell lines, we performed Pr20-
BiTE culture experiments with healthy donor PBMC. When HLA-A2+ PBMC was 
cultured for 16 hours with Pr20-BiTE, we observed no depletion in T or B cell 
lineages. However, we observed significant depletion of the CD14+ monocyte 
population (Fig. 2.7 Left Panels). No substantial depletion of T cell, B cell, or 
monocyte populations was detected in a HLA-A2-Neg healthy PBMC control (Fig. 2.7 
Right Panels) again suggesting off-target cytotoxicity was dependent on HLA-A2 
expression. This observation was unexpected because Pr20 did not demonstrate 
substantial binding in flow cytometry assays to CD14+ populations in HLA-A2+ 
healthy donor whole blood (Fig 1.3E). Together, our data suggests engineering TCRm 
scFv into extremely potent biologic agents such as BiTEs and CARs should be 
approached with caution due to the possibilities of cross-reactive peptide epitopes or 
low-affinity interactions with HLA-A2; both of which can potentially lead to off-target 
toxicities. 
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Figure 2.7. Pr20-BiTE mediates depletion of healthy donor PBMC monocyte 
population. 
Healthy donor PBMC were isolated and cultured for 16 hours with either untreated, in 
the presence of 0.01 ug/mL of control-BiTE (ET901 see materials and methods), or 
Pr20-BiTE.  Flow cytometry was used to determine T cell (CD3+), B cell (CD19+), 
and monocyte (CD14+) populations to assay for depletion. HLA-A2+ CD14+ 
depletion data is representative of three independent experiments with n=3 healthy 
donors. The experiment with HLA-A2-Negative healthy donor was performed once. 
 
DISCUSSION 
The dramatic therapeutic effect when combining Pr20M and CV1 in vivo was an 
exciting observation. Several factors may explain the potent therapy. First, the in vivo 
microenvironment may positively alter macrophage effector function. Second, 
neutrophils express both SIRPα and Fc receptors and have been implicated in 
responses to anti-CD47 antibody treatment. Blocking SIRPα signaling may alter 
neutrophil transmigration, trafficking and therapeutic activity127. Third, the leukemias 
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we evaluated preferentially engrafted in organs with high intrinsic numbers of 
phagocytic cells. Fourth, cross-species differences in Fc receptor biology, as well as 
alternative xenogeneic ligand-receptor interactions between human tumor cells and 
mouse immune effectors may alter antibody and immune cell function152. NSG mice 
are B cell-, T cell-, and NK cell-deficient, and although they have intact IFNγ-
dependent signaling, they have defective innate immunity and cytokine signaling 
pathways153. While it is difficult to draw parallels between human and mouse systems, 
in the human, a greater variety of more potent effectors and an immunocompetent host 
that responds to pro-inflammatory signaling could allow even greater efficacy of this 
drug combination in the human patient. In addition, NSG mice have low circulating 
IgG levels that could compete with TCRm for Fc receptor interactions153. Not 
surprisingly, we found that IFNγ-dependent signaling enhanced TCRm mAb-
dependent, macrophage-mediated phagocytosis in vitro. This enhancement of 
phagocytosis was likely mediated through multiple mechanisms including direct IFNγ-
dependent macrophage activation, as well as indirectly via TCRm-specific 
mechanisms involving increases in tumor cell in HLA expression and antigen 
presentation. Thus, strategies that promote an IFNγ response, could uniquely 
potentiate the activity of TCRm. Therefore, the combination of CV1 and TCRm in this 
specific milieu leads to remarkable tumor kill. It will be important to determine if this 
effect is specific to leukemia, or also other cancers. In conclusion, the greater than 
additive effect of these agents together in vivo is particularly unexpected given the 
extremely low epitope density of the PRAME-derived peptide epitopes. The synergy 
between CV1 and antitumor antibodies may be especially pronounced with TCRm 
compared to traditional mAbs since the targets of TCRm mAbs are presented by HLA 
and are thus regulated by cytokine signaling. Although we demonstrated the unusual 
therapeutic utility of antagonizing CD47 to potentiate the antitumor activity of TCRm, 
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we anticipate this approach may be applicable to other mAbs that target a low cell 
surface density tumor antigen. This strategy could turn poorly efficacious antibodies 
into powerful antitumor therapeutics and significantly expand the possible cancer 
antigen targets of monoclonal antibodies.  
 
In addition, it is important to highlight that several studies have demonstrated that 
effective CD47 blockade therapy in syngeneic mouse models requires stimulation of 
the adaptive immune system, for example through cytosolic DNA sensing via the 
STING pathway in dendritic cells88 and subsequence cross-priming of tumor antigens 
or through immune checkpoint blockade of PD-L1154. Though the biochemical and 
cellular mechanisms of CD47 blockade may be different in syngeneic models and 
xenografts, it is reasonable to hypothesize that in an immunocompetent model, a 
TCRm and CD47 blockade may also synergize to augment cross-presentation engage 
the adaptive immunity for multi-modal immune attack. 
 
The off-target cytotoxicity and T cell activation of the Pr20-BiTE and CAR constructs 
were initially surprising given that using the same panel of PRAME-negative cell lines 
and healthy PBMC populations, our flow cytometry data demonstrated that Pr20 did 
not bind to detectable levels. We hypothesize either that there are cross-reactive 
targets below the limit of detect using flow cytometry-based assays or that the 
antibody ‘footprint’ and contact with the HLA-A2 protein provided enough interaction 
to trigger a T cell response. Recent data has proven that T cell activation can occur 
with as few as 3-10 ligands155,156 and therefore it is reasonable to hypothesize that low-
affinity interactions that were not detected by flow cytometry could be enough to 
mediate T cell activation and cytotoxicity. In addition, Pr20 was designed to have an 
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epitope footprint over the composite structure of ALY and HLA-A2, however, it is 
unknown where and to what extent Pr20 contacts HLA-A2. This is difficult to discern 
without data from a crystal structure. Therefore, it is reasonable to hypothesize that 
enough contact and affinity to HLA-A2 can mediate activation of a potent BiTE or 
CAR T cell. Indeed, upon review of the literature, The Sadelain group at Memorial 
Sloan Kettering recently reported another TCRm CAR targeting a NY-ESO1 tumor 
antigen peptide/HLA-A2 demonstrated reactivity and cytotoxicity against HLA-A2+ 
cells tested irrespective of NY-ESO1 expression148. However, rational mutagenesis to 
minimize contact with HLA-A2 was successful in fine-tuning the NY-ESO1 
peptide/HLA-A2 CAR for specificity to NY-ESO1, and therefore it is reasonable to 
believe that a similar strategy can be applied to Pr20-CAR. Together, our data 
suggests that the engineered Pr20-BiTE and Pr20-CAR constructs have off-target 
activities against peptide/HLA-A2 and are not PRAME-antigen-specific. Our data also 
suggests that caution must be taken when engineering high-affinity scFv fragments 
against peptide/HLA-I into highly potent therapeutic formats such as BiTEs and CARs 
and each construct must be evaluated empirically. 
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CHAPTER III: IDENTIFICATION OF STRATEGIES AND SMALL 
MOLECULES THAT REGULATE HLA-I† 
 
INTRODUCTION 
 
Checkpoint Blockade Immunotherapy Through CTLA4 and PD-1/PD-L1 
Immune checkpoint blockade therapy has recently become a powerful tool to treat 
specific solid tumors and has demonstrated astounding clinical results. Checkpoint 
blockade therapy relies on the concept that anti-tumor T cells are dysfunctional, but 
can be re-activated through blockade of inhibitory signals – ‘releasing the brakes’ 
from the immune system157. It is now well established that cancer patients can develop 
an immune response against their tumor but the tumor-specific T cells are either not 
well-activated or the tumor infiltrating lymphocytes are challenged with a hostile 
tumor microenvironment that suppresses their function. CTLA4 is an inhibitory 
receptor protein found on T cells that competes with the co-stimulatory receptor 
protein CD28 (also found on T cells) for binding to their shared ligand CD80/86 on 
antigen presenting cells157,158. Whereas the interaction of CD28 with CD80/86 is 
necessary for appropriate co-stimulation and T cell priming against an antigen, the 
interaction of CTLA4 with CD80/86 leads to T cell functional inhibition157,158. 
Therefore, checkpoint blockade with mAbs against CTLA4 such as Ipilimumab 
(Bristol-Myers Squibb) can help to prime and activate anti-tumor T cells159. Approved 
by the FDA in 2011 for metastatic melanoma, Ipilimumab demonstrated that immune 
 
† Some experiments were designed and conducted by or in collaboration with Myles 
Fennell from the MSK Gene Editing and Screening Core facility (Fig. 3.1, 3.2, and 
Table 3.1), Christina Bebernitz and Mitchell Wang (Fig. 3.3, 3.4, 3.7), and Lauren 
Dong (Fig. 3.8 and 3.9) 
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checkpoint blockade was indeed a powerful strategy against cancer and a subset of 
patients see long-term durable responses160. Tumors also often upregulate expression 
of another immune checkpoint protein celled PD-L1. PD-L1 binds to PD-1 on T cells 
to inhibit T cell function and can even promote T cell apoptosis161. Therefore, it is 
commonly believed that tumors increase expression of PD-L1 as a mechanism of 
immune evasion. On the basis of this biology, several mAbs against both PD-I and 
PD-L1 were developed. Gratifyingly, several of these mAbs demonstrated superb 
efficacy and gained FDA approval for several solid tumor indications such as the anti-
PD-1 Nivolumab160 (Bristol-Myers Squibb) for metastatic melanoma, non-small cell 
lung cancer, and renal cell carcinoma; and Pembrolizumab162 (Merck and Co.) for 
metastatic melanoma and cancers with microsatellite instability or DNA repair 
deficiencies. Anti-PD-L1 mAbs have also gained approval such as Atezolizumab163 
(Genentech / Roche) for urothelial carcinoma and non-small cell lung cancer; 
Durvalumab164 (MedImmune / Astrazeneca) for urothelial carcinoma, and 
Avelumab165 (Pfizer / Merck KGaA) for Merkel cell carcinoma and urothelial 
carcinoma.  
 
Immunological Activity in Tumor Microenvironment is Important for Successful 
Immune Checkpoint Blockade Therapy  
Although immune checkpoint blockade therapy has been clinically successful, not all 
patients respond and not all tumors respond. We are only beginning to understand the 
prognostic signs that may predict whether a particular tumor would respond to 
checkpoint blockade, and the mechanisms of resistance166. In broad terms, a solid 
tumor can be immunologically ‘hot’ or ‘cold’. Immunologically ‘hot’ tumors are 
inflamed and heavily infiltrated with lymphocytes while immunologically ‘cold’ 
tumors are non-inflamed and exclude T cells. It is now recognized that ‘hot’ tumors 
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respond better to checkpoint blockade therapy167. What makes a tumor 
microenvironment ‘hot’ is less clear. It is commonly accepted that higher tumor 
mutational burden correlates with increased T cell infiltrates and with higher rate of 
response to anti-PD-1 at least in melanoma.168 However, mutational burden is not the 
only prognostic factors, because some tumor types such as clear cell renal cell 
carcinoma do not necessarily have high mutational burden yet are ‘hot’, have a high 
amount of T cell infiltrates, and respond to checkpoint blockade169. It is becoming 
increasingly clear that a major factor that generates a ‘hot’ tumor is appropriate MHC 
antigen presentation machinery expression and an interferon gene signature in the 
tumor168,169. A major focus now in immuno-oncology is developing combinatorial 
strategies to convert a ‘cold’ tumor into a ‘hot’ tumor thereby augmenting endogenous 
anti-tumor T cell responses as well as providing a pool of anti-tumor T cells for 
additional checkpoint blockade to bolster. It is increasingly clear that the innate 
immune system plays a pivotal role in initiating an anti-tumor response. Antigen 
presenting cells such as dendritic cells must sense pathogen associated molecular 
patterns through TLRs170 or damage associated molecular patterns on tumor cells in 
order to prime an effective T cell response171. Several exciting studies demonstrate 
promising strategies to augment innate sensing of tumors through STING agonists171–
173 and enhanced antigen-presenting cell priming of T cells through combination of 
TLR9 agonists and OX40 agonists174. 
 
HLA-I Expression is Essential for a Broad Range of Immunotherapies, Down-
regulation is a Mechanism of Checkpoint Blockade Resistance, and HLA-I can be 
Modulated Pharmacologically 
HLA-I is a central immune recognition molecule that is essential for activity of 
immune checkpoint blockade, TCRm or any TCR-based agent, and cancer vaccines. 
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Immune checkpoint blockade still ultimately relies on recognition of tumor cells 
through peptide/HLA-I and TCR interactions. In fact, a major mechanism of resistance 
to anti-CTLA4, anti-PD1, and anti-PD-L1 checkpoint blockade is down-regulation or 
loss of cell-surface HLA-I expression175–178 demonstrating the importance of HLA-I 
expression for success of drug class. Therefore, strategies to increase tumor-cell 
surface HLA-I would be applicable to augment a broad range of immunotherapies 
including TCRm, TCR-transgenic T cells, cancer vaccines, and check point inhibitors. 
Pro-inflammatory cytokines such as IFNγ can increase HLA-I expression and antigen 
presentation dramatically, but are difficult to use as drugs due to major toxic side 
effects179. Our lab has previously reported a shRNA kinome screen in which we 
determined that MAPK activation decreased HLA-I and pharmacological inhibition of 
the MAPK pathway with the MEK inhibitor Trametinib could increase HLA-I110 . It 
would be useful to understand what pharmacological inhibitors could be used in 
combination with immunotherapy to boost HLA-I expression and tumor-antigen 
presentation. Conversely it is important to know what pharmacological inhibitors 
would decrease HLA-I to determine combinations to avoid. 
 
Cellular Engineering Approaches Risk Introduction of Immunogenic Foreign 
Genes  
Although for cancer immunotherapy it may be most logical to identify strategies to 
increase MHC-I and HLA-I expression, there are also several scenarios where the 
ability to decrease MHC-I expression may be beneficial. For example, modern 
lentiviral and CRISPR/Cas9 technology has allowed genetic engineering of cells ex 
vivo and introduction of functional foreign genes before reinfusion. Indeed, the 
possibilities to introduce bacterial enzymes or synthetic proteins into cells for novel 
functionalities are tantalizing. For example, the herpes simplex virus thymidine kinase 
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gene (HSV-TK) is being explored as a suicide gene in induced neural stem cells. 
These engineered cells can home into a glioblastoma to deliver a localized pro-drug 
activating enzyme system180. Upon systemic administration of the pro-drug 
Ganciclovir, the engineered neural stem cells catalyze formation of a localized 
cytotoxic agent. In addition, CAR T cells have been engineered to express several 
foreign proteins such as immuno-modulating BiTE molecules and flagellin 
adjuvant181, and even a custom-gated synthetic notch receptor coupled with the yeast 
Gal4 transcription factor181,182. However, a concern is that these foreign proteins can 
by processed and presented on MHC-I leading to an endogenous immune response 
that may ultimately kill the required engineered cells. One strategy to prevent host T 
cell responses against transgenic proteins is through ablation of β2M. Because β2M is 
an essential structural component of MHC-I, deletion of β2M functionally prevents 
cell-surface expression of all MHC-I alleles making it an attractive target for gene 
editing strategies such as CRISPR/Cas9183. This strategy is being explored to generate 
universal CAR T cells that circumvent the logistically challenging requirement of 
autologous transductions of current FDA-approved CAR T184. However, MHC-I also 
has a role as an NK cell inhibitory signal and NK cells can lyse cells lacking MHC-
I185,186. This NK cell functionality is thought to have evolved to counter viral 
mechanisms to inhibit MHC-I expression186 to evade adaptive immunity. Instead, we 
hypothesized that inhibition of TAP function could prevent a response against an 
immunogenic transgene. A fraction of MHC-I peptides are TAP-independent and 
therefore cell-surface MHC-I expression would be partially maintained187. Indeed, past 
studies have shown that although murine NK cells detectably lyse TAP-deficient 
splenocytes, they are not as prone to NK cell attack as β2M-deficient splenocytes185. 
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Viral Immunoevasins have Evolved to Modulate Host Cell Antigen Presentation 
Machinery 
Viral immunoevasins are a class of proteins that function to interfere specifically with 
the MHC class I pathway of antigen processing and presentation. They are well 
studied in human cytomegaloviruses and help the virus to minimize immune detection 
by human CD8+ T cells188. They can inhibit several key components of the antigen 
presentation pathway. For example, US11 and US2 induce degradation of MHC-I 
molecules while UL82 delays egress of MHC-I complexes from the ER to the Golgi. 
Multiple viral immunoevasins also target TAP to prevent efficient peptide loading 
onto HLA-I. For example, ICP47 prevents peptide transport through physically 
obstructing the peptide-binding site189. Meanwhile, US6 specifically inhibits TAP by 
inducing conformational changes resulting in abrogated ATP binding to TAP1 thereby 
preventing TAP-mediated peptide transport and shuttling onto MHC-I 
molecules189189,190. In fact, T-Vec (Amgen), the only FDA-approved oncolytic virus 
for cancer (melanoma), was engineered from HSV-1 through the removal of ICP47 to 
increase immunogenicity, and the addition of the GM-CSF gene, a potent immune 
stimulator cytokine that promoters differentiation of progenitor cells into dendritic 
cells191. Together, the goal was to make T-Vec ultimately more immunostimulatory to 
cytotoxic T cells. However, ICP47 has been shown to have minimal activity on murine 
TAP192 and therefore cannot be tested in murine models. Fortunately, US6 inhibits 
murine TAP (although to a lesser degree)193 and therefore is a prime candidate 
immunoevasin to study in an immunocompetent murine model. We hypothesize that 
overexpression of US6 could inhibit TAP to prevent an immune response against a 
transgene product, but still allow for sufficient cell-surface MHC-I to prevent NK cell 
attack. 
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HLA-I is a key immune receptor essential for recognition of viral or tumor-associated 
antigens by cytotoxic T cells. It is commonly believed and documented that cancers 
can down-regulate HLA-I cell-surface expression as a means of immune 
escape177,194,195. In fact, reports show that even the hypoxic tumor microenvironment 
can down-regulate HLA-I196. Appropriate expression of HLA-I is required for success 
of a broad range of cancer immunotherapy strategies including cancer vaccines, 
adoptive T cells, transgenic TCRs, checkpoint blockade therapy, and the experimental 
TCRm antibodies. Therefore, pharmacological strategies to increase expression of 
HLA-I could have strong utility in combination immunotherapy. In contrast, the 
ability to down-regulate HLA-I and antigen processing machinery may allow the use 
of immunogenic transgenes in genetically engineered cells without the concern of an 
endogenous CD8 T cell response.  
 
MATERIALS AND METHODS 
 
High Throughput Screen for Small Molecule Inhibitors that Regulate HLA-I 
Several smaller commercially available compound libraries were concatenated to 
generate a library of approximately 6,700 unique compounds. All libraries consisted of 
only FDA-approved drugs or known bioactive compounds. All pipetting and 
aspiration was performed using robotics. JMN mesothelioma cells were plated at 500 
cells per well in 50 uL in 384-well high-throughput screen grade clear-bottom plates. 
Cells were allowed to settle for 10 minutes at room temperature before placing plates 
into 37°C incubator to prevent temperature-influence on fluid dynamics of the media 
and uneven cell seeding. Plates were incubated overnight at 37°C. Compounds were 
then added from 100 uM stock wells (solubilized in 10% DMSO and 90% PBS) by 
adding 2.5 uL of each compound per well. This leads to a final concentration of 5 uM 
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and 0.5% DMSO. 2.5 uL of 10% DMSO/90% PBS or 100 ng/mL IFNγ were added to 
one column per plate as a negative and positive control respectively. These controls 
could also assist in detecting assay irregularities and trends during robotic pipetting. 
Cells were then incubated for 72 hours at 37°C. Cells were then fixed by adding 10 uL 
of 20% paraformaldehyde, along with an incubation at room temperature for 15 
minutes, followed by 4 washes of 100 uL PBS per wash and aspirating down to 15 uL 
(minimum residual volume allowable through the robotic pipetting without aspirating 
cells off the plate as determined during optimization experiments). Cells were next 
blocked with 15 uL of 6% BSA leading to a final in-well concentration of 3% BSA for 
20 minutes before 3 more washes. 15 uL of primary anti-HLA-A2 antibody (clone 
BB7.2) was then added to each well at a dilution of 2.5 ug/mL in 1% BSA in PBS and 
incubated for 1 hr at room temp. Cells were washed 3 times with PBS before 
secondary antibody: anti-mouse A488 (A-11001 Thermo Fisher Scientific) was added 
at 1:500 in 6% BSA (leading to a final in-well concentration of 3% BSA) and 2.5 
ug/mL of Hoechst dye for nucleus staining. Secondary antibody was incubated at 
room temperature for 1 hr and washed 3 times before high-throughput imagining. 
After acquisition, images were analyzed using high-throughput image analysis 
software to determine average cell florescence intensity (I) and area (A). By 
multiplying (I)x(A) = average signal per cell, we quantified signal per well versus 
DMSO control as a ‘percent of control’ (POC). We also used a reverse ‘normalized 
percent inhibition’ analysis where DMSO controls were set at 0% and IFNγ positive 
controls were set at 100%, and each well was given a NPI quantification along that 
scale. Both POC and NPI analyses were normalized per plate to reduce plate-to-plate 
effects and variation of staining and assay artifacts introduced by plate changes and 
robotics.  
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Flow Cytometry 
For cell surface staining, cells were washed once before being trypsinized from the 
plates using Trypsin-EDTA (0.25%) (Thermo Fischer Scientific 25200056), then 
incubated with appropriate fluorophore-conjugated mAbs for 30 min on ice and 
washed twice before resuspension in a viability dye (either DAPI or propidium iodide 
at 1 µg/mL). Antibodies used include anti-HLA-A2 clone BB7.2-APC (ebioscience 
17-9876-42), BB7.2-FITC (MBL K0186-4), and anti-HLA-A,B,C clone W6/32-APC  
(biolegend 311409). Flow cytometry data were collected on a LSRfortessa (Beckton 
Dickinson) or an Accuri C6 (Beckton Dickinson) and analyzed with FlowJo V10 
software. 
 
Western Blot and qPCR Analysis 
Total cell lysate was extracted using RIPA buffer and quantified using the DC protein 
assay (Biorad). 15-30 µg of protein was loaded and run on 4-12% SDS PAGE gels. 
After 1 hr block with 5% milk at room temperature, immunoblotting was performed 
using antibodies against HLA-A (Santa Cruz A-18), 5-Lipoxygenase (Cell Signaling 
Technology 3289), STAT1 (Cell Signaling 9175), phospho-STAT1Tyr701 (Cell 
Signaling 9167), and IRF1 (Cell Signaling 8478s). Antibodies were probed at 
manufacturers recommended dilution overnight at 4°C before a secondary antibody 
conjugated to HRP was used for imaging. Replicate samples were probed using the 
indicated antibodies when noted, or blots were stripped with RestoreTM Western Blot 
Stripping Buffer (ThermoFisher Scientific 21063), re-blocked with 5% milk, and re-
probed with an anti-GAPDH-HRP direct conjugated antibody (Cell Signaling 
Technology 3683) as a loading control. qPCR was performed using the Taqman real-
time PCR system. RNA was extracted using the Qaigen RNeasy, 1 µg of RNA was 
reverse transcribed into cDNA using qScript cDNA SuperMix (Quanta Biosciences) 
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TaqMan probes and primers were designed from 'assay-on-demand' gene expression 
products (Applied Biosystems). Primer and probes were HLA-A (assay ID number: 
Hs01058806_g1) and the endogenous reference gene control was TATA-box binding 
protein (TBP) (assay ID number: HS99999910). Reactions were carried out in 
triplicates using standard thermocycling conditions (2 minutes at 50°C, 10 minutes at 
95°C, 40 cycles of 15 seconds at 95°C, and 1 minute at 60°C. The results are 
presented as relative differences in expression vs the endogenous reference control 
gene (2-∆Ct), or fold changes based on the differences of normalized Ct values 
compared to control samples, assuming optimal primer efficiency (2-∆∆Ct). Samples 
that did not amplify after 40 cycles or amplified at an equal or later Ct value compared 
to a water sample were considered negative and are not plotted with a value. For RT-
PCR reactions, RNA was extracted using the Qaigen RNeasy, and 1 µg of RNA was 
reverse transcribed into cDNA using qScript cDNA SuperMix (Quanta Biosciences) 
standard PCR cycling was used using the DreamTaq master mix system 
(ThermoFischer Scientific) with standard thermocycling conditions as recommended 
by the manufacturer. Primers used to amplify cDNA were as follows: US6-For: 
GAGGACTTTGCGCACCAATGUS6  US6-Rev: ACAGGTCAGCCTACCCTCAA 
and murine GAPDH-For: TGATGGGTGTGAACCACGAG murine GAPDH-Rev: 
TCTTGCTCAGTGTCCTTGCT. RT-PCR products were run on a 2% agarose gel 
with syber safe gel stain before imaging. 
 
Antibody-dependent Cellular Cytotoxicity 
JMN cells used as ADCC target cells were first pre-treated for 72 hours with 1.5uM 
BW-B70c. They were then trypsinized, washed, and incubated with 50 µCi of 51Cr for 
1 hour at 37 °C and washed 3 time to remove free 51Cr. Indicated concentrations of 
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ESKM were incubated with target cells and fresh PBMCs at effector:target ratios of 
50:1 for 6 hours at 37 °C. The assay was performed in 96-well format with 5000 target 
cells per well and 250,000 PBMC. The supernatant was harvested, and the cytotoxicity 
was measured by scintillation counting.  
 
Transduction of US6 
US6 overexpression vector was a gift from the Tortorella lab at Mount Sinai School of 
Medicine. US6 vector was sequenced to confirm composition of the standard Uniprot 
sequence of CMV US6 (P14334_US06_HCMVA). US6 was cloned into a retroviral 
overexpression vector pLgPW197, which uses a CMV promoter to drive expression of 
US6 along with eGFP driven off of the LTR promoter. US6-pLgPW was packaged 
into retrovirus through transfection of 293T cells expressing retroviral glycoprotein 
along with a VSV-G pseudotyping plasmid. Viral supernatant was collected before 
Spinoculation for 2 hours into EL4-Ova cells. Transduced cells were purified through 
fluorescence activated cell sorting for eGFP+ cells. 
 
CRISPR Knock-out Studies 
LentiCRISPRv2 (Addgene plasmid #52961) 96 was a gift from Feng Zhang (Broad 
Institute, Cambridge, MA). Small guide RNA sequences targeting murine TAP1 and 
β2M were as follows: (TAP1: CCTAGGACTAGGGGTCCGCG β2M: 
AGTCGTCAGCATGGCTCGCT). sgRNA were cloned into the LentiCRISPRv2 and 
lentivirus was produced after transfection with packaging plasmids into HEK293T 
cells. MCA205 were transduced with LentiCRISPRv2 and transduced cells were 
selected using 5 µg/mL puromycin for 48 hours. Successful knockout was detected 
using an indirect method of flow cytometry for H2Kb because TAP1 and β2M both 
control H2Kb expression. Initially, puromycin-resistant cells from MCA205 Cas9- 
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β2M were bimodal for H2Kb expression suggesting that the sgRNA did not mediate 
CRISPR/Cas-9 destruction in a subset of cells. Fluorescence activated cell sorting was 
used to sort out the H2Kb-low cells presumed to be the successful homozygous β2M 
knockouts.  
 
RESULTS 
 
High Throughput Screen for Small Molecule Inhibitors that Regulate HLA-I 
To discover small molecule inhibitors that can be used to regulate HLA-I expression, a 
library of approximately 6,700 FDA-approved or known bioactive compounds were 
used in a high throughput screen. Briefly, the HLA-A2+ JMN mesotheliomas cells 
were plated onto 384-well plates overnight before compounds were added at a final 
concentration of 5 uM using robotics. Cells were incubated for 72 hours before 
washing, fixing with paraformaldehyde, and immunofluorescence staining with an 
anti-HLA-A2. Images were captured through high-throughput plate imaging and 
analyzed for fluorescent signal per cell using software that can distinguish cell 
boarders. Each plate contained 1 column of cells treated with 100 ng/mL IFNγ as a 
positive staining control as well as an assay control to distinguish inter- and intra-plate 
variability that may be introduced during processing and robotic manipulations. The 
screen was performed twice and all data was pooled together. To identify lead 
compound hits, we quantified total HLA-A2 fluorescent signal per cell by the formula 
IxA where I = average cell fluorescence intensity and A = cell area. Average cell 
fluorescence intensity was used because images are collected in two dimensions and 
fluorescence intensity is not homogenous over a given cell due to microscope focus 
and image capture. We used a reverse normalized percent inhibition (NPI) approach 
where DMSO controls were set at 0%, IFNγ positive controls were set at 100%, and 
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values were normalized per plate to account for inter-plate variability. We identified 
lead compounds as those that caused >60% NPI for IxA and had reproducibility of at 
least 2 hits (either between the two independent experiments or within the same 
experiment because several sub-libraries used contained redundant compounds). (Fig. 
3.1A) A column of IFNγ positive controls can be easily visualized on a heat map of 
hits (Fig. 3.1A). Graphical representation demonstrates no obvious patterning of 
experimental hits suggesting there was no major cofounding assay effects such as 
plate effects or obvious errors resulting from faulty robotic pipetting patterns. 
Immunofluorescence signal increases substantially after IFNγ-treatment compared to 
DMSO-treated cells (Fig. 3.1B). We then excluded hits that cell counts of <5% 
compared to DMSO control based on DAPI counting because the cytotoxicity of these 
compounds may confound the data. Finally, we examined hit images manually and 
excluded compounds that were inherently florescent into the A488 detector (used for 
fluorescence microscopy) or if staining had artifacts such as poor-focus and debris. 
From this analysis, we generate a list of 23 lead compounds (Table 3.1). Based on the 
NPI analysis, we examined the known targets for our list of lead compounds. We 
identify 19 hits with known biological targets out of the 23 lead compounds (Table 
3.1). To validate these targets, we repeated the assay with the 23 lead compounds, 
which allows us to perform the experiment in a much smaller scale and preventing 
artifacts that may be introduced from cumbersome handling. We observe that in the 
identical assay using a range of lower doses, most compounds validated and 
demonstrate dose-dependent regulation of HLA-I (Fig. 3.2) as measured by 
immunofluorescence, indicating a level of reproducibility in our initial screen. We also 
included the MEK inhibitor Trametinib, a known regulator of HLA-I in the JMN cell 
line as a positive control. Interestingly, although Trametinib potently increased HLA-I 
in the validation assay (Fig. 3.2), it did not appear as a candidate lead compound in our  
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Figure 3.1. High throughput immunofluorescence screen to identify bioactive 
small molecule regulators of HLA-I. 
 
(A) High throughput immunofluorescence screen was performed with ~6,700 unique 
compounds in an arrayed 384-well format. JMN Cells were treated for 72 hours at 37 
degrees C with 5 uM of compound before washing, fixation, and staining with anti-
HLA-A2. See chapter III material and methods for detailed methods. Heat map of 
>60% NPI for IxA setting the DMSO control to 0% and 100ng/mL IFNγ positive 
control to 100% and normalized per plate to demonstrate distribution of hits on the 
plates. Green denotes an >60% NPI hit while red denotes highest fluorescence. (B) 
Representative anti-HLA-A2 immunofluorescence staining of DMSO control and 
IFNγ-treated JMN cells from optimization experiments performed as in (A). 
HLA-A2 (BB7.2 mAb) 
Negative Control  
(DMSO) 
Positive Control  
(IFNγ 100ng/mL) 
A 
B 
60 NPI 1300 NPI 
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initial screen indicating a level of assay noise or inconsistencies in the stock libraries.  
This is not uncommon in arrayed compound high-throughput screening approaches. 
 
 
 
Table 3.1. Lead compound hits, targets, HLA-A2 expression, and cell count. 
List of lead compound hits from high-throughput screen that increase HLA-A2 
expression. Inhibitor target, (average fluorescence intensity x area) NPI, (average 
fluorescence intensity x area) percent of control (POC), and cell count (POC) by DAPI 
staining is presented. NPI was calculated setting the DMSO control to 0% and 
100ng/mL IFNγ positive control to 100% and normalized per plate 
 
 
 
Compound name Inhibitor Target (IxA) NPI (IxA) POC
Cell Count 
POC
As703026 MEK1/2 103.8 353.2 37.7
Azd4547 FGFR 95.4 233.2 45.0
Azd8330 MEK1/2 103.3 260.5 25.7
Bw-B 70c 5-lipoxygenase 122.3 351.3 33.5
Cediranib (Azd2171) VEGFR 124.9 364.4 21.8
Crizotinib (Pf-02341066) ALK, MET, ROS1 134.9 384.5 9.8
Everolimus (Rad001) mTOR 69.4 253.1 48.1
Gf 109203x Protein Kinase C 63.1 228.3 81.8
GSK1383281A no data 66.2 207.8 5.5
GSK1389063A no data 106.2 311.1 7.2
GW275568A no data 60.9 199.3 74.6
GW684941X no data 155.4 352.2 8.4
Indatraline Hydrochloride Monoamine uptake Ib 65.1 188.4 81.2
Pd0325901 MEK1/2 172.2 421.2 24.0
Pha-665752 c-MET 148.7 379.1 54.4
Pkc412 >99% Multi-Target Kinase Ib 149.6 327.5 10.5
Pyrromycin anthracycline antibiotic 79.3 245.7 73.6
Sertraline Hydrochloride Serotonin Reuptake Ib 105.4 292.0 65.1
Su 5416 VEGFR 76.5 254.7 76.1
T 98475
gonadotropin-releasing 
hormone Receptor 72.2 251.0 69.9
Tae684 (Nvp-Tae684) ALK 390.4 897.3 8.7
Tak-285 EGFR 90.7 275.4 69.6
Tak-733 MEK1/2 78.8 257.3 27.1
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Figure 3.2. Lead compound hits validate in a dose titration assay. 
Lead compound hits from the high-throughput screen were evaluated in a validation 
experiment repeated using similar assay set-up but performed in on small-scale to 
reduce the risk of assay artifacts. Cells were plated at 500 cells per well overnight 
before addition of compounds at a range of lower doses. After 72 hours of incubation 
at 37 degrees C, cells were washed, fixed, stained, and analyzed as in Figure 3.1. Heat 
map of IxA NPI performed in triplicate is plotted for each compound. Black box over 
Pkc412 denotes excluded sample because this dose led to below 5% cell count versus 
DMSO controls. Red arrows denote non-MAPK inhibitor compounds taken forward 
for further evaluation. 
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Validation of Hits Through Flow Cytometry 
The identification of several MAPK pathway kinase inhibitors confirmed our past 
studies that MEK pharmacological inhibition could enhance cell-surface HLA-I110. 
However, we were curious to validate hits that were not directly linked to the MAPK 
pathway. Therefore, we utilized an orthogonal flow-cytometry based assay with the 
goal of validating novel hit compounds that were commercially available. 
Unexpectedly, some compounds (Sertraline, T98475, Indatraline) did not substantially 
increase cell-surface HLA-I at reasonable doses as detected by flow cytometry (Fig. 
3.3). The discrepancy between the flow cytometry data and the immunofluorescence 
data from the screen may be intrinsic to the assay readouts as deliberated further in the 
discussion section. However, treatment with BW-B70c (iron chelating 5-
Lipoxygenase (5-LO) inhibitor198) markedly increased HLA-I on JMN cell surface at 
pharmacologically relevant doses (Fig. 3.3). The mTOR inhibitor Everolimus also 
increased HLA-I to some extant. Because thorough mechanistic studies of 5-LO 
inhibitors on HLA-I expression have not been done, we pursued mechanistic 
evaluation of this novel strategy to enhance HLA-I expression. 
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Figure 3.3. BW-B70c and Everolimus increase cell-surface HLA-A2 in 
orthogonal validation assay. 
JMN cells were treated for 72 hours with the indicated compound over a range of 
concentrations from 5 uM – 0.06 uM (data shown for Everolimus was at lower doses 
of 200 nM – 1 nM due to cellular toxicity at higher doses). Cells were washed, 
trypsinized, and stained with anti-HLA-A2 for flow cytometric analysis using a HLA-
A2-specific antibody (clone BB7.2), or a pan-HLA-I antibody (clone W6/32). Data is 
representative of 3 independent experiments. 
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BW-B70c Increases HLA-A2 Protein Expression Through Transcriptional 
Regulation 
Cell-surface HLA-I is regulated through several mechanisms including transcriptional 
and translational regulation, stability through β2M expression, and enhanced peptide 
loading complex formation. To determine how BW-B70c regulated HLA-I, we treated 
JMN cells for 72 hrs and assayed for HLA-A mRNA transcript levels by qPCR and 
whole-cell protein expression by western blot. We determined that BW-B70c 
enhanced both HLA-A mRNA (Fig. 3.4A) and protein expression (Fig. 3.4B) in a 
dose-dependent manner. Next, we asked if this transcriptional regulation was mediated 
through STAT1 and IRF1, canonical transcription factors that regulates HLA-I 
expression. We demonstrate that upon BW-B70c treatment, there was a dose-
dependent increase in STAT1, activated phospho-STAT1, and IRF1 protein 
expression by western blot analysis (Fig. 3.4B). 
BW-B70c Increases Tumor-antigen Presentation and Sensitizes JMN Cells to 
TCRm-mediated ADCC 
It is reasonable to hypothesize that the increased HLA-I after BW-B70c treatment 
would also enhance tumor-associated peptide/HLA-I complex presentation and 
TCRm-mediated ADCC. JMN does not express consistently detectable PRAME 
protein, but does express the oncofetal protein WT1 and binds another TCRm we 
developed called ESK1, targeting WT1-derived RMFPNAPYL (RMF) peptides in 
complex with HLA-A2. We therefore treated JMN cells with increasing 
concentrations of BW-B70c and determined amount of a ESK1 binding to measure 
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Figure 3.4. BW-B70c transcriptionally regulates HLA-I through IRF1. 
JMN mesothelioma cells were treated with BW-B70c at the indicated concentrations 
for 72 hours. Cells were harvested and HLA-A transcript levels were measured by 
qPCR (A). Relative expression was normalized to TBP. (B) Protein expression of 
HLA-A was determined by western blot analysis. STAT1, phospho-STAT1701, and 
IRF1 protein levels were also determined. Cells treated for 72 hours with IFNγ were 
also included as a positive control.  
 
 
RMF/HLA-A2 presentation. BW-B70c treatment increased ESK1 binding in dose-
dependent manner (Fig. 3.5A). In addition, pre-treatment of JMN cells with BW-B70c 
for 72 hours slightly sensitized JMN to ESKM-mediated (afucosylated form of 
ESK199) ADCC at lower concentrations of TCRm (Fig. 3.5B). Interestingly, the 
maximum ADCC was not enhanced suggesting that there is a maximum antigen-
density threshold—at least for the JMN cell line in the assay—where enhancing 
TCRm-target epitopes does not enhance ADCC. 
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Figure 3.5. BW-B70c increases WT1 tumor antigen presentation on HLA-A2 and 
sensitizes JMN cells to TCRm-mediated ADCC. 
(A) JMN cells were treated with the indicated dose of BW-B70c (ranging from 5uM - 
0.06 uM) for 72 hours before flow cytometry using ESK1, an anti-WT1126-134/HLA-
A2 TCRm antibody was used to determine WT1 tumor antigen presentation. HLA-A2 
cell-surface expression was also measured. (B) JMN cells were pre-treated with 1.5 
uM BW-B70c for 72hours before being washed an used as targets in a 51Cr-release 
ADCC assay with an human PBMC effectors at an E:T of  50:1.  
 
Everolimus and BW-B70c are Additive with MEK Inhibitor Trametinib in 
Increasing Cell-surface HLA-I 
Our previous work had demonstrated that MEK inhibition using Trametinib increases 
cancer cell-surface HLA-I in vitro and MHC-I in vivo110. In addition, other studies 
have established interesting yet complex communication between the MAPK and 
mTOR pathways that can cross-inhibit or cross-activate depending on the 
context199,200. Because the mTOR inhibitor Everolimus seemed to subtly increase 
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HLA-I, we next asked whether there was synergy or antagonism between Everolimus  
(mTOR ib) and Trametinib (MEK ib) for regulation of HLA-I. Both Trametinib and 
Everolimus increased cell-surface HLA-I on the JMN mesothelioma to levels that we 
expected (Fig. 3.6A). However, combination treatment with both Trametinib and 
Everolimus was more than additive for up-regulation of HLA-I (Fig. 3.6A). This 
suggests that in the context of HLA-I regulation, these inhibitors are not antagonistic. 
We were also interested in whether Trametinib was additive with BW-B70c. It is 
unknown if BW-B70c leads to MAPK signaling inhibition which could be a plausible 
mechanism of HLA-I regulation. Instead, we observed an additive effect of Trametinib 
and BW-B70c in vitro (Fig. 3.6B), suggesting that the major mechanism of BW-B70c- 
mediated HLA-I regulation was not through the MAPK pathway. All inhibitors 
decreased tumor viable cell count, which is ultimately a desired effect of therapy (Fig. 
3.6A, B – Bottom Panels). Together, the data presented also suggest that multiple 
signaling pathways can be manipulated to further augment HLA-I expression. This has 
several implications in combination immunotherapy because it will be important to 
identify combination drugs that not only deplete tumor cells, but also sensitize 
remaining cells to immunotherapy. 
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Figure 3.6. Everolimus and BW-B70c are additive with Trametinib in regulating 
HLA-I. 
JMN mesothelioma cells were either left untreated or treated with 100 nM Trametinib 
in combination with either 100 nM Everolimus (A) or 1.5 uM BW-B70c (B) for 72 
hours. Flow cytometry was used to determine cell-surface HLA-A2 expression. Viable 
cell counts (bottom panels) were measured by propidium iodide exclusion and raw 
counts from time-matched flow cytometry. All conditions were performed in 
triplicate. 
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Figure 3.7. 5-LO inhibitor Zileuton does not affect JMN HLA-I expression and 
BW-B70c does not affect HLA-I expression in a 5-LO-high expressing lung 
cancer. 
(A) JMN cells were treated with either BW-B70c or Zileuton at indicated doses for 72 
hours before flow cytometry was used to determine cell-surface HLA-A2 expression. 
Molecular structures of both compounds are illustrated. Graphs include data from 
Figure 3.2 for comparison purposes. (B) JMN, PC9, and NCI-H2228 cell lysates were 
analyzed by western blot for 5-LO protein expression. GAPDH was used as a protein 
loading control. (C) The 5-LO-high expressing NCI-H2228 lung cancer line was 
treated with the indicated doses of BW-B70c for 72 hours before flow cytometric 
analysis for cell-surface HLA-I. 
 
HLA-I regulation by BW-B70c is not dependent on 5-LO 
BW-B70c is not an FDA-approved 5-LO inhibitor. Therefore, we were interested in 
determining if inhibition of 5-LO enzymatic activity with the FDA-approved 5-LO 
inhibitor Zileuton could increase HLA-I. Zileuton is used in the management of 
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BW-B70c198. Disappointingly, Zileuton did not affect HLA-I in the JMN 
mesothelioma cells at any concentration tested suggesting that enzymatic inhibition of 
5-LO may not account for the increased HLA-I after BW-B70c treatment (Fig. 3.7A 
Right Panel). In fact, protein expression of 5-LO in JMN cells was nearly undetectable 
by western blot analysis (Fig. 3.7B). In contrast, the non-small cell lung cancer cell 
lines PC9 and NCI-H2228 expressed high levels of 5-LO, yet NCI-H2228 did not up-
regulate cell-surface HLA-I in response to BW-B70c treatment (Fig. 3.7B,C). Taken 
together, the data suggests that BW-B70c does not upregulate HLA-I on JMN cells 
through enzymatic inhibition of 5-LO. 
 
US6 Immunoevasin Inhibits MHC-I Antigen Presentation  
To determine utility of the CMV US6 immunoevasin protein for protecting engineered 
cells from host CD8+ T cell attack, we utilized a commonly used immunogenic cell 
line EL4-Ova (also known as EG.7)201. EL4-Ova is a derivative of the mouse T cell 
thymoma EL4 that has been engineered to express a copy of the highly immunogenic 
chicken ovalbumin protein202. We overexpressed US6 or vector control (pLgPW with 
GFP) in EL4-Ova through retroviral transduction and demonstrate stable expression as 
measured by RT-PCR for US6 (Fig. 3.8A). US6 inhibits TAP function to chaperone 
MHC-I peptides and as expected, overexpression of US6 led to reduced MHC-I cell- 
surface expression (Fig. 3.8B) confirming previous studies193,203.   In addition, US6 
overexpression decreased presentation of the highly immunogenic Ova257-264 peptide 
(SIINFEKL) as measured using an antibody specific for SIINFEKL/H2Kb (Fig. 3.8C). 
To ensure that vector or US6 overexpression did not intrinsically hinder important 
biological processes that may inhibit viability or cell growth, we measured cell growth 
in vitro. We did not observe any significant difference between parental EL4, EL4-
Ova, EL4-Ova vector control, or EL4-Ova US6 (Fig. 3.8D). To determine whether the  
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Figure 3.8. US6 immunoevasin decreases cell-surface MHC-I, antigen 
presentation, and does not affect cell growth. 
(A) US6 was overexpressed in the EL4-Ova cell line through retro-viral transduction 
of a CMV promoter-based mammalian overexpression vector pLgPW that expresses 
GFP as a selectable marker. RT-PCR was used to confirm expression of US6 
transcript. GAPDH transcript was used as a loading control. (B) Flow cytometry was 
used to determine cell-surface expression of the murine MHC-I allele H2Kb in US6 
overexpressing EL4-Ova versus vector control. (C) Flow cytometry was used to 
determine presentation of a model antigen from Ova: SIINFEKL/H2Kb. 
Quantification of  %SIIN+ cells is represented graphically on the right panel. (D) Each 
cell line or construct indicated was cultured in vitro starting at 1x105 cells and trypan 
blue exclusion counting was performed every day for 4 days. 
US6 
GAPDH 
EL
4-O
VA
  
– V
ec
tor
 C
trl
 
EL
4-O
VA
 
 – 
US
6 
Ve
cto
r C
on
tro
l
US
6
0
1
2
3
4
5
6
7
%
 S
IIN
+
SIIN+ Percentage
A 
C 
B 
H2kb 
Isotype 
EL4-Ova – Vector Ctrl 
EL4-Ova – US6 
SIIN/H2kb SIIN/H2kb 
EL4-Ova – Vector Ctrl EL4-Ova – US6 
D
0 1 2 3 4 5
1×105
1×106
1×107
Day
C
el
l C
ou
nt
In vitro Growth Kinetics
EL4
EL4-OVA
EL4-OVA - Vector Ctrl 
EL4-OVA - US6
n.s.
**** 
	107 
reduced Ova-peptide presentation would reduce immunogenicity in vivo, we engrafted 
mice subcutaneously with the parental EL4, EL4-Ova vector control, or EL4-Ova 
US6. The experiment is currently underway and the results are pending.  
 
Genetic Deletion of TAP and β2M Lead to Loss of Cell-surface MHC-I and TAP 
Deletion in a Cas9-expressing Fibrosarcoma Leads to Reduced Tumor Growth in 
Immunocompetent Mice 
The streptococcus pyogenes-derived Cas9 is thought to be immunogenic in mammals 
leading many to believe this will be a major challenge in utilizing CRISPR/Cas9- 
based therapeutics in humans204. Recent preliminary reports have already hinted that 
humans have pre-existing humoral antibody responses and cytotoxic T cell responses 
against Cas9 and Cas9-expressing cells205. This is important to understand because 
Cas9 is increasingly utilized in mouse models and CD8 T cell responses against Cas9 
could affect experimental outcome. In addition, this may provide a model to study 
strategies to modulate MHC-I to protect foreign Cas9-bearing cellular therapeutics. 
Our US6 studies may be confounded in vivo by the unknown variable of potentially 
immunogenic US6 peptides presented on MHC-I. Therefore, we aimed to generate a 
more robust model by complete TAP deletion and ask how this would affect potential 
immunogenicity of Cas9-expressing cells. Using a murine fibrosarcoma coupled to a 
CRISPR/Cas9 system, we generate MCA205-Cas9 that constitutively expresses Cas9, 
MCA205-Cas9 TAP KO that has TAP1 deleted, and MCA205-Cas9 β2M KO that has 
β2M deleted. These lines were generated through lentiviral transduction of a plasmid 
encoding constitutive expression of Cas9 along with an sgRNA either against an 
irrelevant target, or against the respective TAP1 and β2M targets. All constructs also 
express the puromycin resistance PAC gene. Deletion of TAP1 and β2M led to near 
complete abrogation of MHC-I as measured by flow cytometry against H2Kb (Figure 
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3.9A). As expected, β2M deletion reduced H2Kb more than TAP1 deletion.  To 
simultaneously ask the question of whether Cas9 expression abrogates cell growth 
under immune pressure in vivo and if TAP or β2M deficiency can protect transgenic 
cells in vivo, we engrafted MCA205 WT, MCA205-Cas9, MCA205-Cas9 TAP KO, 
and MCA205-Cas9 β2M KO cells subcutaneously into syngeneic C57BL/6N mice 
(Figure 3.9B). We observe in this preliminary study that MCA205 WT cells grew into 
large tumors by day 22 whereas MCA205-Cas9 tumors grow slower, presumably from 
immune pressures against Cas9, however this was not formally tested. Comparing the 
growth kinetics, MCA205-Cas9 β2M KO cells seemed to have initial growth delay, 
but by day 22 seemed to grow in a typical exponential pattern. Interestingly, 
MCA205-Cas9 TAP KO cells had the slowest growth kinetics and seemed to have 
starting plateauing at the experimental endpoint. The observation that Cas9 expression  
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Figure 3.9. TAP and β2M deletion abrogate MHC-I expression and alters growth 
kinetics in a Cas9-expressing MCA205 tumor. 
TAP1 and β2M were genetically ablated in the MCA205 fibrosarcoma line through 
CRISPR lentiviral transduction of stably expressed Cas9 and respective sgRNAs. (A) 
Flow cytometry to measure cell-surface MHC-I (H2Kb) expression. Overlaid plots are 
compared to an isotype control and MFI values are plotted (bottom panel). (B) 1.5x106 
MCA205 WT, MCA205 Cas9-expressing, MCA205 Cas9 – TAP Knock out, or 
MCA205 Cas9 – β2M knock out cells were engrafted subcutaneously on the hind 
flank of immunocompetent C57BL/6N mice. Tumors were measured over 22 days 
using caliper measurements. Experiment was performed once. 
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Alone slightly slows tumor growth compared to MCA205 WT (p=0.0121) suggests 
that Cas9 expressed in a cell may be immunogenic. The slightly delayed but still 
exponential growth kinetics of MCA205-Cas9 β2M KO suggests that complete loss of 
MHC-I does may not always lead to elimination by NK cells which is a highly 
regulated process and is context dependent. Finally, the delayed growth kinetics and 
day 17-22 plateau of MCA205-Cas9 TAP KO cells (Fig. 3.9B) suggests that complete 
deletion of TAP function would not be a useful strategy to protect cells harboring 
immunogenic proteins. We hypothesize that this may be mediated by immunity 
against non-TAP-dependent peptides either derived from self-proteins or transgenes 
Cas9 or PAC (puromycin resistance), or addition low-level NK-cell cytotoxicity as 
demonstrated against splenocytes from TAP-deficient mice185. 
 
DISCUSSION 
HLA-I is a key immune recognition and modulatory molecule and therefore gaining a 
deeper understanding of how it can be modulated pharmacologically represents an 
attractive strategy to augment tumor immunotherapy. We demonstrate that a high-
throughput immunofluorescence screen can be used to identify small molecule 
regulators of HLA-I. The methods for this approach are easily adaptable to discover 
modulators of other important immune receptor such as PD-L1, CD47, or HLA-II. 
Several inhibitors of the MAPK pathway were characterized as lead hit compounds, 
confirming and highlighting the importance of MAPK in regulation of HLA-I from 
our previous studies110. Two lead compounds validated in an orthogonal flow 
cytometry-based assay: the 5-LO inhibitor BW-B70c and the mTOR inhibitor 
Everolimus. Although we are confident in the reproducibility of the results, the 
discrepancy between the immunofluorescence results and the flow-cytometry results is 
likely due to assay artifacts such as how changes in cellular morphology affect the 
	111 
automatic algorithm for determining boundaries on a cell in two-dimensional images. 
This is especially complex when cells are in contact with each other – a likely 
occurrence when cells are grown from a small number on a small area as was the case 
for our 384-well format plate screen starting with 500 cells per well. Although 
Everolimus only marginally increased HLA-I expression, we were interested in this 
compound because it is an FDA-approved drug used to prevent organ transplant 
rejection in addition to targeted therapy of advanced kidney cancer, progressive 
pancreatic neuroendocrine tumors, and advanced hormone-receptor positive but 
HER2-negative breast cancers. Everolimus had a greater than additive effect for 
increasing HLA-I in combination with the MEK inhibitor Trametinib suggesting that 
these pathways are linked in their regulation of HLA-I. Interestingly, Everolimus is 
known to inhibit T cell activation206 allowing it to be useful for preventing transplant 
rejection. Unfortunately, this suggests it is unlikely that the marginal increase in HLA-
I expression induced by mTOR inhibition would benefit T cell immunotherapy 
because Everolimus also severely inhibits T cell function. However, understanding the 
cross talk between MAPK and mTOR pathways in regulation of HLA-I would shed 
new light on biochemical mechanisms of HLA-I regulation.  
 
Moreover, we were especially interested in the lead compound hit BW-B70c because 
it dramatically increase cell-surface HLA-I through a transcriptional mechanism 
correlated with increases in the canonical STAT1 and IRF1 transcription factors. BW-
B70c increased HLA-I along with presentation of the RMF peptide derived from the 
tumor-associated antigen WT1. This led to increased sensitivity of JMN cells to 
TCRm-mediated ADCC targeting the RMF/HLA-A2 antigen, demonstrating 
functional relevance for regulation of HLA-I. Although BW-B70c was designed to be 
a 5-LO inhibitor, out data suggests that its effect on HLA-I expression was not through 
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inhibition of 5-LO enzymatic activity. 5-LO was nearly undetectable in JMN cells by 
western blot analysis and an additional iron chelator inhibitor of 5-LO Zileuton had no 
effect on HLA-I expression. Moreover, a lung cancer cell line NCI-H2228 that 
expressed abundant 5-LO did not increase HLA-I expression after treatment with BW-
B70c. Determining the putative target of BW-B70c that regulates HLA-I will be shed 
light on how to manipulate HLA-I. 
 
We were also interested in opting viral immunoevasins to protect engineered cellular 
therapeutics from immune recognition and attack. Cellular therapeutics such as stem 
cells and CAR T cells are now being experimentally engineered with synthetic and 
foreign genes, all of which may be immunogenic to host T cells. Therefore, we 
evaluated the use of the CMV immunoevasin US6 to inhibit TAP and functionally 
prevent immunogenic peptide/MHC-I presentation. We confirm that US6 expression 
inhibits cell-surface MHC-I expression and demonstrate that this leads to reduced 
presentation of SIINFEKL/H2Kb using the EL4-Ova mouse thymoma model. It will 
be exciting to see if the reduced antigen presentation would rescue growth under 
immune pressure in vivo. It is important to note that cells will contain vector 
components that may potentially be immunogenic (Neomycin resistance from original 
generation of EL4-Ova202 and GFP from the pLgPW vector), however this is 
accounted for in the vector control experimental arm. Indeed, US6 is another foreign 
viral protein and through NetMHC prediction algorithms, we calculate several US6-
derived peptides that are predicted to have ~100-300 nM affinity to C57BL/6N mouse 
MHC-I alleles H2Kb and H2Db (Table 3.2). This data is only a computational 
prediction and indeed the affinities are not as high as several other well-characterized 
MHC-I peptides such as Ova-derived SIINFEKL (which has a predicted affinity of 
19.37 nM for H2Kb). In addition, the predictions do not account for processing steps 
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through proteasomal degradation or peptide-loading complex interactions that may be 
required to ultimately form stable peptide/MHC-I complexes. However, they still 
represent possible immunogenic peptides derived from US6 that can be tested 
experimentally. 
 
Overexpression of Cas9 alone in the MCA205 fibrosarcoma decreased cell growth in 
an immunocompetent model suggesting that Cas9 has a level of immunogenicity. This 
is not surprising because Cas9 is a large bacterial protein (1368 residues long) and 
several Cas9-derived peptides may bind murine MHC-I and stimulate CD8+ T cell 
responses. Genetic deletion of β2M in the MCA205 fibrosarcoma slightly delayed 
growth in vivo and we hypothesize this to be the effect of NK cell cytotoxicity. Others 
have reported that β2M CRISPR knock out in other murine tumor cell lines prevents 
engraftment mediated by NK cells207. Although our data stands in contrast, the cellular 
mechanisms that govern NK cell activation and inhibition is extremely complex and 
context-specific so the data is not surprising135,208,209. More interestingly, deletion of 
TAP1 in MCA205 led to slower cell growth in vivo, which seemed to have plateaued 
between day 17 and 22. This is interesting because it was opposite of our hypothesis. 
The result could be explained through a combination of mechanisms. First, the lower 
MHC-I expression could promote a level of NK cell lysis. Second, deletion of TAP 
may allow the presentation of peptide epitopes that otherwise would have been 
outcompeted by the large pool of TAP-dependent epitopes. These epitopes are not 
presented on healthy cells and therefore represent T cell epitopes associated with 
impaired peptide processing (TEIPP)210,211. When presented after loss of TAP, these 
epitopes can generate CD8+ T cell responses and is believed to be a mechanism to 
prevent immune escape if there is deletion of TAP210. Although not formally tested, 
this represents a rationale mechanism to explain our results. Together, our data suggest 
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genetic TAP deletion to be a poor strategy in ‘de-immunizing’ genetically engineered 
cellular therapies. 
 
 
Table 3.2. US6-derived Peptides have predicted affinities to murine MHC-I 
alleles. 
The entire CMV US6 protein sequence was queried using NetMHC-Pan4.0 
(http://www.cbs.dtu.dk/services/NetMHC/) to predict affinities of all possible 8, 9, 10, 
and 11-mer peptides to C57BL/6N MHC-I alleles (H2-Kb, H-2Db). The indicated 
peptides were predicted to have affinities of less than 500 nM. Peptide sequence, 
MHC-I allele, and predicted affinity (nM) are presented in the table. 
 
Peptide MHC-I Allele Pred Affinity (nM) 
GAVWNAFRL H2Db 187.1 
LGFLLMCAL H2Kb 265.9 
AVWNAFRLI H2Kb 330 
AVWNAFRL  H2Kb 128.5 
HGFFAVTL  H2Kb 276.2 
RLIERHGFF  H2Kb 239.3 
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THESIS SUMMARY 
Pr20 mAb Binds PRAME+ and HLA-A2+ Cancer Cells and is Therapeutically 
Active in vivo 
mAbs have proven to be a potent therapeutic modality for treating cancers however 
currently marketed mAbs exclusively target cell-surface antigens. TCRm antibodies 
such as Pr20 demonstrate that mAbs can also be used to target intracellular protein-
derived peptides in the context of MHC-I. Pr20 bound to PRAME ALY peptide-
pulsed T2 cells and PRAME+ / HLA-A2+ leukemias and lymphomas, but not healthy 
PBMC populations or PRAME-negative / HLA-A2+ cancer cell lines. We engineered 
the Fc afucosylated Pr20M that could direct ADCC against PRAME+ / HLA-A2+ 
cancer cells in vitro, but did not deplete healthy PBMC populations. Although Pr20M 
reacts against ALY/HLA-A2 much like a TCR-transduced T cell or peptide-stimulated 
T cell might, its mAb format allows for substantial ease of use as a drug. It could be 
directly infused rather than transduced ex vivo into patient-specific T cells and re-
infused. 
 
Pr20M also demonstrated therapeutic utility against xenograft models of AML and 
ALL. Unexpectedly, the AML cells extraction from the bone marrow of Pr20M- 
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treated mice did not lose target antigen expression and in fact bound Pr20 post-therapy 
better than AML cells from control mice. This suggests that there is some mechanism 
of increased antigen regulation that occurs during TCRm-therapy. We speculate that 
Pr20M recruitment of immune effectors such as macrophages in the NSG mouse may 
mediate local cytokine release modulating ALY/HLA-A2 antigen presentation. 
 
The PRAME300-309 ALY Epitope is Regulated by the Immunoproteasome 
Initial studies testing Pr20 binding on a large panel of cell lines demonstrated that 
Pr20 did not bind several melanomas and other solid tumors despite high expression 
of both HLA-A2 and PRAME. This suggested that perhaps there were specific 
peptide-processing mechanisms that were important for generation of the ALY 
peptide. Because leukemias and lymphomas that express the immunoproteasome 
seemed to bind Pr20 better, we hypothesized and demonstrated that 
immunoproteasome expression and catalytic function was important for generation of 
the Pr20 epitope. Dramatic Pr20 binding was induced upon treatment with IFNγ, a 
pro-inflammatory cytokine well established to induce expression of the 
immunoproteasome. The IFNγ-induced Pr20 binding was partly dependent on β5i as 
demonstrated by reduced IFNγ-induced Pr20 binding after genetic ablation of β5i in 
melanoma cell lines. Biochemically, we define the mechanism to be that the 
immunoproteasome better maintains the ALY peptide because based on proteasome 
digestion assays in vitro. Incubation of an elongated pre-cursor peptide with the 
constitutive proteasome led to more internal destructive cleavages within the ALY 10-
mer.  
 
Pr20M and CD47 blockade with CV1 Leads to Dramatic Therapeutic Efficacy 
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Although we illustrate that Pr20M has some therapeutic efficacy alone, monotherapy 
did not lead to cures or long-term AML regression. Therefore we explored strategies 
to increase the therapeutic utility of Pr20M. We hypothesized that Pr20M could 
mediated ADCP from the NSG mouse macrophages and that by inhibiting the CD47 
‘do not eat me’ signal, we could enhance ADCP and augment therapy. Indeed, we 
demonstrate that CD47 blockade using the CD47 antagonist SIRPα-variant peptide 
CV1 can enhance Pr20M-mediated ADCP by both human and NSG mouse 
macrophages in vitro. The phenotype translated well in animal models where 
combination therapy of Pr20M and CV1 led to dramatic therapeutic efficacy and long-
term disease-free survival in AML xenograft studies. 
 
Pr20-BiTE and Pr20-CAR can Potently Direct Lysis of PRAME+ /HLA-A2+ 
Leukemias but have Cross-reactivity to HLA-A2 
We also explored engineering of the Pr20 scFv into the Pr20-BiTE and Pr20-CAR 
formats. BiTEs and CARs have recently gained FDA-approval for B-cell leukemia 
and lymphomas and there have been unprecedented clinical outcomes. Both BiTE and 
CAR formats can potently redirect T cells against a tumor antigen and can even lead to 
the phenomenon of antigen spreading89, leading to further anti-tumor engagement by 
the endogenous immune response. Our data demonstrate that the Pr20 scFv can be 
engineered onto BiTE and second-generation 41BBζ CAR constructs and be expressed 
appropriately. Pr20-BiTE and Pr20-CAR both mediated rapid and robust depletion of 
a PRAME+ / HLA-A2+ AML cell line in vitro demonstrating potency of these 
biologics. However, Pr20-BiTE also mediated depletion of CD14+ monocytes from 
HLA-A2+ healthy donor PBMC suggesting that this population expressed a cross-
reactive epitope at levels below the limit of detection of flow cytometry, but high 
enough for BiTE-mediated cytotoxicity. Pr20-CAR transduced into the Jurkat model T 
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cell line maintained reactivity to ALY/HLA-A2 by tetramer staining and activated 
when co-cultured with PRAME+/HLA-A2+ cells, demonstrating stable and functional 
expression of the construct. However, Pr20-CAR Jurkat cells also activated against a 
panel of PRAME-Negative but HLA-A2+ cell lines suggesting cross reactivity to 
other peptide/HLA-A2 molecules or that baseline reactivity to HLA-A2 alone with the 
CAR construct was sufficient to activate the T cell. Taken together, our data 
demonstrate the need for caution when engineering TCRm scFv into potent BiTE and 
CAR formats perhaps due to their typically higher affinity than natural TCRs. 
 
A High-throughput Screen Validates that MAPK can Regulate HLA-I and 
Identifies BW-B70c as a Lead Experimental Compound that Increases HLA-I 
We utilized an unbiased high-throughput arrayed screen to identify small molecule 
regulators of HLA-I.  Several hit compounds were inhibitors for various kinases along 
the MAPK pathway; validating previous findings in the lab that MAPK pathway is 
important for regulation of HLA-I. We performed further studies on hit compounds 
that were not directly associated with inhibition of MAPK and confirmed that the 
mTOR inhibitor Everolimus and the 5-LO inhibitor BW-B70c could increase JMN 
mesothelioma HLA-I expression. Both of these compounds were additive with the 
MEK inhibitor Trametinib in increasing HLA-I and therefore we concluded that 
Everolimus and BW-B70c regulated HLA-I through pathways independent of MEK. 
We focused on the BW-B70c because it dramatically increased HLA-I. We 
determined the mechanism to be transcriptional through regulation of the STAT1 and 
IRF1 expression. BW-B70c not only increased HLA-I, but also increased cell-surface 
presentation of a WT1-tumor antigen-derived peptide RMF/HLA-A2. This increase in 
presentation sensitized JMN cells to ADCC mediated by ESKM, a TCRm against 
RMF/HLA-A2. However, we concluded that BW-B70c regulated HLA-I 
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independently of 5-LO because other 5-LO inhibitors did not affect HLA-I levels, 
JMN cells do not express appreciable levels of 5-LO, and an additional cell that that 
expressed high levels of 5-LO did not increase HLA-I after treatment of BW-B70c. 
The putative target of BW-B70c responsible for the HLA-I phenotype has yet to be 
determined. 
 
US6 Inhibits Antigen Presentation and Deletion of TAP does not Promote Cell 
Growth in vivo Under Immune Pressure 
We also explored the use of the viral immunoevasin TAP inhibitor US6 to inhibit 
antigen presentation on MHC-I in the ultimate hopes of utilizing US6 to protect 
engineered cells harboring foreign or synthetic genes from host T cells. US6 
overexpression led to decreased MHC-I and Ova-derived SIINFEKL/H2Kb 
presentation. Genetic ablation of TAP also did not increase growth of a fibrosarcoma 
in vivo, and in fact inhibited its growth compared to controls suggesting that genetic 
deletion of TAP was not a effective strategy to ‘de-immunize’ genetically altered cells 
bearing foreign proteins. 
 
 
FUTURE DIRECTIONS 
 
TCRm mAbs change the paradigm for what targets are accessible to antibody-based 
biological agents. The data presented here provide demonstration that TCRm can be 
generated against the tumor-associated antigen PRAME, and have therapeutic utility 
in preclinical models. Indeed, TCRm have diverse potential in cancer therapy. 
However, there are also unique challenges that must be addressed before these agents 
move into clinical evaluations.  Our on-going studies hope to address the challenges 
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and guide the direction of this developing technology. 
 
A major hurdle in development of TCRm antibodies is antigen specificity. Whereas 
traditional anti-cancer mAbs typically recognize a three-dimensional conformational 
epitope allowing for precise specificity, TCRm are designed to recognize a composite 
epitope comprised of a small (8-10 residue) linear peptide sequence buried in a largely 
invariant MHC molecule found on all healthy cells. Some of these residues face in 
toward the binding pocket of MHC and thus do not directly form salt-bridges or other 
interactions with the TCRm. Furthermore, crystal structure analyses of TCRm have 
demonstrated that a substantial portion of binding energy may result from contacts 
with the MHC portion148,212. Therefore the variable and biochemically available 
epitope for TCRm to target is highly limited. Specificity and potential cross-reactivity 
of TCR-based agents is a major concern because a clinical trial using affinity-matured 
TCR-transduced T cells against the MAGE-A3 antigen let to rapid cardiac toxicities 
and death213. It was later discovered that the anti-MAGE-A3 TCR reacted with a 
peptide derived from the protein Titan highly expressed in cardiomyocytes213. Based 
on peptide sequence, the cross-reactivity could not be predicted with the available 
experimental or computational tools despite rigorous preclinical testing. Instead, we 
are developing a high-throughput pooled screen approach to identify possible cross-
reactive targets experimentally. Using a vector constructed with a genetically barcoded 
peptide antigen, we have developed a system called “PresentER” that can encode 
MHC-I peptides. PresentER can be used in a pooled library screen where tens of 
thousands of peptides are transduced into cells and fluorescence activated cell sorting 
(FACS) using the TCRm and subsequence deep sequencing can identify the possible 
cross-reactive targets. The studies using PresentER to determine cross-reactive 
peptide/HLA-A2 targets of Pr20 are currently underway. Moreover, mass 
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spectrometry approaches to elute and identify MHC-bound peptides from cells have 
become increasingly sensitive. Such approaches are powerful because they can 
experimentally identify the MHC-I “peptidome” in contrast to methods that only 
computational predict cross-reactive peptide or even peptides that bind MHC-I. Our 
group is currently developing methods to immunoprecipitate bound ligands of Pr20 to 
determine what cross-reactive epitopes exist.  
 
Another approach to limiting cross-reactive targets is through increased stringency 
when panning for TCRm clones during phage-display. Whereas Pr20 was developed 
using positive panning against the target ALY/HLA-A2 and negative panning against 
a completely irrelevant RHAMM-R3 peptide/HLA-A2, future approaches should 
investigate negative panning against a more biochemically similar peptide in the aims 
of increasing specificity. Additionally, Pr20 primarily bound the C-terminal half of the 
ALY peptide. Future strategies to select TCRm clones that bind with a larger ‘foot-
print’ over the middle residues may increase specificity because the anchor residues at 
the peptide N- and C-termini are relatively conserved across MHC-I binding peptides 
and may therefore be less antigenically unique. Such strategies are currently being 
investigated. 
 
In addition, it will be important to identify tumor-associated peptide/MHC antigens 
that are generated by both the constitutive and immunoproteasome because these 
represent ideal targets of TCRm and TCR-based agents. As demonstrated by the data 
presented here, specific peptides such as the PRAME300-309 ALY peptide and the 
WT1126-134 RMF peptide62 are better generated by the immunoproteasome, and may be 
destroyed by the constitutive proteasome, ultimately limiting the cancers that would 
present ALY and be sensitive to Pr20. Targeting peptide/MHC antigens that are 
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generated by both major proteasome forms would broaden the tumor types that could 
be treated with such therapies and may also help prevent antigen escape relapse that 
down-regulate the proteasome components required to generate the peptide.   
 
Lastly, it will be important to identify rational combination immunotherapies through 
enhancement of HLA-I. Increased antigen presentation may not only sensitize cancers 
to TCRm as shown here and in past work from our lab, but also potentiate other 
immunotherapy strategies such as TCR-transduced T cells, ImmTACs, and check-
point blockade of CTLA-4, PD-1/PD-L1, and several others in current clinical 
investigation. We have yet to identify the pharmacologically important target of BW-
B70c responsible for enhancement of HLA-I in the JMN mesothelioma cell line. We 
aim to approach this through the use of an analog compound of BW-B70c that is 
conjugated to a magnetic bead. The analog compound/magnetic bead can then be used 
to pull-down the putative target protein from cell lysates and be identified using mass 
spec. These exciting studies discussed have been initiated and will continue to 
elucidate unknown biochemical mechanisms of tumor-antigen presentation and refine 
the strategies used to develop TCRm antibodies, vaccines, and other TCR-based 
therapeutic agents and cells. These studies are meaningful and illuminate deep insights 
into cancer biology and immuno-oncology in our ultimate quest to understand, 
command, and conquer cancer. 
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